Mechanistic AI in Medicine: Discovery of Mechanisms and Origins of Diseases

Authors:

Neda Gorjizadeh
Tehran University of Medical Sciences

Najmeh Tavousi
Isfahan University of Medical Sciences

Sina Talebi
Iran University of Medical Sciences

Masoumeh Moallem
Tehran Medical Sciences Branch, Islamic Azad University

Mobina Gheibi
Mazandaran University of Medical Sciences

Sadegh Bagherzadeh
Tehran University of Medical Sciences

Leili Haghighi
Islamic Azad University Tehran Medical Sciences, Dental Branch

Mohammad Hossein Naderi
Shahed University

Monireh Haghifar
Department of Pediatric Dentistry, Islamic Azad University of Tabriz

Kimia Kowsari
Azad University of Sari

Rojan Javaheri
Shiraz of University of Medical Sciences

Mohammad Hossein Hosseiny
Shahid Beheshti University of Medical Sciences

Maedeh Masoumzadeh
Arak University of Medical Sciences

Shabnam Ghasemzaseh
Qazvin University of Medical Sciences

Massoma Rezai
Golestan University of Medical Sciences

Behnaz Shirgir
Near East University

Asma Zamani
Golestan University of Medical Sciences

Nasim Ghasemzadeh
University of Texas at Dallas

Meisam Sargazi
Zahedan University of Medical Sciences

AmirMohammad Larni-Fooeik
Iran University of Science and Technology

Ali Azizi
University of San Diego

Saman Abdollahpour
Shahid Beheshti University of Medical Sciences

Sanaz Amiri Marbini
Islamic Azad University, Tehran Medical Sciences Branch

Paniz Nejati
Islamic Azad University, Tehran Medical Sciences Branch

AmirMasoud Karimi
Alborz University of Medical Sciences

Zahra Khosravani Hasan Kiyadeh
Islamic Azad University Rasht

Book Details:

Publisher: PreferPub (eBook Version) and Kindle (Paperback Version)

Publication Date: April 2026

Language: English

Dimensions: 5 x 0.39 x 8 inches

ISBN-13: 979-8257644375

CONTENTS

Chapters

1. MECHANISTIC AI IN RENAL DISEASES

Background

Mechanistic artificial intelligence in renal diseases represents a growing and transformative field that merges traditional machine learning methodologies with biophysical, biochemical, and physiological models of kidney function. The kidney is one of the most structurally and functionally complex organ systems in the human body. It contains millions of nephrons, each housing intricate networks of glomeruli, tubules, blood vessels, and transport systems that maintain fluid balance, acid base homeostasis, electrolyte equilibrium, metabolic waste clearance, endocrine signaling, and pressure regulation. Conventional artificial intelligence methods have gained traction in nephrology for tasks such as chronic kidney disease detection, prediction of acute kidney injury, risk stratification for progression, and the analysis of imaging or laboratory data. However, classical deep learning models are primarily correlation based, which limits their clinical interpretability and reduces their capacity to provide mechanistic explanations for observed abnormalities. Clinicians must rely on causal reasoning grounded in physiology, and therefore black box AI models

introduce important challenges in trust building, adoption, and clinical translation.

Mechanistic AI addresses these concerns by uniting data driven learning with mechanistic models derived from renal physiology, fluid dynamics, transport kinetics, glomerular filtration principles, hormonal feedback loops, and hemodynamic regulation. Through this integration, mechanistic AI can produce predictions that not only fit data but also explain why outcomes occur, how pathological processes evolve, and which parameters drive disease progression. These models embed biological equations into computational architectures, such as conservation of mass and solute, nonlinear transport functions, Starling forces within the glomerulus, and network laws describing renal blood flow autoregulation. When combined with machine learning, these mathematical structures allow the model to infer latent physiological variables, simulate disease states that are difficult to measure experimentally, and generate hypotheses regarding pathological mechanisms.

Mechanistic AI thus occupies a unique role within the broader movement toward precision nephrology. Its capacity to integrate clinical, laboratory, imaging, and molecular data with mechanistic knowledge supports patient specific modeling, personalized prediction of disease course, and targeted therapeutic planning. It does so with greater transparency and clinical

relevance than conventional black box models, making it well suited to the nuanced decision making and complex pathophysiological terrain of nephrology. As kidney disease continues to impose a rising global burden, mechanistic AI offers a framework through which clinicians and researchers can understand renal disease at a deeper causal level, ultimately helping guide individualized treatment and improve outcomes.

Principles Of Mechanistic AI In Nephrology

Mechanistic AI builds upon several foundational principles that make it particularly relevant for renal physiology and pathology. The first principle is constraint based modeling. Renal function is tightly governed by established physical laws and biochemical relationships, such as the principles of filtration, reabsorption, secretion, and ultrafiltration. Mechanistic AI incorporates these constraints into the learning process to ensure that model predictions remain biologically plausible. When a model learns parameters or produces outputs, those outputs must satisfy mass balance equations, comply with known transport relationships, and maintain consistency with established physiological limits.

The second principle is multiscale integration. Renal disease spans molecular, cellular, tubular, nephron, and whole organ levels. Mechanistic AI seeks to link these levels through nested model-

ing frameworks. For example, alterations in ion channel function or transporter density affect tubular reabsorption. Tubular changes influence nephron level function, which affects glomerular dynamics and subsequently impacts whole kidney hemodynamics. In chronic kidney disease, fibrosis and inflammatory cascades alter tissue architecture, affecting nephron viability and filtration. Mechanistic AI allows researchers to model these interactions across scales, enabling interpretation of how changes at one level propagate to produce measurable clinical outcomes.

The third principle is causal interpretability. Mechanistic AI does not merely map input data to output predictions. It also elucidates which mechanistic pathways and parameters drive the predicted outcome. By identifying the role of glomerular pressure, oncotic gradients, tubular transporter activity, or renin release, the model can explain why a patient's kidney function is deteriorating or why a particular therapeutic strategy might be effective. This transparency allows clinicians to verify model reasoning against established physiological understanding, which is essential for trust and adoption.

Mechanistic AI frequently uses hybrid computational architectures. One common architecture is the physics informed neural network, which embeds renal specific differential equations within neural network training. For example, a model may incorporate glomerular filtration equations,

tubular transport differential equations, or renal blood flow autoregulation laws as constraints during training. Hybrid dynamical systems are also common. In these systems, known mechanistic relationships are expressed through ordinary or partial differential equations, while unknown or incompletely characterized relationships are learned through neural networks. This structure preserves interpretability while allowing flexibility for knowledge gaps.

Mechanistic Modeling Of Renal Physiology

Mechanistic AI is uniquely suited to model renal physiology because the kidney is fundamentally a system of dynamic fluid and solute transport governed by well defined physical laws. The glomerulus operates through principles of ultrafiltration driven by pressure gradients. Tubular segments perform highly specialized reabsorptive and secretory processes mediated by transporter kinetics. Renal blood flow and glomerular pressure are regulated by feedback mechanisms such as tubuloglomerular feedback and the myogenic response. Mechanistic AI can integrate these processes into computational frameworks that represent the kidney as a coupled, nonlinear physiological system.

A central application of mechanistic AI is modeling glomerular filtration. Traditional machine learning might predict estimated glomerular fil-

tration rate for a population but cannot explain how filtration changes arise. Mechanistic AI can represent Starling forces within the glomerular capillary as differential equations describing hydrostatic and oncotic pressures, filtration coefficients, and membrane characteristics. Machine learning components can infer patient specific values for these parameters using laboratory and imaging data. This allows estimation of glomerular filtration based on interpretable, mechanistic variables such as altered capillary permeability or disrupted pressure gradients.

Tubular processes are another area where mechanistic AI offers substantial advantages. Tubular reabsorption and secretion involve complex transporter networks and nonlinear solute concentration gradients. Mechanistic models represent these processes through systems of equations describing sodium transport, potassium handling, bicarbonate buffering, water movement driven by osmotic gradients, and hormonal influences such as aldosterone and antidiuretic hormone. When machine learning is added to calibrate these parameters, mechanistic AI can estimate tubular function under disease states such as acute tubular necrosis, diabetic nephropathy, or drug induced nephrotoxicity. It can also evaluate the impact of altered transporter expression on electrolyte balance.

Renal hemodynamics can also be modeled mechanistically. The kidney maintains stable filtra-

tion rates despite significant fluctuations in systemic blood pressure through autoregulatory mechanisms. Modeling this requires representing the afferent arteriole myogenic response, tubuloglomerular feedback, efferent arteriole tone, and hormonal modulation through systems of differential equations. Mechanistic AI can learn how these feedback loops shift in pathological states like hypertensive nephropathy or cardiorenal syndrome. Predicting renal perfusion and filtration based on mechanistic variables helps clinicians understand the pathophysiological basis of renal function decline rather than simply observing trends.

Mechanistic AI In Acute Kidney Injury

Acute kidney injury is a complex and heterogeneous condition arising from diverse etiologies including ischemia, toxicity, sepsis, volume depletion, and obstruction. Traditional machine learning models can predict acute kidney injury risk, but they do not explain which physiological mechanisms are failing or how injury is evolving. Mechanistic AI, however, can identify impaired autoregulation, disruption of tubular transport, mitochondrial dysfunction, inflammation, and microvascular injury through mechanistically interpretable parameters. This produces a clearer understanding of the biological processes driving acute injury.

For example, in ischemic acute kidney injury, mechanistic AI can simulate how reduced perfusion pressure leads to diminished oxygen delivery and metabolic failure in the proximal tubule. This can be modeled through oxygen transport equations, mitochondrial bioenergetic relationships, and tubular epithelial transport failure. Machine learning components learn patient specific modifications to these parameters based on laboratory, hemodynamic, and imaging data. This enables early detection of subclinical injury by identifying deviations in mechanistic parameters before creatinine rises.

In sepsis induced acute kidney injury, the pathophysiology involves complex interactions between inflammation, microvascular dysfunction, altered hemodynamics, and mitochondrial impairment. Mechanistic AI can incorporate models describing cytokine mediated capillary leak, impaired renal blood flow distribution, and changes in efferent arteriole tone. By integrating inflammatory markers and vital sign trends, machine learning enhances patient specific parameter estimation. This allows identification of mechanistic trajectories such as inflammatory microvascular collapse or dominant hemodynamic instability. These insights can support personalized interventions guiding fluid resuscitation, vasopressor use, and timing of renal replacement therapy.

Mechanistic AI is also valuable for predicting renal

recovery. Many patients with acute kidney injury fail to regain baseline function. Hybrid models linking tubular epithelial injury with repair processes and fibrosis progression can estimate the probability of recovery based on mechanistic variables such as residual tubular integrity, perfusion recovery, and fibrotic signaling pathways. This level of detail surpasses what correlation based models can provide and aligns more closely with clinical decision making.

Mechanistic AI In Chronic Kidney Disease

Chronic kidney disease involves progressive and irreversible decline in renal function due to a wide range of etiologies. The progression of chronic kidney disease is influenced by glomerulosclerosis, inflammation, tubular atrophy, interstitial fibrosis, oxidative stress, microvascular loss, and maladaptive nephron hypertrophy. Mechanistic AI is particularly well suited to modeling such complex, nonlinear progression because it can incorporate multiscale biological mechanisms into predictive frameworks.

One major application is modeling glomerular hypertrophy and hyperfiltration in early chronic kidney disease. Physiology based equations can describe how remaining nephrons increase their filtration load when nephron number declines. Machine learning can estimate patient specific hyperfiltration parameters from laboratory data,

providing insight into compensatory stress and future decline. This approach allows clinicians to identify patients with high mechanistic risk, even when glomerular filtration rate appears preserved. Mechanistic AI also provides a framework for modeling interstitial fibrosis, the central driver of chronic kidney disease progression. Biophysical models describe the activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and degradation of renal architecture. These systems are influenced by cytokines such as transforming growth factor beta, angiotensin signalling, hypoxia, and tubular epithelial cell stress. Machine learning can calibrate these mechanistic pathways for individual patients using biopsy findings, imaging, and laboratory markers. This creates an interpretable map of which fibrotic pathways are dominant, supporting personalized antifibrotic therapy.

Electrolyte and acid base regulation in chronic kidney disease can also be modeled using mechanistic AI. Disturbances in potassium handling, sodium retention, bicarbonate buffering, and phosphate regulation reflect underlying tubular dysfunction, transporter downregulation, and hormonal maladaptation. Mechanistic AI can reveal the mechanistic basis of these imbalances rather than merely predicting laboratory derangements. This helps clinicians understand why abnormalities occur and how treatments such as potassium binders, diuretics, or bicarbonate therapy will affect underlying mechanisms.

Mechanistic AI In Dialysis And Extracorporeal Therapies

Dialysis involves complex fluid and solute transport across semipermeable membranes, influenced by blood flow, dialysate composition, membrane characteristics, and patient physiology. Mechanistic AI can integrate transport equations, hemodynamic models, and machine learning to optimize dialysis prescriptions. Conventional dialysis algorithms focus on target solute concentrations but do not account for patient specific mechanistic variables such as intracellular fluid shifts, intercompartmental gradients, and vascular refilling capacity.

Mechanistic AI can model these processes by representing solute transport through partial differential equations describing diffusion and convection. Machine learning components estimate patient specific transport coefficients, predicting how different dialysis prescriptions will influence plasma solute levels, blood pressure, and fluid shifts. This allows individualized optimization of dialysis duration, ultrafiltration rate, and dialysate composition.

Hemodynamic instability during dialysis is a major clinical challenge. Mechanistic AI can connect cardiovascular models with renal replacement parameters to predict when hypotension or intolerance may occur. This enables clinicians to

identify patients at risk and adjust therapy in advance. In continuous renal replacement therapy for critically ill patients, mechanistic AI can simulate the impact of therapy on acid base balance, solute clearance, and fluid dynamics while integrating real time vital signs.

Digital Twins For Kidney Function

Mechanistic AI supports the creation of digital twins for renal disease, which are personalized, computational replicas of an individual's kidney physiology. These twins integrate patient specific clinical data, imaging, laboratory values, and genetic information with mechanistic equations describing glomerular filtration, tubular transport, vascular regulation, and hormonal feedback. Machine learning updates the twin over time using new data, allowing continuous refinement.

Digital twins can simulate disease progression under different scenarios. For example, a twin for a patient with diabetic nephropathy could predict how changes in blood pressure control, glucose management, or use of specific medications might influence future decline. Similarly, in acute kidney injury, a twin could simulate the effects of different fluid management strategies, nephrotoxic drug exposures, or hemodynamic states. This allows clinicians to test potential treatments in silico before applying them in real patients.

Digital twins also offer insights into the mechanistic drivers of disease within a given patient. By analyzing parameter shifts, a twin can show whether progression is driven primarily by hyperfiltration stress, glomerulosclerosis, tubular injury, or vascular dysfunction. This helps tailor therapy to the patient's mechanistic profile rather than relying on generalized treatment algorithms.

Explainability And Trust In Mechanistic AI

The transparency offered by mechanistic AI is central to its clinical utility. Because these models encode physiological relationships, their predictions can be interpreted in terms of mechanistic variables such as filtration pressure, tubular transporter function, vascular resistance, and fibrotic signaling. Explainability techniques can highlight which pathways or parameters are most influential for an individual prediction. For example, a mechanistic AI model predicting worsening kidney function might reveal that increased glomerular pressure, elevated renin activity, and reduced tubular reabsorption efficiency are key drivers. Such insights help clinicians verify model reasoning and avoid automation bias.

Explainability is also critical for regulatory approval and clinical adoption. Mechanistic AI must demonstrate not only accuracy but also biological plausibility. Transparent alignment with established physiology makes mechanistic AI better suited for these requirements than purely statistical models.

Challenges And Future Directions

Despite rapid progress, mechanistic AI in renal diseases faces several challenges. Renal physiology is highly complex, and comprehensive mechanistic models require large numbers of parameters that are difficult to measure directly. Parameter identifiability is a challenge, requiring robust inference techniques. Data integration is another barrier, since renal disease data come from diverse modalities spanning several temporal and spatial scales. Efficient numerical methods are required to compute mechanistic AI predictions in clinically acceptable time frames. Validation across different populations and settings remains essential for generalizability.

Future research will likely focus on building unified models linking molecular, cellular, tubular, and nephron level processes into cohesive frameworks. Integration with wearable sensors and continuous monitoring could allow dynamic updating of digital twins. Mechanistic AI may also support personalized drug dosing by predicting how renal pathology affects pharmacokinetics and pharmacodynamics. Ultimately, mechanistic AI could become a foundational tool in precision nephrology, providing mechanistic explanations and personalized predictions that guide treatment and improve outcomes.

2. MECHANISTIC AI IN NEUROLOGICAL DISEASES

Background

Artificial intelligence (AI) is playing an important role in medicine by improving diagnostics, data analysis, and clinical decision-making. Topal et al. demonstrated that AI systems, particularly deep learning models, can rival human performance in key medical tasks such as image interpretation and pattern recognition, highlighting their potential to improve patient care. The need to adopt AI-driven innovations is urgent, especially in Alzheimer's disease, a progressive neurodegenerative disorder with a growing prevalence. The incidence and prevalence of Alzheimer's disease and other dementias increased by 147.95% and 160.84%, respectively, from 1990 to 2019, making early detection and effective interventions crucial. AI can be a valuable tool for advancing both research and clinical care in addressing the diagnostic and treatment challenges of Alzheimer's disease.

Artificial intelligence has transformed both diagnostic and therapeutic approaches to Alzheimer's disease. Recent studies show that machine learning (ML) and deep learning (DL) models can significantly enhance diagnostic accuracy when applied to neuroimaging, fluid biomarkers, and digi-

tal data. However, challenges related to validation and practical implementation remain.

Neuroimaging is one of the earliest areas of AI application. Several meta-analyses of deep learning models applied to MRI and PET scans report that deep neural networks and transformer-based models can distinguish Alzheimer's disease and mild cognitive impairment (MCI) with substantially higher sensitivity and specificity than many conventional statistical methods. Although these findings highlight the promising outcomes of AI applications in Alzheimer's research, many studies rely on idealized research cohorts, which may limit the generalizability of these systems.

AI has also been used to analyze speech, eye movements, gait patterns, and other digital biomarkers, which may detect subtle cognitive changes earlier than standard cognitive tests. Explainable AI techniques, such as SHAP and LIME, improve transparency by showing which features contribute most to a system's predictions. This enables clinicians to better understand the reasoning behind AI-generated results.

Prognostic models using machine learning have also shown promising outcomes. Studies indicate that these models can predict conversion from MCI to Alzheimer's disease and estimate rates of cognitive decline, particularly when longitudinal imaging and fluid biomarker data are included. However, external validation and standardized reporting remain essential, as inconsistent methods

currently hinder the reliability and comparability of AI-driven prognostic studies.

The use of AI in treatment is still evolving. Current studies suggest that AI can contribute by accelerating pharmacological research, optimizing patient selection for clinical trials, and identifying digital endpoints for non-pharmacological interventions. AI-based systems may also assist clinicians in making more informed decisions by recommending non-pharmacological interventions such as cognitive training and lifestyle modifications. However, because of the lack of large randomized trials, researchers emphasize that prospective validation is necessary to translate AI's potential therapeutic advantages into practical treatments.

Recurring concerns in the literature include the risk of bias due to small and unrepresentative study populations, limited testing on external datasets, data heterogeneity and interoperability challenges, and ethical issues related to privacy. To integrate AI tools into clinical settings, it is essential to establish standardized datasets, develop transparent AI models, and create appropriate regulatory pathways, while conducting large-scale trials to evaluate their real-world clinical effectiveness.

In conclusion, current research indicates that AI can improve diagnostic accuracy and has the potential to predict disease progression, enhance clinical trials, and support therapeutic discovery.

However, full adoption of AI in clinical practice requires rigorous validation, transparent and explainable outcomes, and strong evidence from large clinical trials demonstrating its clinical value.

Principles Of Mechanistic AI In Neurology

The foundation of mechanistic AI lies in its ability to connect computational learning systems with biological models that have explanatory power. In neurological diseases, this connection is established through several core principles. The first principle is constraint based integration. Biological systems are governed by physical laws and biochemical rules, such as energy conservation, molecular kinetics, and excitatory inhibitory balance within neural circuits. Incorporating these constraints within AI architectures allows the system to infer states and transitions that remain physiologically plausible. The second principle is multiscale modeling. The nervous system operates across levels from ion channels to large scale brain networks, and neurological diseases often exhibit pathology that spans these scales. Mechanistic AI incorporates multiscale representations, enabling models to track the consequences of molecular dysfunction up to behavioral manifestations. The third principle is causal interpretability. Unlike purely statistical deep learning, mechanistic AI seeks to identify cause

effect relationships, thereby providing an avenue for testable mechanistic hypotheses and clinical interventions.

One commonly employed strategy is the use of physics informed neural networks, which integrate differential equations representing phenomena such as membrane potential dynamics or blood flow regulation into neural network training. These networks do not simply fit observed data, but respect underlying physical laws during the learning process. For example, in modeling brain hemodynamics, equations derived from the balloon model of the vascular response can be embedded into a physics informed architecture to produce outputs that remain consistent with known relationships among neuronal activity, oxygen metabolism, and blood volume. Similarly, mechanistic AI can employ biophysical simulators such as the Hodgkin Huxley model for neuronal firing or neural field equations representing cortical waves, enhancing predictive stability and explanatory coherence. Another strategy involves hybrid dynamical systems, where mechanistic components are modeled by differential equations and unknown or unmodeled components are captured by neural networks. This combination provides a balance between interpretability and flexibility, allowing the AI to learn patterns that are difficult to describe mechanistically while preserving grounding in known physiology.

Mechanistic Modeling Of Neural Circuits And Brain Dynamics

Mechanistic AI in neurological diseases heavily relies on accurate models of neural circuits and brain activity. The brain's activity can be viewed as a high dimensional dynamical system composed of interacting neuronal populations governed by excitatory and inhibitory balance, synaptic coupling, and neuromodulatory influences. Conventional neuroimaging based machine learning models, such as those using functional MRI data, have achieved success in identifying biomarkers for conditions like Alzheimer's disease, epilepsy, and major depressive disorder. However, they largely remain statistical in nature. Mechanistic AI advances this by embedding biophysical models of neural interactions directly into learning architectures. The resulting systems can simulate how network dysfunctions lead to observable clinical and imaging signatures.

One compelling example lies in modeling resting state dynamics, which represent spontaneous activity patterns measurable through fMRI or EEG. Mechanistic AI can use neural mass or neural field models to represent the behavior of large scale cortical and subcortical networks, capturing how changes in connectivity or excitability reproduce disease specific signatures. For example, the emergence of hypersynchronous oscillations seen in epileptic seizures can be simulated through bi-

furcation analysis of coupled neuron models, with machine learning optimizing parameter identification for each patient. Such integration allows not only prediction of seizure risk but also insight into which circuit parameters drive transitions between normal and pathological states. Similarly, in disorders such as Parkinson's disease, mechanistic AI can combine data on neuronal firing from the basal ganglia with network models of motor control to explore how dopaminergic depletion alters oscillatory patterns and motor variability. This approach produces interpretable biomarkers that align with known neurophysiological mechanisms.

Another major application is in understanding neurovascular coupling and energy metabolism. Mechanistic AI can connect computational models describing blood oxygenation and flow with physiological observations from functional imaging. These models help explain changes in cerebral blood flow often seen in stroke, traumatic brain injury, or Alzheimer's disease. Instead of passively mapping abnormal patterns, mechanistic AI elucidates underlying processes such as impaired vasoreactivity, regional metabolic compromise, or capillary dysfunction. This capacity to simulate causal processes provides clinicians with a mechanistic understanding of neurovascular pathology that can inform targeted interventions.

Applications In Neuro-

degenerative Diseases

Neurodegenerative diseases offer an ideal domain for mechanistic AI because their pathogenesis unfolds over long timescales and involves well characterized biochemical and cellular interactions. In disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis, brain dysfunction arises from progressive molecular and cellular alterations, including protein misfolding, synaptic failure, neuroinflammation, and neuronal death. Mechanistic AI can incorporate such biological processes as coupled differential equations describing toxic protein kinetics, oxidative stress responses, or connectivity degeneration, while machine learning components fine tune model parameters based on patient data. This synergy allows prediction of disease progression, evaluation of therapeutic responses, and identification of patient specific mechanisms of decline.

In Alzheimer's disease, mechanistic AI has been used to model amyloid beta and tau propagation through brain networks. These models represent the spatial diffusion of pathogenic proteins along structural connectivity pathways, mathematically similar to epidemiological diffusion processes. Machine learning enhances these models by optimizing transport coefficients to match observed imaging or cerebrospinal fluid measures. By linking these parameters to cognitive outcomes, mechanistic AI creates interpretable trajectories explain-

ing how pathology progresses from microscopic aggregation to macroscopic network failure and cognitive decline. Furthermore, the integration of metabolic and inflammatory pathways into these frameworks provides a holistic picture of disease evolution. The same modeling philosophy applies to Parkinson's disease, where hybrid systems connect dopamine neuron loss in the substantia nigra to striatal network dysfunction and motor performance decline. By embedding physiological equations for dopamine dependent modulation and synaptic coupling, models can predict the impact of medication, deep brain stimulation, or disease progression under different assumptions of cellular damage.

Mechanistic AI also enhances drug discovery and therapeutic targeting in neurodegeneration. Classical drug response modeling relies on pharmacokinetic and pharmacodynamic equations, but these alone cannot capture the complexities of brain transport barriers and metabolic interactions. Integrating machine learning with physiologically based pharmacokinetic models enables accurate estimation of patient specific responses while maintaining mechanistic interpretability. For example, combining compartmental models of drug diffusion in brain tissue with neural network corrections trained on imaging and clinical outcomes allows prediction of effective drug concentrations at target sites. Such approaches can accelerate the design of treatment

strategies personalized to the patient's neurobiology.

Mechanistic AI For Epilepsy And Network Disorders

Epilepsy represents one of the earliest and clearest examples of a neurological disorder fundamentally governed by network dynamics. Traditional AI models in epilepsy have focused on seizure prediction based on EEG pattern recognition. Mechanistic AI extends this by connecting predictions to the underlying dynamical systems generating these patterns. Neural mass models, for example, describe how populations of excitatory and inhibitory neurons interact to produce oscillations. Incorporating these models into AI frameworks allows parameter inference directly from EEG data, transforming black box prediction into mechanistically grounded understanding. Such systems can identify which parameters, such as synaptic gain or coupling strength, are shifting toward thresholds that generate seizures.

Furthermore, mechanistic AI can simulate the effects of interventions. For instance, by integrating pharmacodynamic models describing the action of antiepileptic drugs on ionic currents, AI systems can predict how drug dosage or timing affects seizure thresholds in individual patients. Similarly, models of cortical excitability can inform noninvasive stimulation protocols aimed at stabilizing abnormal neural oscillations. These ap-

plications not only improve prediction accuracy but also provide actionable mechanistic insights guiding personalized therapy.

Epileptic brain networks can also be studied through structural and functional connectivity data obtained from diffusion MRI and functional MRI. Mechanistic AI connects these data with graph theoretical models and dynamic systems equations, allowing simulations of how structural damage or abnormal synaptic strengths lead to pathological synchronization. This mechanistically grounded interpretation supports clinical decision making about surgical resection or stimulation targets by predicting network level outcomes. The integration of such models across scales, from cellular excitability to whole brain connectivity, makes mechanistic AI a powerful tool for understanding network disorders.

Applications In Cerebrovascular And Demyelinating Diseases

Disorders such as stroke, cerebral vasospasm, and multiple sclerosis are characterized by vascular and structural changes that evolve over time. Mechanistic AI can capture the interplay between blood flow dynamics, tissue oxygenation, inflammation, and repair. In ischemic stroke, for example, hybrid models can represent perfusion deficits as partial differential equations describing mass transport and metabolic consumption, while AI components infer parameters such as diffusion

coefficients and tissue viability thresholds from imaging data. This integration can delineate the core infarct zone from the salvageable penumbra with improved precision and biological interpretability. The same principles can help forecast secondary injury mechanisms such as reperfusion hemorrhage, allowing clinicians to strategize time sensitive treatments.

In multiple sclerosis, mechanistic AI provides a framework to unify immune, cellular, and network perspectives. Disease models may combine equations describing demyelination and axonal degeneration with learning modules that assimilate MRI lesion data and clinical scores. These models can track the cumulative effects of immune activity, remyelination, and network reorganization, explaining why lesion load does not always correlate directly with disability progression. The capacity to simulate functional compensation and network plasticity gives mechanistic AI an advantage over purely correlational methods, offering a deeper understanding of ongoing processes within the central nervous system.

Neurodevelopmental And Psychiatric Disorders

While neurodegenerative disorders emphasize progressive tissue loss, neurodevelopmental and psychiatric conditions involve maladaptive neural circuit formation and plasticity. Mechanistic AI can contribute to these areas by modeling devel-

opmental trajectories of brain connectivity and neurotransmission. In autism spectrum disorder, attention deficit hyperactivity disorder, or schizophrenia, abnormalities often occur at synaptic and microcircuit levels, yet manifest as cognitive or behavioral outcomes observable at the macroscopic scale. Mechanistic AI uses computational models of synaptic plasticity, neuromodulatory balance, and hierarchical connectivity to explore how micro scale dysfunctions generate large scale phenotypes. By linking patient specific imaging and behavioral data with mechanistic simulations, AI systems can uncover candidate mechanisms underlying distinct clinical subtypes.

In psychiatric applications, mechanistic AI is particularly suited for modeling neurochemical dynamics involved in mood regulation, perception, and decision making. For instance, reinforcement learning models can be extended with mechanistic representations of dopaminergic and serotonergic signaling pathways to explain altered reward processing in addiction or depression. These models illuminate causal mechanisms that cannot be captured by conventional machine learning or statistical regression alone. The insights derived from mechanistic AI are essential for developing mechanistically targeted pharmacological and behavioral interventions.

Mechanistic Digital Twins For The Nervous System

Digital twins represent one of the most promising applications of mechanistic AI in neurology. A neurological digital twin is a virtual replica of an individual's brain that evolves dynamically according to both mechanistic models and real patient data. Such systems integrate neuroimaging, electrophysiological signals, genetic markers, and clinical observations into multiscale simulations of neural function. The mechanistic foundation could include biophysical models of synaptic transmission, network oscillations, or neurovascular dynamics, while machine learning components adapt the twin to the specific patient by optimizing parameters and updating with new data. These digital twins can simulate disease progression, test therapeutic scenarios, and predict outcomes under various interventions.

In neurocritical care, for example, a digital twin of a patient's brain could predict the impact of different ventilation or perfusion strategies on intracranial pressure and brain oxygenation, supporting personalized management. In degenerative diseases, a longitudinal digital twin could project future cognitive decline based on current metabolic and structural indicators, guiding therapeutic timing. The real power of these mechanistic twins lies in their ability to maintain interpretability: each prediction is grounded in a set of physiologically meaningful parameters and equations, allowing clinicians to understand and trust the reasoning behind recommendations. This para-

digm marks the evolution from descriptive AI systems to truly mechanistic and patient centered intelligence.

Explainability, Trust, And Ethical Implications

Transparency and interpretability are essential for the adoption of mechanistic AI in neurology. Even when models incorporate physiological knowledge, their hybrid architecture can remain partially opaque. Explainable AI methods must therefore bridge the gap between complex mathematical representations and clinically meaningful insights. Techniques such as sensitivity analysis, parameter attribution, and visualization of learned representations can highlight which features or mechanisms primarily drive a model's conclusions. For instance, identifying that changes in modeled synaptic coupling strength drive the predicted onset of seizure activity allows neurologists to validate results against established neurobiology.

Trust in mechanistic AI also depends on rigorous validation and ethical deployment. Because these models can influence critical medical decisions, especially in acute neurological care, developers must ensure that predictions are reproducible and unbiased. Bias can emerge from data imbalance, measurement error, or assumptions encoded in mechanistic equations. Comprehensive validation against multi institutional datasets and transparent publication of model architectures are vital steps toward trustworthy AI. Ethical challenges further include maintaining data privacy, obtaining informed consent for using patient data in training digital twins, and addressing the potential for automation bias among clinicians. Education and collaboration between AI developers and neurologists are therefore crucial for responsible integration of mechanistic AI into clinical workflows.

Challenges And Future Directions

Despite significant promise, multiple challenges hinder the full realization of mechanistic AI in neurological diseases. The first challenge is model complexity. The nervous system's nonlinear, high dimensional behavior makes it difficult to capture all relevant interactions within a tractable computational framework. Simplification must strike a balance between realism and generalizability. The second challenge is parameter estimation. Many mechanistic equations include parameters that are not directly measurable in humans and must be inferred from limited data. This process is computationally demanding and may result in non unique solutions without proper regularization or prior information. The third challenge involves data integration. Combining multimodal datasets such as MRI, EEG, and molecular biomarkers into a coherent mechanistic framework requires harmonization across temporal and spatial resolu-

tions.

Scalability and clinical translation are additional hurdles. Mechanistic AI systems must operate efficiently enough to provide real time or near real time guidance in clinical environments. Achieving this goal calls for advancements in numerical solvers, adaptive modeling techniques, and hardware acceleration tailored for hybrid AI computations. Moreover, regulatory pathways for approving such complex models remain underdeveloped, as traditional validation methods based on fixed algorithms do not easily apply to adaptive, data informed systems. Addressing these issues will require multidisciplinary collaboration among neuroscientists, engineers, clinicians, and policy makers.

Looking forward, research is likely to focus on several strategic directions. One is the development of unified frameworks that couple cellular mechanistic models with systems level network simulations, thereby spanning the full cascade from molecular events to cortical dynamics. Another is the refinement of patient specific digital twins that incorporate continuous data streams from wearable devices and remote monitoring, creating living models that evolve with the patient's condition. Integration of mechanistic AI with neuroscience oriented brain computer interfaces could enable real time feedback control for neuromodulation therapies. In neurodegenerative conditions, mechanistic AI may guide precision

pharmacology by predicting how genetic and metabolic variations influence disease progression and treatment efficacy. These advances point toward a future in which mechanistic AI becomes a central tool for understanding, predicting, and preventing neurological diseases through physiologically interpretable intelligence.

Conclusion

Mechanistic artificial intelligence represents a paradigm shift in the study and treatment of neurological diseases. By combining the explanatory depth of mechanistic modeling with the predictive power of machine learning, it enables a new level of understanding that connects data driven predictions with biological causation. From modeling network dynamics in epilepsy to simulating protein aggregation in neurodegeneration, mechanistic AI transforms fragmented insights into coherent mechanistic frameworks. It enhances interpretability, supports trust, and opens the door to personalized interventions guided by scientifically grounded reasoning. As computational capacity, data quality, and interdisciplinary collaboration continue to advance, mechanistic AI will likely redefine clinical neurology, transforming it from an observational science into a truly predictive and mechanistically informed discipline.

3. MECHANISTIC AI IN INFECTIOUS DISEASES

Background

Numerous pathogens continue to pose serious life-threatening risks to humans. Host–pathogen interactions trigger immune responses, yet pathogens often develop ways to evade these defenses. Major pandemics, such as the 1918 influenza outbreak and the HIV/AIDS pandemic identified in 1981, together caused an estimated 87 million deaths by 2020, demonstrating that medically significant viruses remain difficult to control despite ongoing advancements in vaccine development.

To better understand and manage large-scale infectious disease dynamics, mathematical and computational models have long been used to describe pathogen transmission and host–population interactions. For many years, mechanistic epidemiological models have served as foundational tools for representing disease processes based on key epidemiological principles, including population dynamics, herd immunity, and the effects of interventions. These models have been widely applied across numerous infectious diseases and played a central role during the COVID-19 pandemic, particularly in forecasting, scenario analysis, and shaping public health decisions.

However, their usefulness is limited by several challenges, such as strong dependence on accurate parameter estimation, reliance on oversimplified assumptions, inadequate integration of heterogeneous and real-time data sources, and intensive computational demands needed for calibration and validation—especially under rapidly changing epidemic conditions. The extensive use of mechanistic models during the COVID-19 crisis also revealed difficulties in timely calibration, transparency, and effective communication with decision-makers.

Because of these shortcomings, recent advances in artificial intelligence (AI), particularly in machine learning and deep learning, have been explored to complement mechanistic modeling. AI methods can analyze vast and complex datasets, infer time-varying parameters, and improve forecasting and calibration performance. Rather than replacing mechanistic models, integrated approaches that combine data-driven AI techniques with the explanatory framework of mechanistic modeling have demonstrated enhanced accuracy in infectious disease prediction, parameter estimation, and outbreak control. These hybrid models represent a potential path toward more adaptive, scalable, and informative epidemiological systems.

Mechanistic AI in infectious disease research refers to this class of integrated modeling approaches that merge data-driven artificial intelligence with mechanistic epidemiological models. These models learn from complex and heterogeneous data while maintaining biologically interpretable structures that describe disease transmission and host–population dynamics.

Mechanistic artificial intelligence in infectious diseases represents a rapidly advancing paradigm that merges machine learning with biological, epidemiological, and immunological models to understand how infections emerge, spread, evolve, and respond to interventions. Infectious diseases are shaped by complex processes including host pathogen interactions, immune responses, pathogen life cycles, genetic variability, environmental conditions, population structure, and behavioral patterns. Traditional machine learning models can detect patterns, predict probabilities, and perform classification tasks, yet they often do so without an underlying mechanistic rationale. This limits interpretability and reduces confidence among clinicians, epidemiologists, immunologists, and public health authorities who rely on understanding causality rather than correlations.
Mechanistic AI bridges these gaps by embedding structured biological knowledge into computational frameworks. Instead of learning only from data, mechanistic AI incorporates mathematical models that describe pathogen kinetics, transmission pathways, immune dynamics, pharmacokin-

etics and pharmacodynamics, and ecological interactions. These models constrain the training of machine learning components, ensuring that predictions remain physiologically plausible and consistent with known principles. As infectious diseases continue to impose global health challenges, mechanistic AI offers a pathway toward more accurate forecasting, personalized treatment, and mechanistic understanding that supports actionable decision making.

Mechanistic AI reflects a broader shift in computational medicine. It recognizes that infectious disease systems are nonlinear, multiscale, and often only partially observed. Purely data driven models struggle when data are sparse, noisy, or unrepresentative, which often occurs during emerging outbreaks. Mechanistic AI, by contrast, can infer latent variables such as viral load trajectories, immune response strength, transmission probabilities, or pathogen fitness landscapes even when direct measurements are unavailable. This opens new opportunities for guiding interventions, designing therapies, improving outbreak preparedness, and deepening scientific understanding of pathogenesis.

Principles Of Mechanistic AI In Infectious Diseases

Mechanistic AI in infectious diseases builds on several core principles. The first is the integration of mechanistic models with machine learn-

ing. Mechanistic models describe processes such as viral replication, bacterial growth, immune activation, antibody waning, or environmental survival using differential equations or stochastic rules. Machine learning algorithms then estimate unknown parameters, infer hidden states, or learn functional forms of poorly understood relationships. This hybridization allows the model to capture both known biological mechanisms and data driven patterns.

The second principle is adherence to biological constraints. Infectious disease processes must follow rules such as mass balance, conservation of virions or bacterial cells, and limits imposed by tissue resources. Mechanistic AI enforces these constraints during model training, which prevents biologically implausible predictions. This is especially important for safety critical applications such as predicting pathogen load under therapy, evaluating outbreak interventions, or estimating vaccine impacts.

A third principle is causal interpretability. Mechanistic AI identifies which biological pathways or epidemiological parameters influence outcomes. For example, if a model predicts that a patient with influenza is likely to progress to severe disease, mechanistic AI can identify whether viral replication rate, immune dysregulation, or secondary bacterial infection risk is driving this prediction. In population level modeling, mechanistic AI can specify whether transmission is being driven by

superspreading events, changes in mobility, or pathogen evolution. These explanations help align models with established scientific understanding and support confident decision making.

A fourth principle is multiscale modeling. Infectious diseases span processes from viral entry into a single cell to spread across entire populations. Mechanistic AI integrates models across these scales, connecting within host dynamics to between host transmission. For example, within host viral load trajectories influence contagiousness. Mechanistic AI can model both scales simultaneously, supporting more realistic forecasts and targeted interventions.

Finally, mechanistic AI relies on continuous updating. Infectious diseases evolve, immunity wanes, treatments change, and human behavior shifts. Mechanistic AI systems update parameters in real time as new data arrive, ensuring that predictions remain current. Digital twins of infected individuals or communities can evolve dynamically to reflect changing biological or epidemiological conditions.

Mechanistic Modeling Of Pathogen Replication And Host Response

A central domain of mechanistic AI is the modeling of within host infectious disease dynamics. Many infections follow characteristic patterns involving pathogen entry, replication, immune recognition, immune activation, peak pathogen bur-

den, and eventual clearance or persistence. Mechanistic AI represents these stages through equations describing pathogen population growth, immune cell activation, cytokine signaling, tissue damage, and drug interactions.

One of the most widely used mechanistic models is the target cell limited model, which has applications in viral infections such as influenza, SARS CoV 2, HIV, and hepatitis viruses. This model divides host cells into susceptible, infected, and virus producing compartments and describes transitions between these states. Traditional mechanistic models require fixed parameters, yet these parameters can vary widely between individuals. Mechanistic AI allows machine learning to infer patient specific parameters such as infection rate, viral production rate, and immune mediated clearance. This supports personalized predictions of disease severity, treatment response, and viral shedding.

Mechanistic AI can also model bacterial infections. Bacterial dynamics involve exponential growth, resource limitation, biofilm formation, quorum sensing, and immune evasion. Mechanistic frameworks can represent these processes through logistic growth equations, diffusion equations for nutrient transport, and models of neutrophil or macrophage responses. Machine learning enhances these models by estimating parameters in real time from clinical data such as laboratory values, imaging, and vital signs.

The immune response is another critical component. Immune models often include innate and adaptive components, describing processes such as interferon signaling, antibody generation, cytotoxic T cell activation, and cytokine release. In severe infections, immune dysregulation such as cytokine storms can occur. Mechanistic AI can simulate how early innate responses influence downstream adaptive immunity and disease resolution. It can also identify mechanistic signatures of severe disease such as delayed interferon response or excessive proinflammatory cytokines. This enhances risk stratification and supports personalized immunomodulatory therapy.

Mechanistic AI additionally incorporates tissue level models. For respiratory infections, models can describe viral spread in the airway, mucus layer dynamics, ciliary clearance, epithelial turnover, and alveolar immune interactions. In systemic infections, models may represent bacterial dissemination through the bloodstream, endothelial barrier disruption, or organ specific inflammation. Machine learning refines these models using imaging, biomarkers, and physiologic signals, allowing mechanistic inference that would otherwise require invasive sampling.

Mechanistic AI In Transmission And Epidemiology

Mechanistic AI extends beyond individual hosts to model infection spread across populations.

Classical epidemiological models such as susceptible exposed infectious recovered models describe transitions between states, but they often use fixed parameters and simplified structures. Mechanistic AI enriches these models through data driven parameter estimation, incorporation of additional heterogeneities, and integration with mobility, environmental, and genomic data.

Heterogeneity in contact patterns is a major challenge in infectious disease modeling. Mechanistic AI can incorporate network structures describing households, workplaces, transportation, and social interactions. Machine learning identifies clusters or communities with high transmission potential and learns how behavior changes influence contact rates. This supports targeted interventions such as vaccination of high risk groups or closure of specific settings.

Mechanistic AI can also model environmental transmission. Many pathogens spread through aerosols, droplets, surfaces, or water systems. Mechanistic models represent processes such as aerosol decay, airborne dispersion, humidity effects, or waterborne transport. Machine learning calibrates these models using environmental sensor data, outbreak investigations, and experimental measurements. This provides mechanistic insights into how environmental conditions influence spread.

Pathogen evolution is another important dimension. Mechanistic AI can represent mutation

processes, selection pressures, fitness landscapes, and competition between variants. Machine learning analyzes genomic sequencing data to estimate fitness advantages and predict which variants are likely to dominate. Mechanistic models can simulate interactions between immune escape, transmissibility, and virulence. This helps anticipate future waves and inform vaccine design.

Mechanistic AI also improves forecasting accuracy. Classical models struggle when data are scarce or when disease dynamics shift. Mechanistic AI incorporates mechanistic constraints that make predictions more stable. It also allows models to infer latent variables such as true infection incidence, asymptomatic rates, or immunity waning, even when direct measurements are lacking. Forecasts become grounded in biological realism and therefore more reliable during early outbreak phases.

Mechanistic AI And Antimicrobial Resistance

Antimicrobial resistance is shaped by interactions between pathogens, drugs, host immunity, and environmental factors. Mechanistic AI can model how antibiotics, antivirals, and antifungals influence pathogen populations through equations describing drug binding, bacterial kill rates, viral suppression, mutation emergence, and fitness costs associated with resistance.

Pharmacokinetic and pharmacodynamic models are central to understanding antimicrobial therapy. Mechanistic AI integrates these with machine learning to estimate patient specific parameters such as drug clearance, tissue penetration, immune synergy, or bacterial tolerance. This enables personalized dosing strategies that maximize efficacy while minimizing resistance selection.

Mechanistic models can also describe bacterial population heterogeneity. Persister cells, biofilm communities, and tolerant subpopulations require nonlinear modeling. Machine learning refines these models by identifying patterns in drug response data. This supports development of combination therapies and treatment regimens that target mechanistic vulnerabilities.

At the population level, mechanistic AI links antimicrobial use patterns with resistance spread. It can simulate how prescribing behaviors, infection control policies, and community transmission interact to drive resistance. This supports the design of stewardship strategies grounded in mechanistic understanding.

Mechanistic AI For Vaccine Modeling And Immune Memory

Vaccination involves complex processes including antigen presentation, B cell activation, T cell priming, germinal center maturation, memory formation, and antibody waning. Mechanistic AI can integrate these immunological processes with machine learning to predict vaccine effectiveness, durability, and protection against variants.

Mechanistic models can describe antibody kinetics using differential equations that represent production, decay, and affinity maturation. Machine learning calibrates parameters based on serological data. This allows estimation of when immunity wanes and when booster vaccinations might be necessary.

Mechanistic AI also supports evaluation of vaccine strategies. For example, it can simulate how dose spacing influences germinal center dynamics and memory formation. It can test scenarios such as targeting high transmission groups, older adults, or individuals with immune compromise. Because these models are mechanistic, they reveal why certain strategies outperform others.

Mechanistic AI is also valuable for understanding breakthrough infections. It can integrate within host and population level models to assess how variant properties such as immune escape affect protection. This helps guide updates to vaccine formulations.

Digital Twins In Infectious Diseases

Digital twins represent dynamic, personalized models of an individual's infectious disease state. Mechanistic AI supports digital twins by integrating within host dynamics, immune responses, drug interactions, and clinical data streams into a unified framework.

A digital twin for a patient with viral infection can simulate viral load trajectories, immune responses, and expected disease course. It can explore hypothetical interventions such as earlier antiviral therapy or immune modulation. These simulations provide personalized decision support.

For bacterial infections, digital twins can incorporate antibiotic pharmacokinetics and pharmacodynamics, resistance emergence, inflammatory responses, and tissue level pathology. Machine learning updates the twin using laboratory values, vital signs, and imaging, making the model increasingly accurate.

Digital twins can also be applied at the population level. Entire communities can have digital representations incorporating transmission networks, immunity profiles, and behavior. These models support real time outbreak response.

Explainability And Trust In Mechanistic AI For Infectious Diseases

Explainability is essential for clinical adoption of mechanistic AI. Because predictions derive from mechanistic pathways, the model can provide causal explanations. For example, if a mechanistic AI system predicts that an infection will worsen, it can identify whether this results from rapid pathogen replication, delayed immune activation, or inadequate drug concentration levels.

Explainability also applies to epidemiological predictions. Mechanistic AI can specify whether an expected rise in cases is due to increased transmis-

sion, waning immunity, or a more transmissible variant. This transparency supports informed public health decisions. Mechanistic AI aligns more closely with clinical reasoning than purely statistical models. Clinicians can evaluate mechanistic explanations against their own knowledge, strengthening trust and adoption.

Challenges And Future Directions

Mechanistic AI in infectious diseases faces several challenges. One challenge is parameter identifiability. Mechanistic models often contain many parameters that are difficult to estimate directly. Machine learning helps, but uncertainty must be rigorously quantified. Data availability is another obstacle. Infectious disease data come from diverse sources including clinical records, laboratory measurements, genomic sequencing, environmental sensors, and mobility traces. Integrating these multimodal data streams requires advanced statistical and computational approaches.

Computational complexity is another challenge. Simultaneously modeling within host dynamics, transmission networks, and evolution requires efficient algorithms. Advances in numerical solvers, neural differential equation methods, and scalable training frameworks will be critical.

Validation is essential. Mechanistic AI models must be validated across diverse populations, pathogens, and settings. Real world data, clinical trials, and experimental systems will play key

roles.

Future development will likely include deeper integration of genomics with mechanistic models. Pathogen evolution, host genetics, and immune diversity can all be incorporated into mechanistic AI. Another direction is the expansion of digital twins for personalized infectious disease management. These twins could evolve dynamically as new data are collected, offering continuously updated predictions.

Mechanistic AI may also support rapid response during emerging outbreaks. When little data are available, mechanistic constraints become invaluable. Mechanistic AI can provide early estimates of transmission, severity, and intervention effectiveness. It can also generate hypotheses about pathogenesis that guide early research.

As infectious disease complexity grows due to global interconnectedness, climate change, antimicrobial resistance, and pathogen evolution, mechanistic AI offers a robust, interpretable, and biologically grounded approach. Through its capacity to unify machine learning with mechanistic understanding, mechanistic AI has the potential to transform clinical care, epidemiology, immunology, pharmacology, and global health.

4. MECHANISTIC AI IN CARDIAC DISEASES

Background

Mechanistic artificial intelligence (AI) in cardiac diseases represents a transformative approach that integrates mechanistic models with advanced AI techniques to improve understanding of cardiovascular disorders. Historically, cardiac research has relied on mechanistic models such as electrophysiological models of the heart's electrical activity and hemodynamic models describing blood flow dynamics. These models provide a physics-based understanding of the heart's complex behavior. However, traditional mechanistic approaches often face challenges when scaling to large datasets or capturing the variability found across diverse patient populations.

In contrast, AI, particularly machine learning and deep learning, has significantly advanced diagnostic accuracy and predictive capabilities in cardiology. Yet, these data-driven models frequently function as black boxes, generating predictions without clear interpretability or mechanistic explanation.

Integrating mechanistic models with AI aims to address these limitations by combining the strengths of both approaches. Mechanistic AI

leverages the computational power of AI to process large and complex datasets while maintaining the physiological insights provided by mechanistic modeling. This combination has created new opportunities for advancing the diagnosis and management of cardiac diseases, from arrhythmias to heart failure, resulting in more accurate diagnostics, improved prognostication, and more personalized treatment planning.

Cardiovascular diseases remain the leading cause of death worldwide, increasing the need for more sophisticated diagnostic and therapeutic tools. Traditional diagnostic methods such as electrocardiograms, echocardiograms, and cardiac MRI remain essential, yet they require expert interpretation and may not always reveal the underlying disease mechanisms. Mechanistic AI can analyze these data sources more comprehensively, offering insights into underlying pathology that conventional methods might overlook. For example, AI models trained on electrocardiogram datasets can accurately predict arrhythmic events while incorporating mechanistic knowledge of ion channels, conduction pathways, and tissue characteristics to improve reliability.

Despite these promising developments, mechanistic AI in cardiology is still emerging, and several challenges must be addressed. One major obstacle is ensuring that mechanistic models are sufficiently detailed to reflect cardiovascular com-

plexity while remaining computationally efficient. Another challenge concerns model interpretability. AI systems must provide accurate predictions and also clarify the causal relationships between variables, which is essential for clinical decision-making. Additionally, regulatory requirements and concerns about transparency and reliability continue to limit adoption in clinical practice, especially in high-risk healthcare environments.

This review aims to explore the current landscape of mechanistic AI in cardiac diseases by outlining the most promising applications, methodologies, and challenges. It examines how AI is integrated with traditional mechanistic models to improve diagnosis, treatment, and patient outcomes. It also addresses key issues including model validation, ethical considerations, and regulatory pathways, offering direction for future research in this advancing field.

In conclusion, mechanistic AI has the potential to transform the diagnosis and treatment of cardiac diseases by uniting the strengths of mechanistic modeling with AI techniques. Although challenges remain, particularly in model interpretability and clinical integration, ongoing progress in AI, computational modeling, and data accessibility is likely to reshape our understanding and management of heart disease. Future work must focus on resolving current limitations and developing standardized methods for validating and

implementing these models in real-world clinical settings.

Mechanistic AI in cardiac diseases integrates advanced computational models with established cardiovascular physiology to improve predictive accuracy and interpretability. Artificial intelligence is increasingly poised to transform cardiovascular care and support personalized, precise interventions, but widespread clinical adoption requires models that are transparent and trustworthy. Traditional deep learning often functions as a black box, making it difficult for clinicians to trust its predictions. Mechanistic modeling approaches address this limitation by incorporating physical knowledge, such as hemodynamic equations or anatomical structure, directly into AI architectures, while explainable AI techniques aim to clarify the model's decision making.

One important approach is the use of physics informed neural networks and related hybrid models. These networks embed governing equations, such as the Navier Stokes equations for blood flow, into the training process, which effectively encodes the laws of fluid dynamics within the model. This enables AI systems to simulate cardiovascular phenomena such as pressure and flow fields with minimal labeled data, functioning as a fast surrogate for traditional computational fluid dynamics. These models can estimate hemodynamic variables that obey physical conservation laws even when empirical data are limited. By embedding domain equations and constraints, mechanistic AI ensures that outputs remain physiologically plausible and consistent with established cardiovascular science. Recent research also shows that physics informed neural networks can model cardiac electrophysiology in complex three dimensional geometries, estimate biophysical parameters from sparse data, and simulate responses to antiarrhythmic drugs, even under fibrillatory conditions.

Another major frontier is the development of cardiovascular digital twins, which are virtual patient specific hearts that integrate mechanistic simulations with individual clinical data. Contemporary digital twin models incorporate multimodal information such as imaging, electrophysiology, and genomic profiles into physics based simulations to create a physiologically accurate replica of a patient's heart. These in silico models allow clinicians to test treatment strategies and predict disease trajectories on a virtual platform, supporting personalized care planning. Importantly, digital twins are grounded in cardiac mechanics and hemodynamics. They are powered by mechanistic models that encode laws of motion, blood flow, and electrophysiology, with data driven components used for patient specific calibration. This integration of physiological knowledge with AI produces predictions that align closely with known disease mechanisms and re-

flect clinical understanding.

Ensuring transparency through explainable AI is equally essential. Even when physics based constraints are built into the system, complex AI components may remain difficult to interpret. Explainable AI methods aim to make the model's reasoning accessible by highlighting influential features, visualizing learned patterns, or mapping internal computations to clinically meaningful concepts. This level of interpretability is central to building clinical trust, and it is increasingly viewed as an ethical requirement for medical AI. For example, saliency based techniques applied to a cardiac risk model have identified the specific factors contributing to individual patient risk, offering mechanistic insight into the model's decisions. When these explanations are aligned with established cardiovascular knowledge, clinicians can validate the AI's reasoning and gain confidence in its recommendations.

Despite promising progress, several challenges must be addressed before widespread adoption can occur. Many mechanistic AI models have been evaluated only in simplified settings or small cohorts, and broader validation using real world clinical data is necessary to ensure generalizability. Although incorporating physics improves physiological plausibility, it does not guarantee that the model will perform consistently across all patient populations. Explainable AI methods also

require careful evaluation, as some studies apply XAI without verifying that the explanations are correct, which may create a false sense of reliability. Additionally, successful implementation in clinical practice will require intuitive user interfaces, clinician training, regulatory approval, and strong protections against bias and privacy risks. Overcoming these challenges is essential for transitioning mechanistic AI from early prototypes to dependable clinical tools.

Principles Of Mechanistic AI In Cardiac Diseases

Mechanistic AI in cardiac diseases rests on several fundamental principles. The first is adherence to physical and physiological constraints. Cardiac function follows known laws describing electrical conduction, myocardial tension, ventricular pressure volume relationships, coronary perfusion, and fluid dynamics. Mechanistic AI incorporates these laws into model structure, ensuring predictions remain physiologically plausible. This constraint driven approach prevents the biologically incorrect outputs that sometimes arise in unconstrained machine learning models.

The second principle is multiscale integration. Cardiac physiology spans molecular ion channels, sarcomere level contraction, tissue level electrical propagation, whole organ mechanics, vascular network hemodynamics, and systemic cardiovascular regulation. Mechanistic AI integrates these

scales through nested or coupled models. For example, electrical activation at the cellular level influences tissue level conduction, which shapes mechanical contraction patterns, which then determine pressure and flow generation. Machine learning calibrates each layer using data, allowing the model to reflect individual variability.

A third principle is hybrid modeling. Mechanistic AI systems frequently combine mechanistic equations with neural networks. In some cases, known physiological processes are represented explicitly using differential equations, while neural networks model unknown functions such as pathological remodeling, fibrosis progression, or autonomic dysregulation. This division of labor allows the model to remain interpretable while accommodating knowledge gaps.

A fourth principle is inference of latent variables. Cardiac diseases involve parameters that are not directly measurable, such as tissue conductivity, myocardial stiffness, or coronary microvascular resistance. Machine learning can infer these variables by observing their effects on measurable data such as imaging, electrocardiograms, or pressure curves. Mechanistic models constrain the inference so that latent variables remain physiologically meaningful.

Finally, mechanistic AI emphasizes explainability. Each prediction can be decomposed into its mechanistic components, revealing which variables and pathways drive the outcome. This supports clin-

ician trust and aligns with regulatory requirements for transparency.

Mechanistic Modeling Of Cardiac Electrophysiology

Electrical conduction is fundamental to cardiac function. It determines heart rhythm, synchrony of contraction, and susceptibility to arrhythmias. Mechanistic models of electrophysiology often use systems of differential equations describing ion channel kinetics, membrane potentials, action potential propagation, and tissue conductivity. These models build on classical frameworks such as Hodgkin Huxley type models and more advanced formulations like the Ten Tusscher or Courtemanche models.

Mechanistic AI enhances these electrophysiological models by estimating patient specific parameters. For example, machine learning algorithms can infer ion channel conductances, cell coupling strengths, or fibrosis induced conduction blocks using clinical electrocardiograms, intracardiac mapping, or imaging data. These parameters differ across individuals due to genetics, disease states, medications, and aging. Mechanistic AI provides a personalized electrophysiologic model capable of simulating arrhythmia initiation, conduction pathways, and response to antiarrhythmic drugs.

In atrial fibrillation, mechanistic AI can identify regions prone to reentry by simulating wave

propagation under different assumptions. Machine learning informs the model by learning structural remodeling patterns from imaging or mapping data. In ventricular tachycardia, mechanistic AI can determine circuits created by scar tissue. Personalized models enable prediction of ablation targets and outcomes. These models provide insights into why arrhythmias occur rather than merely identifying their presence.

Mechanistic AI also contributes to understanding conduction abnormalities such as bundle branch blocks, long QT syndrome, and Brugada syndrome. By integrating ion channel dynamics with genetic information and electrocardiographic signals, mechanistic AI can simulate how specific mutations or structural abnormalities alter electrical propagation. This supports personalized risk assessment and therapeutic planning, including device implantation or pharmacologic interventions.

Mechanistic Modeling Of Myocardial Mechanics

Myocardial contraction results from complex interactions between calcium dynamics, sarcomere cross bridge cycling, tissue elasticity, and ventricular geometry. Mechanistic models capture these processes using equations describing active tension generation, passive elasticity, fiber orientation, and ventricular wall motion. Finite element models allow representation of three dimen-

sional cardiac mechanics, incorporating deformation, stress, and strain under physiological loading conditions.

Machine learning enhances these models by estimating parameters that are difficult to measure, such as myocardial stiffness, contractility, and fiber orientation. Imaging modalities such as echocardiography, cardiac MRI, and CT provide data for parameter inference. Mechanistic AI can reconstruct patient specific mechanical models by relating observed motion patterns to underlying mechanical properties. This is valuable for conditions such as heart failure, myocardial infarction, cardiomyopathies, and valvular disease.

In heart failure with reduced ejection fraction, mechanistic AI can simulate how contractile dysfunction interacts with dilation, sympathetic activation, and fluid overload. It can estimate the relative contribution of contractility loss, ventricular stiffness increase, and geometric remodeling. In heart failure with preserved ejection fraction, mechanistic AI helps elucidate diastolic dysfunction, altered relaxation, and microvascular impairment. Personalized models can predict responses to therapies such as diuretics, afterload reduction, or device based interventions.

After myocardial infarction, mechanistic AI can model scar formation, border zone remodeling, and changes in ventricular geometry. Machine learning identifies patterns of strain and wall motion abnormalities that inform the mechanistic

model. This supports prediction of post infarction complications such as ventricular aneurysm, heart failure development, or arrhythmia risk.

Mechanistic AI In Hemodynamics And Circulation

Hemodynamics involves interactions between cardiac output, vascular resistance, arterial compliance, venous return, and autonomic control. Mechanistic models represent these interactions using equations governing pressure, volume, flow, and resistance. The cardiovascular system is often modeled as a closed loop system where changes in one component influence the others.

Mechanistic AI enhances these models by personalizing parameters using clinical data such as blood pressure, cardiac imaging, wearable sensor data, and hemodynamic measurements. This enables simulation of circulatory dynamics under different conditions including exercise, stress, dehydration, heart failure, or shock.

Coronary circulation requires special modeling because myocardial perfusion occurs primarily during diastole and is influenced by intramyocardial pressures. Mechanistic models represent coronary flow using equations describing pressure gradients, vessel compliance, microvascular resistance, and autoregulatory mechanisms. Machine learning calibrates these models using coronary angiography, perfusion imaging, or fractional flow reserve data. Personalized models can identify re-

gions of impaired flow, predict ischemic risk, and guide decisions about revascularization.

Mechanistic AI also models pulmonary circulation, which is important in conditions such as pulmonary hypertension, right heart failure, and congenital heart disease. Hybrid models that combine mechanistic representation of pulmonary vascular dynamics with machine learning can estimate pulmonary vascular resistance, compliance, and right ventricular afterload. These models help clinicians evaluate disease severity and choose appropriate interventions.

Mechanistic AI In Cardiac Imaging

Cardiac imaging provides rich spatial and temporal information about cardiac structure and function. Mechanistic AI integrates imaging with physiological models to extract more meaningful and interpretable insights.

In echocardiography, mechanistic AI can relate observed wall motion to underlying mechanical properties. Neural networks process raw images to identify boundaries, strain patterns, or motion fields, while mechanistic models translate these features into physiological variables such as stiffness, contractility, and pressure changes. This bridges the gap between imaging and physiology.

In cardiac MRI, mechanistic AI can use motion tracking, late gadolinium enhancement, and T1 or T2 mapping to identify fibrosis, inflammation, or myocardial edema. Mechanistic models

then simulate how these structural abnormalities affect mechanical function, electrical conduction, and perfusion. This integrated approach supports risk stratification in cardiomyopathies and prediction of arrhythmic risk.

Mechanistic AI also enhances CT based modeling of coronary arteries. Machine learning segments vessels and detects stenosis, while mechanistic models compute fractional flow reserve noninvasively, estimating whether a stenosis impairs blood flow. This provides functional assessment without invasive procedures.

Mechanistic AI In Heart Failure

Heart failure involves complex interactions between systolic function, diastolic function, neurohormonal activation, fluid balance, vascular tone, and comorbidities. Mechanistic AI integrates these processes into computational frameworks that can simulate patient specific trajectories.

One major application is modeling the transition from compensated to decompensated heart failure. Mechanistic models describe how the heart compensates for reduced output through sympathetic activation, renin angiotensin aldosterone system stimulation, ventricular dilation, and hypertrophy. Machine learning identifies patient specific thresholds where these compensatory mechanisms become maladaptive. Personalized predictions can forecast when a patient is at risk of acute decompensation, guiding early intervention.

Mechanistic AI can also simulate the effects of medications such as beta blockers, ACE inhibitors, angiotensin receptor blockers, SGLT2 inhibitors, and diuretics. By modeling pharmacokinetic and pharmacodynamic interactions with cardiovascular physiology, mechanistic AI can predict therapeutic response and optimize dosing. Digital twins of heart failure patients allow exploration of hypothetical scenarios such as adjusting medications, changing device settings, or modifying fluid intake.

Another application is device therapy. Mechanistic AI can simulate cardiac resynchronization therapy by modeling electrical activation and mechanical contraction patterns. It can identify patients likely to respond and suggest optimal lead placement. In patients with implanted devices, mechanistic AI can analyze device signals to detect early signs of deterioration.

Mechanistic AI In Coronary Artery Disease And Ischemia

Coronary artery disease involves plaque formation, stenosis, endothelial dysfunction, and microvascular impairment. Mechanistic AI can model blood flow through stenosed arteries using fluid dynamics equations. Machine learning processes imaging data to reconstruct vessel geometry, while mechanistic models compute pressure drops, flow limitations, and shear stress patterns.

Mechanistic AI predicts how a given stenosis will affect myocardial perfusion under rest or stress. It can simulate the effects of interventions such as stenting or bypass surgery. These simulations provide physiological interpretations that complement anatomical imaging.

Microvascular disease requires modeling of small vessel resistance, compliance, and autoregulation. Mechanistic AI combines physiological models with imaging and biomarker data to identify microvascular dysfunction, which is often missed in standard testing. This supports more accurate diagnosis of ischemia in patients without obstructive coronary artery disease.

Digital Twins In Cardiology

Digital twins represent personalized computational replicas of a patient's heart and circulation. Mechanistic AI supports digital twin creation by integrating individual imaging, electrocardiographic signals, hemodynamic measurements, wearable data, and laboratory values with mechanistic models describing electrophysiology, mechanics, and hemodynamics.

A cardiac digital twin can simulate disease progression, therapeutic responses, and hypothetical interventions. For example, in a patient with ventricular tachycardia, the twin can simulate ablation strategies. In heart failure, the twin can simulate medication adjustments. In coronary disease, it can simulate stenting outcomes. The twin

evolves as new data arrive, improving its accuracy over time.

Digital twins have potential in preventive cardiology as well. By simulating how lifestyle changes, blood pressure control, or lipid lowering affect long term outcomes, they support personalized prevention strategies.

Explainability And Clinical Trust In Mechanistic AI

Mechanistic AI enhances interpretability because predictions derive from physiologic relationships. When a model predicts development of heart failure, it can specify whether the driver is elevated filling pressures, impaired contractility, autonomic imbalance, or vascular dysfunction. In arrhythmia prediction, mechanistic AI can identify specific conduction pathways or regions of slow conduction. In ischemia evaluation, it can distinguish plaque related flow limitation from microvascular dysfunction.

This explanatory capacity aligns with clinical reasoning, making mechanistic AI more trustworthy for clinicians. It also aligns with regulatory expectations for transparency in medical AI systems.

Challenges And Future Directions

Mechanistic AI in cardiac diseases faces challenges, including high dimensional parameter spaces, data limitations, and computational com-

plexity. Parameter identifiability is a major issue because many mechanistic models contain numerous variables that influence outputs in similar ways. Robust inference techniques are required.

Data integration is also challenging because cardiac data come from diverse sources including imaging, wearable sensors, electrophysiologic recordings, genetic testing, and laboratory measurements. Harmonizing these data requires sophisticated pipelines.

Computational demands are substantial, especially for large scale simulations involving three dimensional mechanics or fluid dynamics. Advances in numerical solvers, neural differential equation models, and hardware acceleration will be important.

Despite these challenges, mechanistic AI is poised to transform cardiology. It will enable deeper mechanistic understanding, more precise diagnosis, personalized therapy, and predictive modeling of complex disease trajectories. As models become more refined and data become more integrated, mechanistic AI will support truly individualized cardiac care.

5. MECHANISTIC AI IN DERMATOLOGICAL DISEASES

Background

Mechanistic artificial intelligence in dermatological diseases is an emerging discipline that integrates machine learning with mechanistic models of skin biology, immunology, wound healing, barrier function, and dermatopathology. The skin is a complex organ composed of multiple layers, immune cell networks, microbiome structures, vasculature, and appendages such as hair follicles and sweat glands. It provides protection, regulates temperature, maintains hydration, and interacts continuously with the external environment. Dermatological diseases arise when these tightly coordinated processes fail due to genetic susceptibility, immune dysregulation, environmental exposures, metabolic disturbances, or infections. Because many dermatological disorders involve nonlinear biological feedback loops and multiscale interactions, models based purely on pattern recognition create challenges in interpretability and generalization.

Traditional machine learning has contributed significantly to dermatology, especially in the analysis of clinical photographs, dermoscopic images, histopathology slides, and segmentation tasks.

Machine learning systems can classify skin lesions, estimate malignancy risk, support triage of suspicious moles, and assist in diagnosing conditions such as melanoma, eczema, psoriasis, and fungal infections. However, these models rely solely on correlations present in the training data. They do not incorporate underlying biological mechanisms such as immune pathways, epidermal turnover dynamics, keratinocyte proliferation, melanocyte behavior, inflammatory signaling networks, or barrier integrity. As a result, traditional models struggle to explain their predictions, adapt to atypical presentations, or simulate disease progression.

Mechanistic AI offers a solution by integrating machine learning with computational models derived from dermatological physiology and immunology. Mechanistic models describe biological processes using mathematical equations, often differential equations, that represent keratinocyte dynamics, cytokine interactions, T cell activation, melanocyte behavior, wound healing cascades, and pathogen load. Machine learning enhances these models by estimating patient specific parameters, identifying hidden variables, learning unknown functions, and assimilating multimodal data such as imaging, laboratory tests, genomics, microbiome profiles, and clinical history. The result is a hybrid system that maintains biological plausibility while gaining predictive power and personalization.

In dermatology, mechanistic AI supports tasks that require understanding of underlying physiology rather than mere pattern recognition. These tasks include predicting flare ups, modeling immune responses to biologics, estimating wound healing rates, simulating skin barrier restoration, and forecasting treatment outcomes. Mechanistic AI also supports dermatological drug development by modeling pharmacokinetics and pharmacodynamics in the skin, predicting responses to topical therapies, and simulating molecular interactions. As the field advances, mechanistic AI is poised to provide clinicians with interpretable, personalized tools that deepen understanding of dermatological diseases while enhancing diagnosis and management.

Principles Of Mechanistic AI In Dermatological Diseases

Mechanistic AI in dermatology is grounded in several foundational principles that guide the integration of machine learning and biology. The first principle is biological fidelity. Skin physiology involves cellular turnover, immunological signaling, microbiome interactions, mechanical properties, hydration gradients, and wound repair pathways. Mechanistic AI incorporates these processes into model structures, preventing biologically implausible outcomes. For example, a mechanistic model ensures that keratinocyte proliferation respects homeostatic limits, that immune responses follow

known cytokine cascades, and that pigment production aligns with melanocyte biology.

The second principle is multiscale modeling. Dermatological diseases reflect interactions across molecular, cellular, tissue, and visible clinical scales. Psoriasis involves molecular level cytokines, cellular level keratinocyte proliferation, tissue level scaling, and clinical level plaque formation. Vitiligo involves melanocyte destruction, immune activation, pattern propagation, and visible depigmentation. Mechanistic AI links these scales through coupled models, while machine learning calibrates them using patient specific data.

A third principle is hybridization. Mechanistic equations represent known processes such as epidermal turnover, immune feedback loops, or wound healing rates. Neural networks model unknown or partially known processes such as environmental triggers, microbiome shifts, or patient specific sensitivities to allergens. This allows the model to remain interpretable while capturing complex data patterns.

A fourth principle is latent variable inference. Many important dermatological variables cannot be measured directly, such as barrier coefficient based hydration diffusion, melanocyte survival probability, or subclinical inflammation levels. Machine learning infers these hidden variables using observable data such as skin images, thermographic patterns, biomarker levels, or tran-

scriptomic profiles. Mechanistic models constrain the inference to ensure physiological plausibility.
A fifth principle is explainability. Predictions can be decomposed into contributions from mechanistic components. If a model predicts a psoriasis flare, it can attribute the cause to increased cytokine output, accelerated keratinocyte proliferation, microbiome imbalance, or barrier breakdown. This aligns with dermatological reasoning and supports clinician trust.

Mechanistic Modeling Of Skin Structure And Barrier Function

The skin barrier maintains hydration, protects against pathogens, regulates temperature, and prevents entry of toxins. Mechanistic models describe barrier function using equations for transepidermal water loss, lipid layer organization, corneocyte turnover, and stratum corneum hydration kinetics. These models incorporate diffusion equations, cellular proliferation rates, and biochemical interactions.
Machine learning enhances these models by estimating parameters such as barrier repair rate, corneocyte shedding rate, lipid composition variability, and hydration dynamics. Imaging modalities such as Raman spectroscopy, confocal microscopy, optical coherence tomography, and high resolution photography provide data for inference. Mechanistic AI can translate visible dryness or scaling patterns into underlying physiological

variables such as lipid deficiency, abnormal proliferation, or increased protein loss.
Mechanistic AI is particularly valuable in conditions like atopic dermatitis, where barrier dysfunction plays a central role. In atopic dermatitis, mechanistic models describe defects in filaggrin, increased permeability, immune activation, and microbial colonization. Machine learning analyzes imaging and biomarker data to estimate patient specific barrier integrity. Personalized models can forecast flare up risk, simulate the effects of moisturizers or topical steroids, and evaluate responses to systemic therapies.
Psoriasis also benefits from barrier modeling. Hyperproliferation leads to thickened epidermis and increased turnover. Mechanistic models describe the interplay between proliferation, differentiation, and desquamation. Mechanistic AI helps distinguish between subtypes of psoriasis, predict plaque evolution, and simulate response to biologics targeting cytokines such as TNF alpha, IL 17, and IL 23.

Mechanistic Modeling Of Immune Pathways In Dermatology

Dermatological diseases frequently involve dysregulation of immune pathways. Mechanistic models capture cytokine interactions, T cell differentiation, antigen presentation, and inflammatory feedback loops using systems of differential equations. These models describe how stimuli

activate immune cells, how cytokines propagate inflammation, and how regulatory mechanisms restore balance.

Machine learning enhances these models by integrating genomic data, proteomic signatures, microbiome profiles, and inflammatory markers. In diseases such as psoriasis, vitiligo, alopecia areata, atopic dermatitis, lupus, and hidradenitis suppurativa, mechanistic AI helps estimate individual variability in immune responses. It can quantify cytokine sensitivities, T cell activation thresholds, and regulatory deficiencies.

In psoriasis, mechanistic AI models the IL 23 IL 17 axis, keratinocyte mediated inflammation, and feedback between immune cells and skin cells. Machine learning calibrates the model using clinical severity scores, inflammatory biomarkers, imaging data, and genetic predispositions. Personalized models simulate treatment responses to biologics, predict flare durations, and evaluate alternative therapies.

In atopic dermatitis, mechanistic AI captures Th2 dominated immune responses, barrier dysfunction, microbial dysbiosis, and environmental triggers. Machine learning integrates transcriptomic data and skin microbiome profiles to refine mechanistic parameters. The model can simulate how moisturizers, immunomodulators, or biologics influence inflammatory pathways.

In vitiligo, mechanistic AI links melanocyte destruction with autoimmunity and oxidative stress.

It can simulate repigmentation patterns under phototherapy or topical treatments. Machine learning identifies patient specific responses to treatment, enabling personalized therapy selection.

Mechanistic Modeling Of Wound Healing

Wound healing is a complex multistage process involving inflammation, proliferation, angiogenesis, reepithelialization, and remodeling. Mechanistic models describe these stages using equations representing fibroblast activity, collagen deposition, keratinocyte migration, cytokine signaling, oxygen diffusion, and angiogenic responses.

Machine learning supports wound healing models by analyzing clinical photographs, thermography, imaging biomarkers, and sensor data. For example, machine learning can extract wound size, depth, tissue composition, and granulation status from images, providing inputs to mechanistic models.

Mechanistic AI is particularly valuable for chronic wounds such as diabetic ulcers, venous ulcers, and pressure injuries. Chronic wounds involve impaired immune response, reduced perfusion, sustained inflammation, microbiome shifts, and metabolic dysfunction. Mechanistic AI integrates these factors to predict wound healing trajectories. Personalized models can simulate the effects of interventions such as debridement, compres-

sion therapy, dressings, oxygen therapy, and skin grafts.

In surgical wound healing, mechanistic AI can predict dehiscence risk, simulate scar formation, and guide postoperative care. In burns, mechanistic AI can model fluid shifts, inflammatory cascades, and reepithelialization rates to guide treatment decisions.

Mechanistic AI For Pigmentary Disorders

Pigmentary disorders involve melanocyte biology, melanin synthesis, pigment transfer, and inflammatory interactions. Mechanistic models describe melanin production using equations representing tyrosinase activity, UV stimulation, oxidative stress, and melanocyte dendricity. They also capture melanocyte migration and survival.

Machine learning enhances these models by analyzing images for pigmentation patterns, extracting color distributions, and identifying subclinical depigmentation. Integrating genomic and transcriptomic data supports parameter estimation related to melanocyte health, immune activity, and oxidative stress responses.

Vitiligo benefits significantly from mechanistic AI. Mechanistic models describe autoimmune destruction of melanocytes, oxidative stress, cytokine mediated recruitment of immune cells, and repigmentation under therapy. Machine learning identifies patient specific features such as activity

level, trigger sensitivity, and depigmentation patterns. Personalized mechanistic models can simulate treatment outcomes under phototherapy, topical agents, or systemic immunomodulators.

Melasma also benefits from mechanistic AI by modeling hormonal influences, UV exposure, melanocyte hyperactivity, and dermal inflammatory pathways. Integrating mechanistic models with data from imaging, hormone levels, and UV exposure patterns supports personalized treatment planning.

Mechanistic AI In Skin Cancer

Skin cancer diagnosis and management rely heavily on pattern recognition from clinical and dermoscopic images, histopathology, and genomic testing. Mechanistic AI extends beyond classification by modeling tumor growth, invasion, angiogenesis, and interactions with the immune system. Mechanistic models describe tumor proliferation using growth equations, vascular supply models, and immune evasion mechanisms.

Machine learning processes dermoscopic images, histopathology slides, and molecular data to infer parameters related to tumor aggressiveness, proliferation rate, and microenvironmental interactions. Mechanistic AI creates patient specific tumor growth models that can forecast progression, estimate treatment response, and evaluate surgical or nonsurgical interventions.

In melanoma, mechanistic AI models complex be-

haviors such as vertical and radial growth phases, immune infiltration, and metastasis risk. Integrating genomic data reveals driver mutations and immunological vulnerabilities. These models can support decisions about immunotherapy, targeted therapy, and surgical margins.

In basal cell carcinoma and squamous cell carcinoma, mechanistic AI can simulate local invasion patterns, predict recurrence risks, and evaluate outcomes of topical therapies or photodynamic therapy. In rare skin cancers such as Merkel cell carcinoma, mechanistic AI can integrate viral, immune, and molecular models to support personalized treatment strategies.

Mechanistic AI And The Skin Microbiome

The skin microbiome influences barrier integrity, immune function, inflammation, and infection risk. Mechanistic models describe microbial growth dynamics, host microbe interactions, and competition between commensal and pathogenic organisms. Equations represent nutrient availability, immune pressure, diffusion of antimicrobial peptides, and bacterial signaling.

Machine learning analyzes sequencing data, metabolomic profiles, and imaging to infer microbial community structure. Mechanistic AI integrates these data to model interactions between microbes and the host. Conditions such as atopic dermatitis, acne, rosacea, hidradenitis suppurativa, and chronic wounds involve dysbiosis. Mechanistic AI can simulate how microbiome changes influence disease progression and predict the effects of treatments such as probiotics, antibiotics, or microbiome targeted therapies.

In acne, mechanistic AI models the interactions between Cutibacterium acnes, sebum production, inflammation, and follicular occlusion. Machine learning extracts patterns from images to estimate lesion types and severity. Personalized models can simulate responses to retinoids, antibiotics, and hormonal treatments.

In atopic dermatitis, mechanistic AI models the competition between Staphylococcus aureus and commensal bacteria, integrating immune and barrier models. Personalized predictions can guide antimicrobial or microbiome restoring treatments.

Mechanistic AI In Dermatopathology

Histopathology provides microscopic insights into tissue architecture, cellular organization, inflammation, and malignancy. Machine learning has achieved strong performance in classifying histopathology slides. Mechanistic AI goes further by integrating biological understanding of cell proliferation, immune infiltration, collagen remodeling, and angiogenesis.

Mechanistic models simulate tissue level interactions, while machine learning interprets micro-

scopic images, extracts structural features, and informs parameter estimation. These hybrid models can support diagnostics, grading, and treatment planning.

In inflammatory diseases, mechanistic AI captures T cell infiltration, cytokine patterns, and keratinocyte responses. In skin cancers, mechanistic AI models tumor architecture, stromal interactions, and invasion depth. In scarring disorders, mechanistic AI models fibrosis pathways and collagen deposition, supported by histopathology derived features.

Digital Twins In Dermatology

Digital twins provide personalized computational replicas of a patient's skin, incorporating imaging, biomarker data, immune profiles, microbiome compositions, and genomic information. Mechanistic AI powers these digital twins by integrating mechanistic models with data driven inference.

A digital twin of a psoriasis patient can simulate plaque evolution, treatment responses, and flare dynamics. A digital twin of a vitiligo patient can simulate repigmentation trajectories under phototherapy. A twin of a chronic wound patient can predict healing rates and optimal interventions. These models evolve over time as new data become available, becoming progressively more accurate.

Digital twins support personalized medicine, patient education, and clinical decision making.

They can evaluate hypothetical scenarios such as initiating therapy, adjusting doses, modifying skin care routines, or altering environmental exposures.

Clinical Explainability And Trust In Mechanistic AI

Mechanistic AI enhances interpretability by grounding predictions in physiological processes. When a model predicts a flare in atopic dermatitis, it can identify whether the driver is barrier dysfunction, immune activation, microbiome disturbance, or environmental exposure. When predicting wound healing delays, it can attribute them to perfusion deficits, excessive inflammation, or bacterial load. When assessing melanoma risk, it can explain how structural patterns relate to mechanistic tumor behavior.

This aligns with dermatological reasoning, supports clinical adoption, and meets regulatory requirements for explainability.

Challenges And Future Directions

Mechanistic AI in dermatology faces challenges including parameter identifiability, model validation, data heterogeneity, and computational complexity. Skin biology involves many interacting processes, making it difficult to identify parameter values uniquely. High quality multimodal data are needed for model calibration, including images, biomarkers, genomics, proteom-

ics, and microbiome profiles.
Computational demands increase for three dimensional models, stochastic immune simulations, and high resolution image analysis. Advances in numerical solvers, neural differential equation frameworks, and hardware acceleration will support progress.
Despite challenges, mechanistic AI is poised to transform dermatology. It will enable mechanistic disease insights, personalized therapy planning, prediction of flares and remission, simulation of treatment responses, and integration of biological and clinical data. Mechanistic AI represents a shift from pattern recognition toward causal modeling, offering a deeper and more holistic understanding of dermatological diseases.

6. MECHANISTIC AI IN CANCERS

Background

Over the last thirty years, significant progress in the detection, treatment, and clinical management of cancer has contributed to a 33% decline in overall cancer-related mortality. However, the incidence of many cancer types continues to rise, and cancer remains a major global health challenge.

Clinical oncology continuously generates an overwhelming volume of data from molecular assays, imaging studies, drug development research, and routine biological analyses. This creates challenges that cannot be adequately addressed using conventional statistical methods alone. Advances in molecular research and high-resolution imaging technologies have further expanded the scale and complexity of biological and clinical data. This rapid growth is shifting oncology toward a more data-driven approach and compelling researchers to identify meaningful patterns within large datasets while extracting clinically relevant insights. In recent years, machine learning and deep learning techniques have become increasingly widespread because of their strong ability to identify complex patterns in large datasets.

AI-based analytical tools provide a practical approach for analyzing biological network data.

These systems use computational models that simulate aspects of human reasoning, enabling them to perform classification, clustering, and predictive tasks on complex network structures without being overwhelmed by data volume or complexity. AI systems can analyze intricate gene-to-protein interactions that drive cancer development within large biological networks. Applying these methods can expand our understanding of tumor initiation and progression and help researchers identify novel therapeutic targets that have not yet been fully explored.

The complex and adaptive nature of cancer limits the effectiveness of single-agent therapies, as tumors frequently develop drug resistance. Combination therapies help address this issue by targeting multiple signaling pathways simultaneously, thereby reducing the likelihood of resistance and often improving therapeutic outcomes.

Tumor drug resistance continues to compromise treatment effectiveness and remains a persistent challenge in oncology. Artificial intelligence is increasingly being applied in research on tumor drug resistance and in efforts to improve treatment precision. It is also influencing the design of nanomedicine-based strategies aimed at overcoming resistance. These approaches can enhance targeting accuracy, improve tolerability, and reduce adverse effects, while also providing strategic guidance for rational drug combinations. Several research groups suggest that the integration of AI

technologies with nanoscale engineering will further advance precision medicine, offer practical strategies to address cancer drug resistance, and accelerate the rapid screening of novel intelligent materials.

AI has the potential to shift oncology toward a more proactive discipline that emphasizes early intervention, risk prediction, patient engagement in decision-making, and individualized treatment optimization rather than standardized treatment approaches. By maintaining a patient-centered focus and fostering collaboration between research laboratories and clinical settings, AI could move cancer care toward a more effective era characterized by precise data utilization, outcome-oriented planning, and broader clinical impact.

Drug discovery has traditionally followed a slow and costly pathway, progressing from initial target identification to regulatory approval over a period that often exceeds a decade. This lengthy process places substantial pressure on academic institutions and biotechnology companies. The application of AI to identify new therapeutic uses for existing drugs offers a more efficient strategy that may reduce both development time and overall costs.

Cancer is a highly complex, heterogeneous, and dynamically evolving disease shaped by multiscale interactions among genetic mutations, signaling pathways, tumor–microenvironment components, immune dynamics, and therapeutic

interventions. This biological complexity challenges conventional modeling approaches and requires computational frameworks that integrate mechanistic understanding with data-driven inference. Traditional machine learning and deep learning techniques have shown strong performance in identifying latent patterns within large molecular and imaging datasets, yet they frequently operate as black boxes with limited interpretability and weak connections to biological causality. In contrast, mechanistic models rooted in biophysics, pharmacology, and systems biology provide interpretable representations of tumor behavior, drug transport, and cell–microenvironment interactions, but they often struggle to address high-dimensional data and patient-specific heterogeneity. These complementary strengths and limitations have led to the emergence of mechanistic artificial intelligence, a hybrid paradigm that integrates biological theory with data-driven methods to improve prediction, personalization, and transparency in oncology.

Mechanistic modeling includes mathematical formalisms that span multiple biological scales. At the cellular and subcellular levels, ordinary differential equation models describe temporal changes in tumor burden, signaling dynamics, and pharmacologic responses. Partial differential equation models build on this by representing spatial heterogeneity, including invasion fronts,

diffusion-driven proliferation, and morphological patterning. Beyond the tumor itself, physiologically based pharmacokinetic models treat the body as interconnected compartments that represent organ-level physiology, enabling quantitative predictions of drug absorption, distribution, metabolism, and clearance. More recent mechanistic frameworks incorporate biophysical determinants such as extracellular matrix stiffness, mechanical stress, fluid dynamics, and mechanotransduction, all of which significantly influence tumor progression, immune evasion, and therapeutic resistance.

Although mechanistic models are transparent and biologically interpretable, they are often limited by uncertain or nonidentifiable parameters, incomplete understanding of tumor biology, and difficulty in capturing patient-specific and high-dimensional variation. Machine learning models, by contrast, can learn complex patterns from large omics, imaging, and clinical datasets but generally lack explicit mechanistic grounding and remain hard to interpret. This complementarity has motivated mechanistic learning, in which mechanistic and machine learning models are combined in a structured manner. Sequential coupling uses mechanistic outputs, such as growth or immune parameters, as inputs to machine learning models. Parallel coupling merges predictions from both model types. Extrinsic coupling uses machine learning to calibrate or extend mechanistic models. Intrinsic coupling embeds mechanistic equations directly within machine learning architectures.

Recent applications highlight the transformative potential of mechanistic AI. One example is a hybrid deep learning model that incorporates mechanistically derived tumor–immune parameters to predict time-to-event outcomes in patients receiving immune checkpoint inhibitors. This combined approach outperforms models based solely on clinical variables or mechanistic inputs, illustrating the value of mechanistic AI for precision immuno-oncology. Another example is the use of Bayesian methods to integrate mechanistic predictions with sparse clinical data to generate personalized forecasts of tumor growth in gliomas, ovarian cancer, and leukemia. These studies demonstrate how mechanistic priors can regularize machine learning models, improving generalization and biological plausibility. Intrinsic strategies such as physics-informed neural networks enforce consistency between deep learning predictions and known governing equations, ensuring that learned representations respect the biological and physical constraints of tumor growth. Additionally, deep learning imaging methods can infer tumor geometry, spatial heterogeneity, vascular architecture, and microenvironmental conditions, providing individualized initial conditions and inputs for mechanistic models. This bidirectional

flow of information, where machine learning informs mechanistic structures and mechanistic theory constrains machine learning behavior, creates a more biologically grounded predictive system. Mechanistic models also contribute to machine learning workflows by generating synthetic data, inferring unobserved biological states, or serving as digital twins, virtual patient models that continuously update to forecast therapeutic outcomes and support adaptive treatment strategies. Integrated platforms that incorporate machine learning-inferred omics associations into large mechanistic signaling models further highlight the ability of mechanistic AI to uncover previously unrecognized regulatory interactions relevant to cancer therapy.

These developments demonstrate that mechanistic AI is a promising approach for building cancer models that are more interpretable, more closely aligned with real biology, and more tailored to individual patients. Hybrid methods such as Bayesian combinations of mechanistic and statistical models, digital twins, and survival models that integrate mechanistic information already outperform approaches that rely solely on data-driven or purely mechanistic models. However, the field remains diverse and not yet unified, and significant challenges persist. These include parameter identification, integration of multimodal data, and translation of mechanistic AI methods into

clinical practice.

A powerful application of this mechanistic perspective is the prediction of effective combination therapies. The complexity and adaptability of cancer often necessitate shifting from single-agent treatments to synergistic drug combinations. Mechanistically explainable AI models have been applied successfully to predict such combinations, including the pairing of atezolizumab and cobimetinib in melanoma. By explicitly modeling biological interactions, these systems can explain why certain drug combinations are more effective, providing actionable insights rather than simple predictions.

Despite rapid progress driven by AI in cancer research, several challenges remain. Although complex AI models achieve impressive predictive performance, they can be prone to overfitting, and this issue is worsened by the limited availability of clinical data. To address concerns related to black box behavior and spurious correlations, researchers are working to improve model validation using advanced interpretability techniques. One example is the development of SemanticLens, an approach designed to map knowledge graphs onto neural network modules, enabling automated functional role annotation and identification of modules associated with spurious correlations. Such tools are essential for validating large-scale AI models. Future progress

in AI for cancer research will likely rely on further improvements in self-supervised and semi-supervised learning, as well as the continued advancement of three-dimensional Vision Transformer architectures.

Principles Of Mechanistic AI In Cancers

Mechanistic AI in oncology is built on several core principles. The first is physiological consistency. Tumors grow according to biophysical constraints that govern cell division, nutrient supply, metabolic demands, and diffusion of oxygen and drugs. Mechanistic AI incorporates these constraints directly into the model architecture, ensuring that predictions align with known principles of cancer biology. This reduces the risk of biologically implausible outputs, such as growth rates that exceed physical limits or treatment responses that contradict pharmacological laws.

The second principle is multiscale integration. Cancer is a disease that unfolds across multiple biological scales. Genetic mutations drive aberrant molecular signaling. These signaling networks regulate cellular behaviors such as proliferation, apoptosis, and differentiation. Populations of cells then form complex tissue structures influenced by mechanical stresses, extracellular matrix composition, and microenvironmental conditions. Mechanistic AI integrates these scales into unified models. Machine learning calibrates parameters at

each scale using genomic, proteomic, radiological, and clinical data.

A third principle is hybrid modeling. Mechanistic models represent well understood biological processes using mathematical equations. Neural networks model unknown functions or components for which mechanistic knowledge is incomplete. For example, while cell cycle regulation is mechanistically well characterized, tumor immune evasion strategies involve processes that are partially understood. Neural networks can approximate these unknown components while mechanistic elements anchor the model in established biology.

A fourth principle is latent variable inference. Key variables in oncology cannot be measured directly. These include tumor oxygenation status, cell cycle phase distributions, clonal composition, spatial heterogeneity, and drug penetration. Machine learning can infer these variables from external observations such as imaging features or biomarker levels. Mechanistic models restrict inference results to biologically valid ranges.

A fifth principle is interpretability. Mechanistic AI produces explanations grounded in biology. If a model predicts resistance to a therapy, it can identify whether the cause is increased efflux pump activity, hypoxia induced quiescence, reduced drug penetration, clonal evolution, or immune evasion. This interpretability supports clinician trust, enables hypothesis generation, and aligns with regu-

latory expectations.

Mechanistic Modeling Of Tumor Growth And Proliferation

Tumor growth is driven by cellular proliferation, nutrient availability, metabolic reprogramming, and interactions with the microenvironment. Mechanistic models often represent tumor growth using systems of ordinary or partial differential equations describing cell division, death, nutrient diffusion, oxygen concentration, and mechanical pressure. Common frameworks include logistic growth models, Gompertzian models, reaction diffusion models, and agent based models.

Machine learning enhances these models by integrating patient specific data from imaging, biopsy, circulating biomarkers, and genomics. Imaging modalities such as MRI, CT, PET, and ultrasound provide information about tumor size, shape, density, metabolic activity, and perfusion. Machine learning processes these data to estimate proliferation rates, necrotic fractions, hypoxic regions, and clonal architecture. Mechanistic models then simulate trajectories of growth under different physiological or therapeutic conditions.

Mechanistic AI can distinguish between indolent tumors and aggressive ones by identifying differences in proliferation dynamics. For example, prostate cancer often includes slowly growing tumors that may not require aggressive treatment.

Mechanistic AI can simulate long term growth trajectories to support clinical decision making. In contrast, aggressive tumors such as glioblastoma exhibit rapid growth, infiltration, and treatment resistance. Mechanistic AI can simulate invasion patterns, identify high risk regions, and predict response to surgery, radiation, and chemotherapy.

Mechanistic AI also provides insights into metastasis. Mechanistic models represent intravasation, circulation, extravasation, and colonization processes. Machine learning analyzes imaging and sequencing data to identify metastatic potential. Hybrid models simulate metastatic patterns and assess the effects of interventions that target dissemination pathways.

Mechanistic Modeling Of Tumor Metabolism And Hypoxia

Tumor metabolism is characterized by phenomena such as the Warburg effect, increased glycolysis, altered oxidative phosphorylation, and metabolic flexibility under stress. Mechanistic models describe these processes using equations representing glucose uptake, oxygen consumption, ATP production, lactate secretion, and enzyme kinetics.

Machine learning integrates metabolomic data, imaging biomarkers such as FDG PET uptake, and transcriptomic signatures to estimate metabolic parameters. Mechanistic AI can simulate how tu-

mors adapt to nutrient deprivation, hypoxia, or interventions that target metabolism.

Hypoxia is a key driver of treatment resistance, angiogenesis, and metastasis. Mechanistic models represent oxygen diffusion, consumption, and spatial gradients. Machine learning extracts hypoxia indicators from MRI, PET, or CT imaging. Personalized models estimate hypoxic burden and identify regions that may resist radiation or chemotherapy. These models support strategies such as hypoxia targeted therapy, dose painting in radiation therapy, or scheduling modifications to enhance treatment efficacy.

Mechanistic Modeling Of Angiogenesis And Vascular Dynamics

Tumors induce angiogenesis to secure nutrient and oxygen supply. Mechanistic models describe vascular network formation using equations representing endothelial cell migration, vessel sprouting, branching, regression, and perfusion. Models often incorporate VEGF signaling dynamics and oxygen dependent feedback loops.

Machine learning supports these models by analyzing imaging data such as contrast enhanced MRI, CT perfusion imaging, PET, and ultrasound. These data capture vessel density, perfusion, permeability, and flow patterns. Mechanistic AI integrates these features to estimate angiogenic activity, perfusion efficiency, and regional heterogen-

eity.

This is valuable in predicting response to anti angiogenic therapies. Personalized mechanistic models can simulate how treatments such as VEGF inhibitors alter vascular structure, perfusion, oxygenation, and drug delivery. These predictions help clinicians determine optimal dosing and combination strategies.

Mechanistic AI also models vascular normalization, a transient state where anti angiogenic therapy improves vessel structure and enhances drug delivery. Predicting the timing and magnitude of this window can optimize combination therapy with chemotherapy or immunotherapy.

Mechanistic AI In Tumor Immunology And Immunotherapy

Tumor immunology involves complex interactions between cancer cells, dendritic cells, T cells, macrophages, cytokines, and suppressive cells such as regulatory T cells and myeloid derived suppressor cells. Mechanistic models describe these interactions using systems of differential equations representing immune cell activation, proliferation, trafficking, exhaustion, and killing functions.

Machine learning integrates immunogenomic data, tumor infiltrating lymphocyte profiles, cytokine levels, and imaging features to calibrate these models. Mechanistic AI can simulate im-

mune responses to immunotherapies such as checkpoint inhibitors, CAR T cell therapy, cancer vaccines, and cytokine based treatments.

In checkpoint inhibitor therapy, mechanistic AI models PD 1 and CTLA 4 pathways, T cell exhaustion dynamics, and tumor antigen presentation. Machine learning identifies biomarkers of response such as mutation burden, neoantigen load, and immune infiltration patterns. Personalized models predict response likelihood, optimal dosing intervals, and potential toxicities.

In CAR T cell therapy, mechanistic AI can simulate CAR T cell expansion, trafficking, cytokine release, and tumor killing. It can forecast risk of cytokine release syndrome or neurotoxicity. It can also optimize CAR design by integrating mechanistic insights with machine learning predictions.

Mechanistic AI supports combination therapy planning by simulating how immunotherapy interacts with radiation, chemotherapy, or targeted therapy. These interactions often involve emergent behaviors, making mechanistic modeling essential.

Mechanistic Modeling Of Treatment Response And Resistance

Resistance to therapy is one of the most challenging aspects of oncology. Tumors adapt through genetic mutations, epigenetic changes, signaling pathway reprogramming, drug efflux, altered

metabolism, and microenvironmental changes. Mechanistic AI provides a framework for modeling these adaptation processes.

Mechanistic models describe pharmacokinetics, pharmacodynamics, cell cycle specific drug effects, DNA damage repair, and clonal evolution. Machine learning analyzes sequencing data, single cell profiles, imaging features, and biomarker trajectories to infer resistance mechanisms.

In targeted therapy, mechanistic AI can identify pathway reactivation, compensatory signaling, or mutations that confer resistance. In chemotherapy, mechanistic AI can model cell cycle phase specific killing and predict optimal scheduling. In radiation therapy, mechanistic AI can simulate DNA repair, hypoxic modulation, and fractionation strategies.

Mechanistic AI can evaluate adaptive therapy approaches that seek to control rather than eliminate tumors by exploiting evolutionary trade offs. Hybrid models simulate competition between sensitive and resistant clones, suggesting dosing strategies that maintain long term control.

Mechanistic AI In Radiology And Radiomics

Radiology plays a central role in cancer diagnosis and monitoring. Mechanistic AI integrates radiomics, which extracts features from images, with mechanistic models describing tumor

biology. Machine learning identifies patterns associated with proliferation, necrosis, hypoxia, and vascularity. Mechanistic models then contextualize these patterns within biological frameworks.

In MRI, mechanistic AI can interpret diffusion weighted imaging to infer cellular density, perfusion imaging to assess vascular function, and spectroscopy to evaluate metabolic status. In CT, mechanistic AI integrates information about density, heterogeneity, and structural features. In PET, mechanistic AI models tracer kinetics to estimate metabolic rates.

This integration enhances diagnostic accuracy, supports earlier detection of treatment response, and provides biologically grounded interpretations of imaging changes.

Mechanistic AI In Pathology And Histology

Histopathology offers detailed insights into tumor architecture, cell morphology, mitotic activity, stromal composition, and immune infiltration. Machine learning excels at analyzing whole slide images, identifying cancerous regions, grading tumors, and detecting subtle patterns. Mechanistic AI extends these capabilities by linking microscopic patterns with mechanistic processes.

Mechanistic models simulate cell population dynamics, cell cycle distributions, and interactions with the microenvironment. Machine

learning extracts features such as nuclear shape, spatial cell arrangements, and stromal patterns. Mechanistic AI connects these features with biological processes such as proliferation rate, treatment sensitivity, and invasion potential.

In breast cancer, mechanistic AI can link histopathology patterns to mechanistic models of hormone receptor signaling. In colorectal cancer, mechanistic AI can interpret invasive margin patterns using models of epithelial mesenchymal transition. In lymphoma, mechanistic AI integrates histology with immune cell dynamics.

Mechanistic AI In Cancer Genomics And Evolution

Cancer evolves through accumulation of mutations, chromosomal alterations, epigenetic changes, and clonal competition. Mechanistic models describe evolutionary dynamics using evolutionary game theory, branching processes, or stochastic models. Machine learning analyzes sequencing data to infer clonal architecture and evolutionary trajectories.

Mechanistic AI can simulate how treatment shapes clonal selection, predict emergence of resistant clones, and identify optimal strategies to delay resistance. It can model bottlenecks created by surgery, radiation, or targeted therapy. It can also evaluate combination therapy strategies that restrict evolutionary escape routes.

In precision oncology, mechanistic AI supports selection of targeted therapies based on mechanistic simulations informed by genomic alterations. It can evaluate synthetic lethality interactions and predict vulnerabilities unique to specific genetic backgrounds.

Mechanistic AI In Pharmacology And Drug Development

Mechanistic models of pharmacokinetics and pharmacodynamics describe absorption, distribution, metabolism, excretion, target binding, and downstream effects. Machine learning assists by analyzing drug response data, predicting toxicity, and identifying molecular features associated with efficacy.

Mechanistic AI can simulate dose response curves, optimize schedules, design combination therapies, and predict off target effects. It supports early stage drug development by identifying promising compounds and predicting their behavior in biological systems.

Mechanistic AI also supports design of personalized dosing strategies based on patient specific physiology, genetics, and tumor characteristics.

Digital Twins Of Cancer Patients

A digital twin in oncology is a computational replica of a patient's tumor and physiology. Mechanistic AI enables creation of such twins by integrating imaging, genomics, histology, biomarkers, and clinical data with mechanistic models of tumor growth, metabolism, and treatment response.

Digital twins can simulate disease progression, evaluate treatment options, predict resistance, and optimize therapy. They evolve over time as new data become available, improving accuracy. Digital twins support personalized medicine, clinical decision making, trial design, and patient education.

Interpretability And Clinical Trust In Mechanistic AI

Mechanistic AI enhances trust by grounding predictions in biology. It explains outcomes in terms of mechanistic pathways rather than opaque statistical patterns. Clinicians can view how variables such as proliferation rate, immune infiltration, drug penetration, or metabolic changes influence predictions. This interpretability supports adoption in clinical settings and aligns with regulatory expectations for transparency.

Challenges And Future Directions

Mechanistic AI in cancers faces challenges including high dimensional parameter spaces, data heterogeneity, model validation, and computational demands. Tumors are heterogeneous, requiring detailed multimodal datasets for accurate modeling. Parameter identifiability is often difficult because many biological processes interact.

Computational complexity increases for three dimensional simulations, agent based models, and stochastic evolutionary models.

Future directions include integration of single cell data, multiomics, wearable sensors, and remote monitoring systems. Advances in neural differential equations, physics informed neural networks, and high performance computing will enhance model scalability. As mechanistic AI continues to mature, it will support more precise, interpretable, and effective oncology care.

7. MECHANISTIC AI IN ORAL DISEASES

Background

Almost 50% of people worldwide are affected by oral disorders, indicating substantial socioeconomic and healthcare burdens. Current treatments for oral diseases such as dental caries, oral cancer, and periodontal disease often focus on managing symptoms rather than addressing the underlying causes.

There is an urgent need for advanced models to clarify the underlying mechanisms of these diseases and to develop more effective treatments, given their high prevalence and significant impact on overall health. Oral disorders present unique challenges because of the diversity of cell types involved. Conditions such as dental caries, oral cancer, and periodontitis involve complex pathological processes that are difficult to study using conventional two-dimensional cell cultures or animal models.

The availability of disease-related datasets has increased in recent years, creating opportunities to apply data-driven approaches to improve understanding of disease etiology. Oral organoids, which replicate the structure and function of oral tissues such as dental pulp, gingiva, and periodontal

ligament, have emerged as particularly valuable models. These systems enable the development of personalized medicine strategies and innovative therapeutic approaches.

However, the development and application of oral organoids face several challenges, including suboptimal construction strategies, labor-intensive image analysis, and the complex integration of multi-omics data. The incorporation of artificial intelligence has become a significant advancement in oral organoid research, enhancing our ability to interpret complex biological structures and design improved treatment strategies. AI technologies have been applied to analyze the high-dimensional data generated by organoid systems. These approaches facilitate a deeper understanding of the molecular mechanisms underlying oral diseases. AI-enabled organoids also improve the accuracy and efficiency of evaluating complex biological systems, strengthening diagnostic capabilities and expanding insight into disease mechanisms.

The human microbiota represents a dynamic and complex ecosystem composed of viruses, fungi, and bacteria that inhabit various anatomical niches of the body. This diverse microbial community interacts with the host through intricate cellular signaling pathways and influences numerous physiological processes, including immune system development, nutrient metabolism,

and regulation of inflammatory responses. These interactions have profound effects on human health and disease susceptibility. The oral microbiome is now recognized as playing a crucial role in maintaining oral health and in the development of several oral conditions, including oral cancer and periodontal diseases.

Identifying complex interactions between the oral microbiome and disease remains challenging and is sometimes overlooked. Machine learning, a major subfield of artificial intelligence, encompasses a broad range of computational methods. Machine learning algorithms can process complex microbial signatures, making them valuable tools in microbiome research, particularly in studies of host–microbe interactions. The capacity of artificial intelligence to manage high-dimensional and multidimensional datasets makes it well suited for extracting meaningful insights from microbiome data. Computational algorithms designed to analyze complex datasets can help researchers more accurately identify microbial patterns associated with disease.

Given the rapid advancement of artificial intelligence technologies, it is reasonable to expect that related publications in the field of dentistry will continue to increase.

Artificial intelligence has progressed from a theoretical concept in computer science to a practical set of tools integrated into contemporary

healthcare, including dentistry. Artificial intelligence systems already assist clinicians across many fields with image interpretation, decision support, and risk prediction. Recent narrative and systematic reviews in dentistry show similar growth, describing rapid expansion of deep learning and machine learning applications across radiology, restorative dentistry, endodontics, periodontology, and orthodontics.

The most advanced applications are in image-based diagnosis. Convolutional neural networks have been trained on periapical radiographs, panoramic images, and cone beam computed tomography (CBCT) to identify periodontal bone loss, apical pathology, and anatomical variations, often demonstrating performance comparable to that of specialists. Models for detecting caries now operate using bitewing radiographs, intraoral photographs, and even smartphone images, identifying both proximal and early enamel lesions. At the same time, plaque and gingivitis detection networks delineate biofilm in children or orthodontic patients, providing a more objective evaluation of local disease-related factors.

AI is increasingly used not only for diagnosis but also for predicting outcomes and risks. Researchers have developed machine learning models to predict outcomes of endodontic microsurgery, the likelihood of developing root caries, and the risk of new lesions in older adults. Other

studies generate risk scores for early childhood or adolescent caries based on behavioral, environmental, and genetic variables. Systematic reviews show that these algorithms often exceed the performance of traditional statistical models, although their real-world impact is limited by small, single-center datasets and inconsistent outcome definitions.

Most current dental AI systems function by identifying patterns within data. They move from pixels or feature vectors to labels such as “caries present” or “severe bone loss” without accounting for the biological mechanisms behind these conditions. This gap reduces interpretability, limits clinical usefulness, and complicates causal understanding. For example, caries risk models may detect correlations between microbiome profiles and lesions without considering the specific microbial communities, host responses, and dietary factors that contribute to demineralization. Similar concerns apply to periodontal models that classify radiographic bone loss without integrating inflammatory pathways, tissue remodeling, or mechanical loading.

Mechanistic artificial intelligence offers a potential path forward. This approach incorporates structured representations of disease processes, such as biofilm development, salivary buffering, enamel geometry, or immune signaling, into machine learning models. By combining biological

knowledge with data-driven inference, artificial intelligence systems can model how changes in microbiota, host immunity, or behavior influence the onset and progression of lesions. In caries research, this involves integrating microbiome meta-analyses with clinical and behavioral data to generate individualized disease trajectories rather than static risk scores. In periodontology, mechanistic frameworks may combine imaging-based assessments of bone morphology with models of immune dysregulation and occlusal forces to guide more personalized treatment planning.

Artificial intelligence the field advances, future work in dental artificial intelligence will require larger and more diverse datasets, standardized outcome measures, rigorous external validation, and careful consideration of privacy, bias, and interpretability. Artificial intelligence in dentistry has the potential not only to detect disease earlier but also to clarify why conditions develop and how they can be prevented or treated for each individual. This is becoming increasingly feasible as the field shifts from purely correlational systems to mechanistic, biologically informed models.

Foundations Of Mechanistic AI In Oral Biology

Mechanistic AI in oral diseases relies on combining biological models with machine learning algorithms. Mechanistic models represent biological

processes using mathematical equations derived from principles of physiology, microbiology, biochemistry, and tissue mechanics. In oral biology, such models may describe bacterial growth dynamics in dental plaque, mineral dissolution and remineralization of tooth enamel, inflammatory signaling in periodontal tissues, epithelial cell proliferation, or diffusion of nutrients and drugs through saliva and tissues.

Machine learning complements these models by analyzing large datasets to identify patterns and estimate parameters that are difficult to measure directly. For example, microbial interactions within dental plaque involve hundreds of bacterial species whose metabolic activities influence each other. Machine learning can analyze metagenomic sequencing data to estimate microbial interaction networks, while mechanistic models represent how these interactions affect acid production and biofilm structure.

One key concept in mechanistic AI is physiological constraint. Predictions generated by the model must remain consistent with known biological principles. For instance, enamel demineralization cannot occur without acid production and a drop in pH below critical thresholds. A mechanistic AI model therefore incorporates equations that describe these chemical processes, ensuring that predictions remain biologically plausible even when learning from data.

Another important concept is multiscale integration. Oral diseases arise from interactions occurring at molecular, cellular, tissue, and ecological levels. Genetic mutations influence cellular behavior. Cells interact with extracellular matrices and immune cells. Bacteria form complex biofilms that influence tissue health. Mechanistic AI integrates these layers by combining models that operate at different scales.

A further principle involves the inference of hidden variables. Many important biological states cannot be measured directly in clinical practice. Examples include local pH levels inside dental plaque, oxygen concentration in periodontal pockets, or molecular signaling activity within oral epithelial cells. Machine learning methods can infer these hidden variables from observable data such as imaging features, microbial composition, or clinical measurements. Mechanistic models then constrain these inferences according to biological laws.

Mechanistic AI models can also incorporate feedback loops that reflect real biological systems. For example, bacterial acid production reduces local pH, which in turn affects bacterial growth and enamel mineralization. Similarly, immune responses in periodontal tissues alter microbial communities, which further influence inflammation. Modeling these feedback mechanisms allows mechanistic AI systems to simulate disease dynamics over

time.

Mechanistic AI In Dental Caries

Dental caries is a biofilm mediated disease characterized by progressive demineralization of tooth structures due to acids produced by bacteria metabolizing dietary carbohydrates. Traditional caries risk assessment models rely on clinical observations, patient history, and simple scoring systems. While useful, these approaches do not fully capture the complex biological processes underlying caries development.

Mechanistic models of dental caries describe the chemical equilibrium between demineralization and remineralization processes in tooth enamel and dentin. These models include equations representing diffusion of acids and minerals, buffering capacity of saliva, and bacterial metabolism within dental plaque. Factors such as saliva flow rate, fluoride concentration, and dietary sugar intake influence these processes.

Machine learning algorithms can analyze data from radiographs, optical imaging devices, microbial sequencing, and patient records to estimate parameters within these mechanistic models. For example, deep learning models can detect early enamel lesions from bitewing radiographs. These imaging features can then be integrated into mechanistic models that estimate lesion progression rates based on mineral diffusion dynamics

and plaque acidity.

Mechanistic AI can also simulate the impact of preventive interventions. Fluoride treatments enhance remineralization by promoting formation of fluorapatite, which is more resistant to acid dissolution. Mechanistic models incorporate chemical reactions describing this process, while machine learning estimates patient specific variables such as saliva composition and plaque microbiota. This allows prediction of how fluoride therapies will influence lesion progression in individual patients.

Another important application involves dietary behavior modeling. Frequent sugar intake increases acid production by oral bacteria. Machine learning can analyze dietary logs, wearable sensor data, or behavioral patterns to estimate sugar exposure frequency. Mechanistic models then simulate how these exposures influence plaque pH dynamics and mineral loss over time. This approach supports personalized preventive strategies that account for both biological and behavioral factors.

Mechanistic AI In Periodontal Diseases

Periodontal diseases involve inflammatory destruction of the tissues that support teeth, including gingiva, periodontal ligament, cementum, and alveolar bone. These conditions arise from com-

plex interactions between microbial biofilms and host immune responses. While bacterial plaque initiates disease, tissue destruction results largely from dysregulated inflammation.

Mechanistic models of periodontal disease describe bacterial growth within periodontal pockets, immune cell recruitment, cytokine signaling, and bone remodeling processes. These models often incorporate equations representing osteoclast activation, collagen degradation, and inflammatory mediator diffusion.

Machine learning can analyze clinical periodontal measurements such as probing depth, bleeding on probing, and attachment loss, as well as radiographic bone levels. In addition, microbiome sequencing provides detailed profiles of bacterial communities associated with periodontal health or disease. Mechanistic AI integrates these datasets to estimate inflammatory activity and predict disease progression.

One important aspect of periodontal disease is its episodic nature. Tissue destruction does not occur at a constant rate but rather in bursts of activity followed by periods of stability. Mechanistic AI models can capture this dynamic behavior by incorporating feedback loops between microbial populations and host immune responses. Machine learning algorithms identify patterns in longitudinal patient data that signal transitions between stable and active disease states.

These models can also support personalized treatment planning. For example, scaling and root planing reduces bacterial load, while adjunctive therapies such as antibiotics or host modulation agents influence inflammatory pathways. Mechanistic AI can simulate how different interventions alter microbial ecology and immune responses in individual patients, helping clinicians choose optimal treatment strategies.

Mechanistic AI In Oral Cancer

Oral squamous cell carcinoma is the most common form of oral cancer and represents a major global health concern. Early detection significantly improves survival rates, yet many cases are diagnosed at advanced stages. Artificial intelligence has been applied to detect oral lesions from clinical photographs, histopathology slides, and imaging studies. Mechanistic AI expands these capabilities by modeling the biological processes underlying tumor development and progression.

Mechanistic models of oral cancer describe cellular proliferation, apoptosis, angiogenesis, metabolic changes, and genetic mutations. These models may incorporate signaling pathways such as epidermal growth factor receptor signaling, p53 regulation, and pathways controlling epithelial differentiation.

Machine learning analyzes multimodal datasets including genomic sequencing, transcriptomic

profiles, histopathology images, and radiographic scans. These data provide information about tumor heterogeneity, mutation patterns, and microenvironment characteristics. Mechanistic AI integrates this information to simulate tumor growth and predict response to treatments such as surgery, radiation therapy, chemotherapy, and immunotherapy.

Another key feature of oral cancer is field cancerization, where large areas of mucosa undergo genetic alterations that predispose them to malignant transformation. Mechanistic AI models can simulate how genetic mutations accumulate within epithelial cell populations and spread across tissue fields. Machine learning helps identify molecular signatures associated with high risk lesions, improving early detection strategies.

Mechanistic AI may also assist in predicting treatment toxicity and functional outcomes. For example, radiation therapy can damage salivary glands and oral tissues. Mechanistic models describing radiation effects on tissues combined with machine learning predictions based on imaging and clinical data can help optimize treatment planning to minimize complications.

Mechanistic AI In Oral Microbiome Research

The oral cavity hosts one of the most diverse microbial communities in the human body, containing hundreds of bacterial species as well as fungi and viruses. These microorganisms form complex biofilms on tooth surfaces, mucosa, and prosthetic materials. The composition and metabolic activity of the oral microbiome influence the development of many oral diseases.

Mechanistic models of microbial ecosystems describe interactions among species, nutrient utilization, metabolic byproducts, and environmental conditions such as pH and oxygen availability. These models often use systems of differential equations or ecological frameworks that represent competition and cooperation among microorganisms.

Machine learning analyzes high throughput sequencing data to identify microbial community structures associated with health or disease. However, purely statistical analysis may not reveal causal relationships. Mechanistic AI integrates sequencing data with ecological models to understand how microbial communities evolve over time and how they respond to environmental changes.

For example, in dental caries the balance shifts toward acid producing bacteria that thrive in low pH environments. Mechanistic AI models can simulate how dietary sugars, saliva flow, and fluoride exposure influence microbial composition. Similarly, in periodontal disease anaerobic bacteria dominate within deep periodontal pockets.

Mechanistic models describe oxygen diffusion and nutrient gradients that shape these microbial communities.

This integration supports development of targeted microbiome therapies such as probiotics, antimicrobial peptides, and ecological interventions that restore healthy microbial balance.

Mechanistic AI In Oral Tissue Engineering And Regeneration

Regenerative dentistry aims to restore damaged oral tissues including bone, periodontal ligament, dentin, and pulp. Advances in biomaterials, stem cell therapy, and tissue engineering have created new opportunities for regenerative treatments. Mechanistic AI can assist in designing and optimizing these therapies.

Mechanistic models describe cell differentiation, extracellular matrix formation, growth factor signaling, and scaffold degradation. These models simulate how stem cells interact with biomaterials and biological signals to regenerate tissues.

Machine learning analyzes experimental data from cell cultures, animal models, and clinical studies to estimate parameters and identify patterns associated with successful regeneration. Mechanistic AI can predict how variations in scaffold composition, growth factor concentration, or cell type influence tissue formation.

In periodontal regeneration, for instance, models may simulate interactions among osteoblasts, fibroblasts, and immune cells within regenerative scaffolds. Machine learning can analyze imaging and histological data to evaluate tissue formation. The integration of these approaches helps researchers design therapies that promote stable regeneration of periodontal structures.

Digital Twins In Oral Health

A digital twin in oral healthcare is a computational representation of an individual patient's oral environment. Mechanistic AI enables the creation of digital twins by integrating imaging data, microbiome profiles, clinical measurements, and lifestyle information into mechanistic models of oral biology.

Such digital twins can simulate disease progression and evaluate potential interventions before they are implemented clinically. For example, a digital twin could model how changes in oral hygiene practices, dietary habits, or fluoride use would affect caries risk over time. In periodontal disease, a digital twin could simulate responses to different treatment strategies and maintenance schedules.

Digital twins also support continuous monitoring of oral health. Data from smart toothbrushes, wearable sensors, and mobile health applications can update the digital model in real time. Mech-

anistic AI interprets these data within biological frameworks, providing personalized recommendations for prevention and treatment.

Challenges And Future Directions

Despite its promise, mechanistic AI in oral diseases faces several challenges. One challenge involves data integration. Oral health data are often fragmented across dental records, imaging systems, laboratory databases, and research datasets. Integrating these sources requires standardized data formats and interoperable systems.

Another challenge involves parameter estimation for mechanistic models. Biological systems often involve many interacting variables, and obtaining accurate measurements for all parameters is difficult. Machine learning methods help address this issue but require high quality datasets.

Computational complexity is also a concern, particularly when models incorporate spatial dynamics, large microbial ecosystems, or multiscale biological processes. Advances in computational methods and high performance computing will be necessary to make these models practical for clinical use.

Ethical considerations also arise when implementing AI in healthcare. Patient privacy, algorithm transparency, and equitable access to technology must be addressed to ensure responsible adoption.

Future developments will likely involve integration of multiomics data, advanced imaging technologies, and real time health monitoring systems. As mechanistic AI models become more sophisticated, they may transform dentistry by enabling predictive diagnostics, personalized prevention strategies, and optimized treatment planning.

Mechanistic AI represents a convergence of computational science, oral biology, and clinical dentistry. By combining mechanistic understanding with data driven learning, it offers a powerful framework for advancing knowledge and improving patient care in oral diseases.

8. MECHANISTIC AI IN ORTHOPEDIC DISEASES

Background

Orthopedic diseases encompass a wide range of disorders affecting bones, joints, muscles, tendons, ligaments, cartilage, and connective tissues. These conditions include osteoarthritis, osteoporosis, fractures, spinal deformities, sports injuries, inflammatory disorders, and degenerative musculoskeletal diseases. They represent some of the most common causes of disability, pain, and reduced mobility worldwide. The global burden of orthopedic diseases continues to grow due to aging populations, sedentary lifestyles, rising obesity rates, and increased physical demands from occupational and sports activities. Clinicians rely on imaging, physical examination, biomechanical assessments, laboratory testing, and patient history to diagnose and manage these conditions. However, musculoskeletal diseases often involve complex interactions among biological, mechanical, metabolic, and behavioral factors. Traditional diagnostic and predictive models struggle to fully capture the dynamic and multiscale nature of musculoskeletal pathophysiology.

Artificial intelligence has contributed significantly to orthopedic medicine by improving image

interpretation, risk prediction, and clinical decision making. Machine learning models have been developed for automated fracture detection from radiographs, prediction of osteoarthritis progression from magnetic resonance imaging, identification of osteoporosis from bone density scans, interpretation of gait data, and forecasting surgical outcomes. Although these systems have demonstrated high accuracy, they often operate as black box models that rely on statistical correlations rather than biological or biomechanical mechanisms. This limits their generalizability, interpretability, and usefulness in personalized care.
Mechanistic artificial intelligence integrates mechanistic models grounded in physics, biomechanics, and biology with data driven machine learning. This approach is particularly suited to orthopedic diseases because many aspects of musculoskeletal physiology are well described by physical laws. Bone remodeling follows mechanobiological principles that can be represented mathematically. Joint biomechanics depend on tissue geometry, mechanical loading, cartilage composition, and synovial fluid dynamics. Tendon and ligament function follows nonlinear viscoelastic properties. Fracture healing is governed by biological and mechanical processes that progress through inflammation, repair, and remodeling phases. Mechanistic models capture these processes through equations that represent tissue mechanics, cellular behavior, material properties,

fluid dynamics, metabolic activity, and structural adaptation.
Machine learning enhances mechanistic models by estimating unknown parameters, inferring patient specific states, integrating multimodal data, and identifying patterns that improve model accuracy. Combining these approaches results in predictive systems that align with biological and biomechanical principles while benefiting from the adaptability and pattern recognition capabilities of machine learning. Mechanistic AI in orthopedics holds promise for improving diagnosis, predicting disease progression, guiding rehabilitation, optimizing surgical planning, developing personalized implants, and advancing regenerative medicine.
The multiscale nature of orthopedic diseases makes them an ideal domain for mechanistic AI. At the molecular level, bone and cartilage tissues respond to biochemical signals and hormonal influences. At the cellular level, osteoblasts, osteoclasts, chondrocytes, fibroblasts, and immune cells contribute to tissue homeostasis and repair. At the tissue level, mechanical loading influences remodeling and degeneration. At the organ level, joints, bones, and muscles function as integrated biomechanical systems. At the whole body level, movement patterns, neuromuscular control, and behavioral factors affect musculoskeletal health. Mechanistic AI unifies these scales within frameworks that facilitate personalized predictions.

As digital health technologies evolve, orthopedic care is increasingly supported by wearable sensors, smart implants, three dimensional imaging, motion capture systems, and electronic health records. These data sources provide rich inputs for mechanistic AI frameworks. By integrating mechanistic modeling with machine learning, clinicians can move beyond descriptive assessments toward predictive and explanatory systems that optimize patient care.

Foundations Of Mechanistic AI In Musculoskeletal Biology

Mechanistic AI relies on mathematical representations of biological and biomechanical processes. In orthopedics, these processes include bone remodeling, cartilage degradation, synovial fluid flow, joint articulation, muscle mechanics, tendon loading, and fracture healing. Many of these processes have well established mechanistic bases that can be described using differential equations, finite element models, constitutive equations, or multiscale simulation frameworks.

Bone follows Wolff's law, which states that bone adapts its structure according to mechanical loads. Mechanistic models represent bone remodeling as a function of strain energy density, osteoblast and osteoclast activity, hormonal influences, and nutrient supply. These models capture how changes in loading during physical activity, injury, or disease affect bone density and strength.

Cartilage exhibits complex biomechanical behavior including viscoelasticity, fluid flow within the extracellular matrix, and depth dependent mechanical properties. Mechanistic models describe cartilage deformation under loading, nutrient diffusion within cartilage, and biochemical processes driving degradation in osteoarthritis.

Muscle function is governed by activation dynamics, force length relationships, force velocity relationships, and energy metabolism. Mechanistic models simulate these processes to understand muscle performance during movement and rehabilitation.

Tendons and ligaments display nonlinear stress strain behavior influenced by collagen organization and crosslinking. Mechanistic models simulate these properties to predict tissue strain and the risk of injury.

Machine learning contributes by analyzing large datasets to estimate parameters, identify unmeasured states, and refine model structure. For example, machine learning can infer patient specific loading patterns from gait data, wearable sensors, or imaging. These inferred states feed into mechanistic models that simulate tissue responses. Machine learning also integrates diverse data including genomics, metabolomics, clinical measurements, and patient reported outcomes.

Mechanistic AI systems can capture nonlinear feedback loops. For instance, altered gait due to pain affects joint loading, which accelerates car-

tilage wear, leading to further pain. Mechanistic models simulate these loops, and machine learning identifies patterns that signal transitions in disease state. This combination supports early intervention and personalized management.

Mechanistic AI In Osteoarthritis

Osteoarthritis is a degenerative joint disease characterized by progressive cartilage breakdown, subchondral bone remodeling, synovial inflammation, and changes in joint biomechanics. It is influenced by aging, genetics, mechanical factors, metabolic conditions, and injury history. Osteoarthritis develops over years or decades, making predictive modeling challenging.

Mechanistic models of osteoarthritis describe interactions between cartilage mechanics, biochemical degradation, and cellular responses. These models represent collagen fiber damage, proteoglycan loss, chondrocyte activity, and fluid flow within cartilage. They also incorporate mechanical loading from daily activities and joint alignment.

Machine learning can extract imaging features from radiographs, MRI, and three dimensional CT scans to estimate cartilage thickness, bone shape, and joint space width. Deep learning can detect early signs of degeneration such as subtle changes in cartilage texture or bone morphology. These imaging features inform mechanistic models that simulate cartilage stress, wear, and degradation

under different loading patterns.

Wearable sensors and gait analysis provide data on joint loading during movement. Machine learning can convert these data into biomechanical parameters such as joint reaction forces and shear stresses. Mechanistic models then use these parameters to simulate how altered loading accelerates or slows osteoarthritis progression.

Mechanistic AI can also evaluate the impact of interventions. For example, weight loss reduces joint loading. Physical therapy improves muscle strength and neuromuscular control. Orthotics and braces modify alignment and redistribute forces. Mechanistic models simulate how these interventions influence cartilage stress and biochemical responses. Machine learning identifies patient characteristics associated with positive outcomes. This combination enables personalized treatment planning.

Pharmacological treatments such as anti inflammatory drugs or disease modifying osteoarthritis drugs can be incorporated into mechanistic models that represent biochemical effects on inflammatory mediators and cartilage metabolism. Machine learning predicts which patients are most likely to benefit based on molecular and clinical data.

Mechanistic AI In Bone Diseases And Fractures

Bone diseases such as osteoporosis involve de-

creased bone mass and deterioration of bone microarchitecture. This increases the risk of fractures, which represent major causes of morbidity in older adults. Mechanistic AI can improve risk prediction, treatment planning, and fracture healing.

Mechanistic models of bone remodeling represent osteoblast and osteoclast activity, mineralization, and responses to mechanical loading. These models describe how hormonal changes, vitamin D levels, diet, and mechanical forces interact to influence bone density. Finite element models simulate bone mechanics under loading to estimate fracture risk.

Machine learning analyzes dual energy X ray absorptiometry scans, quantitative CT images, and clinical data to identify patterns associated with low bone density or microstructural deterioration. These patterns provide parameters for mechanistic models that simulate bone strength.

Mechanistic AI can generate patient specific fracture risk predictions. For example, bone density data combined with loading patterns derived from gait analysis can produce simulations of bone failure under various scenarios. This goes beyond traditional bone density metrics by incorporating biomechanics and tissue level properties.

Fracture healing also benefits from mechanistic AI. Healing involves inflammation, soft callus formation, hard callus formation, and remodeling. Mechanistic models represent biological processes

such as angiogenesis, cellular proliferation, and matrix deposition as well as mechanical processes such as callus stiffness and stability.

Machine learning integrates clinical data, imaging, and sensor data from smart implants to monitor healing progress. These data calibrate mechanistic models that predict healing trajectories. Mechanistic AI can detect delayed healing or nonunion earlier than traditional clinical assessments. It can also simulate the effects of weight bearing, fixation techniques, and biological therapies on healing.

Mechanistic AI In Spinal Disorders

Spinal disorders include degenerative disc disease, scoliosis, spinal stenosis, vertebral fractures, and inflammatory conditions. These disorders affect vertebral alignment, disc mechanics, nerve function, and musculoskeletal stability.

Mechanistic models of the spine represent disc biomechanics, vertebral loading, ligament tension, muscle forces, and neural structures. These models simulate how degeneration alters disc height, hydration, and mechanical properties. They also describe how changes in spinal curvature affect biomechanics.

Machine learning can analyze MRI, CT, radiographs, and motion data to estimate disc health, spinal alignment, and muscle function. These parameters feed mechanistic models that simulate disease progression. For example, in

scoliosis mechanistic models can simulate how asymmetric loading influences curvature progression. Machine learning identifies risk factors for rapid progression based on imaging and clinical data.

Mechanistic AI also supports surgical planning. Finite element models simulate how corrective surgeries alter spinal biomechanics. Machine learning predicts postoperative outcomes based on patient characteristics, implant design, and surgical technique. Mechanistic AI integrates these predictions to optimize surgical strategies and reduce complications.

Intervertebral disc regeneration and biologic therapies can be evaluated using mechanistic models describing cell behavior, matrix deposition, and mechanical stimulation. Machine learning analyzes laboratory and clinical data to identify patients who may respond to regenerative approaches.

Mechanistic AI In Tendon And Ligament Disorders

Tendon and ligament injuries are common in sports and occupational settings. These tissues exhibit nonlinear viscoelastic properties and have limited healing capacity. Mechanistic models simulate tendon strain, collagen fiber alignment, viscoelastic behavior, and response to loading.

Machine learning extracts features from ultrasound, MRI, and motion capture data to estimate

tissue properties such as stiffness and elasticity. These estimates calibrate mechanistic models that predict injury risk or healing outcomes.

Mechanistic AI can guide rehabilitation by simulating how different loading regimens influence tendon adaptation. Machine learning integrates wearable sensor data to track patient adherence and movement patterns. Mechanistic models simulate tissue response to rehabilitation exercises, providing personalized recommendations.

In ligament injuries such as anterior cruciate ligament tears, mechanistic AI can simulate joint stability under various conditions. Machine learning analyzes gait and sports movement data to identify risk factors for reinjury. These insights guide rehabilitation and return to sport decisions.

Mechanistic AI In Orthopedic Surgery And Implant Design

Orthopedic surgery relies heavily on biomechanics, imaging, and clinical expertise. Mechanistic AI can improve preoperative planning, intraoperative guidance, and postoperative monitoring.

Mechanistic models simulate joint mechanics, implant loading, bone remodeling around implants, and the stability of fixation devices. These models predict how implants will interact with patient specific anatomy and loading patterns.

Machine learning integrates imaging data, surgical records, and postoperative outcomes to identify variables that influence surgical success.

Mechanistic AI uses these insights to personalize implant selection and optimize implant positioning.

In total joint arthroplasty, mechanistic AI can simulate wear, implant loosening, and bone remodeling around the implant. Machine learning predicts failure risk based on patient characteristics and biomechanics. This integrated approach improves implant longevity and reduces complications.

Robotic assisted surgery can also benefit from mechanistic AI. Machine learning provides real time feedback from sensors and imaging, while mechanistic models ensure that robotic movements remain biomechanically optimal.

Mechanistic AI In Rehabilitation And Movement Analysis

Rehabilitation is essential for restoring function after orthopedic injuries and surgeries. Mechanistic AI can optimize rehabilitation by integrating biomechanics with data driven insights.

Mechanistic models describe musculoskeletal dynamics during movement. These models simulate muscle activation, joint forces, and tissue loading. Machine learning analyzes data from wearable sensors, motion capture, and electromyography to infer patient specific movement patterns.

The combined framework enables personalized rehabilitation plans. Mechanistic AI identifies harm-

ful loading patterns that may impede recovery. It simulates how corrective exercises influence biomechanics and tissue healing. Machine learning tracks progress and adapts recommendations in real time.

Mechanistic AI can also support fall risk prediction and balance training by analyzing gait stability and postural control.

Digital Twins In Orthopedic Medicine

A digital twin in orthopedics is a computational replica of a patient's musculoskeletal system. Mechanistic AI enables the construction of digital twins that integrate imaging, biomechanics, sensor data, and clinical records.

Digital twins can simulate disease progression, surgical outcomes, and rehabilitation response. For example, a digital twin of a knee joint can simulate cartilage wear under different gait patterns. A spinal digital twin can evaluate curvature progression in scoliosis. A bone digital twin can simulate fracture risk and healing.

Digital twins evolve as new data such as imaging or wearable sensor data are incorporated. Mechanistic AI interprets these data within the context of biomechanical and biological models. This continuous updating allows personalized monitoring and intervention.

Digital twins can also improve clinical trials by allowing virtual testing of therapies.

Challenges And Future Directions

Mechanistic AI in orthopedic diseases faces several challenges. One challenge is data integration across imaging, biomechanics, genomics, and clinical records. Standardized data formats and interoperable systems are needed.

Another challenge is parameter estimation in complex mechanistic models. Many biomechanical and biological parameters vary among individuals. Machine learning helps estimate these parameters but requires large high quality datasets.

Computational complexity is also a concern. Finite element models and multiscale simulations can be computationally intensive, limiting real time applications. Advances in computing and model reduction techniques are needed.

Ethical considerations include data privacy, transparency of algorithms, and ensuring equitable access to technology.

Future directions include integration of multiomics data, smart implants with real time sensing, advanced imaging modalities, and personalized regenerative therapies. Mechanistic AI will likely expand into sports science, occupational health, and preventive orthopedics.

As mechanistic AI evolves, it has the potential to transform orthopedic care by providing biologically grounded, personalized, and predictive models that support diagnosis, treatment, rehabilitation, and long term management.

9. MECHANISTIC AI IN OPHTHALMIC DISEASES

Background

Artificial intelligence has rapidly transformed ophthalmology, particularly through deep learning applications in imaging-based diagnosis and screening. Although conventional AI systems achieve high predictive accuracy, they are predominantly correlational and often function as black boxes. Mechanistic artificial intelligence represents an important evolution in the field, aiming to integrate data-driven learning with established biological, physiological, and physical models. For ophthalmology, a specialty deeply rooted in structure–function relationships, mechanistic AI offers a framework that helps explain not only what disease is present, but also why it occurs and how it progresses. Ophthalmic diseases encompass a wide spectrum of conditions affecting the eye and visual system, including disorders of the cornea, lens, retina, optic nerve, ocular surface, extraocular muscles, vasculature, and the neural pathways responsible for vision. These diseases include refractive errors, cataracts, glaucoma, age related macular degeneration, diabetic retinopathy, uveitis, inherited retinal disorders, retinal vascular diseases, ocular trauma, and neuro ophthal-

mic conditions. Visual impairment and blindness represent major global health burdens and are among the leading causes of disability worldwide. As populations age and chronic diseases become more prevalent, the incidence of ophthalmic disorders continues to rise. Early detection and personalized management are crucial for preserving visual function, preventing irreversible damage, and improving quality of life.

Traditional clinical decision making in ophthalmology relies on examinations using slit lamp imaging, fundus photography, optical coherence tomography, perimetry, ultrasound, angiography, visual acuity tests, and detailed patient histories. While these tools allow clinicians to detect abnormalities, ophthalmic diseases often progress through complex interactions between cellular biology, microvascular dynamics, biomechanics, neural degeneration, and metabolic processes. The eye is one of the most biologically and mechanically intricate organs in the human body. Small deviations in pressure, fluid dynamics, retinal metabolism, or neural pathways can lead to structural changes and functional deficits. Traditional statistical models and conventional AI techniques, although helpful in classification and image recognition, often lack the ability to capture causal processes and multiscale interactions underlying ophthalmic pathology.

Mechanistic artificial intelligence integrates

mechanistic models rooted in physiology, physics, biomechanics, and disease biology with machine learning models that extract patterns from data. This hybrid paradigm is well suited for ophthalmology because the eye's anatomy, optical properties, fluid dynamics, tissue biomechanics, neural responses, and molecular processes are well described through mathematical formulations. Mechanistic models can represent aqueous humor flow, retinal oxygenation, optical aberrations, phototransduction, neurovascular coupling, inflammatory cascades, extracellular matrix turnover, and biomechanical behavior of ocular tissues. Machine learning enhances these models by learning parameters from imaging, genomics, electrophysiology, and clinical measurements, enabling patient specific simulation and prediction.

The advantages of mechanistic AI in ophthalmology include improved transparency, explainability, better generalization beyond the training dataset, and the ability to make predictions based on biological principles rather than correlations. It enables personalized modeling of disease trajectories and treatment responses, which is critical in conditions such as glaucoma where optimal target pressure varies among patients, or macular degeneration where anti vascular endothelial growth factor treatment response differs substantially between individuals. Mechanistic AI contributes to early detection, risk prediction, optimized therapy

schedules, drug development, surgical planning, and digital twins of the eye and visual system.

The rest of this chapter expands on the principles, foundations, and applications of mechanistic AI across major ophthalmic disease categories, including glaucoma, retinal diseases, corneal and ocular surface disorders, cataracts, ocular biomechanics, neuro ophthalmology, and pediatric ophthalmic conditions. It also explores challenges, opportunities, and future directions in integrating mechanistic modeling with machine learning for superior ophthalmic care and research.

Foundations Of Mechanistic AI In Ocular Physiology And Vision Science

Mechanistic AI combines machine learning with explicit representations of underlying mechanisms. These mechanisms may include biochemical pathways, cellular interactions, tissue biomechanics, fluid dynamics, or neural signal processing. Instead of replacing mechanistic models, AI is used to estimate unknown parameters, learn residual behaviors, or adapt mechanistic formulations to patient-specific data. Unlike purely data-driven approaches, mechanistic AI is grounded in causality. For example, rather than directly predicting glaucoma progression from optic disc images, a mechanistic AI model may incorporate intraocular pressure dynamics, lamina cribrosa biomech-

anics, axonal transport disruption, and retinal ganglion cell loss. This hybrid structure allows predictions to be interpreted in terms of known disease processes.

Mechanistic models in ophthalmology rely on mathematical representations of the biological, optical, biomechanical, and neurophysiological processes that govern eye structure and function. These models describe how light interacts with ocular tissues, how fluids circulate within the eye, how mechanical forces act on tissues, and how neural circuits process visual information. Integrating these mechanistic models with machine learning enables development of predictive tools that combine biological insight with data driven adaptability.

The eye is governed by several key physiological systems. The optical system includes the cornea, lens, aqueous humor, and vitreous body. Mechanistic models describe how refractive surfaces bend light, how the corneal curvature and lens shape determine aberrations, and how age related changes such as lens stiffening affect accommodation. Ray tracing models simulate optical performance, while biomechanical models of the cornea and lens capture tissue deformation under intraocular pressure or external stimuli.

The aqueous humor circulation system regulates intraocular pressure and nutrient supply to avascular tissues. Mechanistic models represent aque-

ous humor production, trabecular outflow, uveoscleral outflow, and episcleral venous pressure. These models simulate how changes in outflow resistance lead to intraocular pressure elevation and optic nerve damage in glaucoma.

The retina and choroid involve neurovascular interactions, phototransduction, synaptic transmission, and metabolic activity. Mechanistic models describe photoreceptor dynamics, oxygen diffusion, vascular autoregulation, and retinal pigment epithelium functions. Retinal diseases often stem from dysregulation of these processes, making mechanistic modeling essential.

Machine learning complements mechanistic modeling by learning unknown parameters and integrating multimodal data. For example, deep learning can extract quantitative biomarkers from optical coherence tomography and angiography, providing estimates of retinal layer thickness, vascular density, or optic nerve head deformation. These data calibrate mechanistic models that simulate disease progression. Machine learning also uncovers hidden patterns in genomics, proteomics, and metabolomics that can refine mechanistic equations related to inflammation, oxidative stress, or angiogenesis.

Mechanistic AI systems can capture feedback loops. For instance, elevated intraocular pressure leads to optic nerve head deformation, which impairs axonal transport and causes retinal ganglion

cell death. This neural loss alters neurovascular interactions and influences retinal metabolism. Mechanistic models describe these interactions, while machine learning identifies patient specific risk patterns.

Mechanistic AI supports real time decision making by linking dynamic processes such as fluid flow, tissue mechanics, and neural activity with longitudinal patient data. As new imaging or sensor data become available, machine learning updates state estimates and parameters, enabling adaptive prediction. This integration lays the foundation for digital twins of the eye, which continuously evolve and provide personalized insights.

Multiscale Origins Of Ophthalmic Disease

Ophthalmic diseases typically arise from interactions occurring across multiple biological scales. Mechanistic AI is particularly well suited for modeling these multiscale processes.

Molecular And Genetic Mechanisms

At the molecular level, many eye diseases stem from genetic mutations, altered protein expression, and dysregulated signaling pathways. Examples include mutations in MYOC and OPTN in glaucoma, ABCA4 in inherited retinal dystrophies, and complement pathway dysregulation in age-related macular degeneration. These molecu-

lar abnormalities can initiate cascades of oxidative stress, inflammation, and metabolic dysfunction.

Mechanistic AI can incorporate gene regulatory networks and biochemical kinetics to model how molecular perturbations translate into cellular damage over time. Such models are valuable for understanding disease susceptibility and early pathogenesis, often before clinical signs become detectable.

Cellular And Tissue Level Pathophysiology

Cellular mechanisms such as apoptosis of retinal ganglion cells, dysfunction of the retinal pigment epithelium, pericyte loss in diabetic retinopathy, and endothelial cell activation are central to disease progression. At the tissue level, changes in extracellular matrix composition, basement membrane thickening, and altered biomechanical properties contribute to structural remodeling.

By integrating imaging data such as optical coherence tomography or OCT angiography with biophysical models, mechanistic AI can link observed structural changes to underlying tissue stress, deformation, or ischemia. This approach improves understanding of structure–function relationships and explains variability in disease progression among patients.

System Level And Neural

Mechanisms

Visual dysfunction often reflects system-level processes that extend beyond localized tissue damage. Retinal signal processing, optic nerve conduction, and cortical adaptation all influence functional outcomes. In conditions such as advanced glaucoma or optic neuropathies, functional loss may exceed what structural damage alone would predict.

Mechanistic AI can integrate computational models of retinal circuits and neural pathways with clinical data, enabling differentiation between primary ocular pathology and secondary neural plasticity. This is particularly relevant for understanding visual field loss and the potential for recovery.

Disease Specific Examples

In glaucoma, mechanistic AI models integrate pressure-related stress, optic nerve head biomechanics, vascular factors, and neurodegenerative pathways. These models help distinguish pressure-dependent from pressure-independent mechanisms and support personalized therapeutic strategies. In diabetic retinopathy, mechanistic AI links systemic metabolic dysregulation to retinal microvascular damage by modeling blood flow, oxygen diffusion, inflammation, and vascular endothelial growth factor signaling. This provides a more mechanistic interpretation of disease

severity and treatment response. In age-related macular degeneration, long-term interactions among lipid metabolism, oxidative stress, complement activation, and retinal pigment epithelium dysfunction can be simulated with mechanistic AI, offering insight into disease initiation and progression over many years.

Advantages And Limitations

The principal advantage of mechanistic AI is its interpretability and causal grounding. By embedding biological knowledge, these models improve generalizability, reduce reliance on large labeled datasets, and align more closely with clinical reasoning. However, limitations include incomplete mechanistic understanding, challenges in parameter estimation, and increased computational demands.

Conclusion

Mechanistic AI represents a significant shift in ophthalmology, moving the field from descriptive pattern recognition toward causal understanding of disease mechanisms and origins. By integrating biological principles with advanced AI methods, mechanistic AI provides a powerful tool for elucidating ophthalmic disease pathophysiology and advancing precision medicine in clinical practice.

10. MECHANISTIC AI IN OTHER DISEASES

Mechanistic AI In Emergency Medicine: Discovering Mechanisms And Origins Of Disease In The Emergency Department

Mechanistic artificial intelligence integrates data-driven learning with explicit representations of physiology, pathophysiology, or population-based dynamics. Unlike black box models, mechanistic AI encodes established scientific knowledge directly into the structural components of learning systems. These hybrid models are more data efficient, physiologically consistent, and particularly suitable for emergency medicine because they can generate interpretable and causal hypotheses about the mechanisms underlying acute disease presentations.

Emergency departments represent a unique and challenging environment for mechanistic AI. Patients arrive with diverse medical histories, variable triage data, rapidly evolving physiology, and an urgent need for potentially life-saving interventions. Traditional predictive models may estimate the risk of deterioration but often fail to explain why a patient is worsening or which underlying mechanisms are driving instability. Mechanistic

AI helps bridge this gap by linking predictions to physiological processes.

Sepsis is a well-studied target for artificial intelligence because it is time sensitive and pathophysiologically complex. Conventional AI models in emergency triage can estimate sepsis risk. Mechanistic AI extends this capability by modeling key pathophysiologic processes, such as hypovolemia or endothelial dysfunction, to inform differential resuscitation strategies. For example, it may support decisions between a fluid-first approach, early vasopressor initiation, or prompt source control, depending on the dominant mechanism of shock.

We propose several potential applications of mechanistic AI tailored to the emergency department setting.

1. Real Time Mechanistic Triage Digital Twin. A rapid, patient-specific digital twin could integrate triage data, initial diagnostic tests, and clinician notes. A physics informed neural network or neural ordinary differential equation lumped parameter model could infer latent physiological variables such as preload, systemic vascular resistance, cardiac output, and intrapulmonary shunt fraction. The emergency clinician would view not only a risk score but also a mechanistically classified profile, for example identifying a patient with predominantly low systemic vascular resistance who would benefit from early vasopressor initiation, with estimated volume responsiveness of 10 percent. The system could also present

counterfactual scenarios, such as projected clinical trajectories after administration of 1000 mL of crystalloid compared with initiation of norepinephrine at 10 micrograms per minute. This approach would support more targeted and mechanism-guided resuscitation.

2. Mechanism Aware Over Triage Management. Many emergency departments experience alert fatigue and inefficient resource utilization. Mechanistic AI could classify incoming cases according to the underlying emergency mechanism, such as rapidly progressive septic shock versus compensated heart failure. Emergency department protocols could then prioritize physician evaluation, dynamically allocate beds, and suggest tailored order sets based on mechanistic risk rather than solely on symptom severity.

Mechanistic AI in Autoimmune Diseases

Background

Autoimmune diseases comprise a diverse group of disorders in which the immune system mistakenly recognizes components of the body's own tissues as foreign and mounts an immune response against them. These diseases affect millions of individuals worldwide and include conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel

disease, autoimmune thyroid disorders, and systemic sclerosis. Although each disease manifests in different organs and tissues, they share fundamental immunological mechanisms including loss of immune tolerance, chronic inflammation, autoantibody production, dysregulated cytokine signaling, and tissue destruction. The complexity of autoimmune diseases arises from interactions between genetic predisposition, environmental exposures, microbial influences, epigenetic regulation, metabolic states, and immune network dynamics.

Traditional clinical approaches to autoimmune diseases rely on clinical examination, laboratory biomarkers, imaging, and histopathological findings to diagnose and monitor disease progression. Therapeutic strategies often include immunosuppressive medications, biologic therapies targeting specific cytokines or immune cells, and supportive treatments aimed at controlling symptoms and preventing organ damage. However, autoimmune diseases frequently follow unpredictable courses characterized by flare ups and remission phases. Patients with the same diagnosis can exhibit dramatically different disease trajectories, organ involvement patterns, and treatment responses. This heterogeneity makes accurate prediction and personalized therapy difficult.

Artificial intelligence has increasingly been applied to autoimmune disease research and clin-

ical care. Machine learning models analyze electronic health records, genetic data, imaging studies, and laboratory results to identify diagnostic patterns, predict treatment responses, and stratify patient populations. Deep learning models have demonstrated strong performance in recognizing radiologic features of inflammatory arthritis, detecting inflammatory bowel disease from endoscopy images, and predicting disease flares from clinical data streams. Despite these successes, conventional artificial intelligence systems typically rely on correlations within datasets rather than explicit representations of biological mechanisms. Many models function as black boxes that provide predictions without explaining how underlying biological processes drive the results. This limitation reduces trust in clinical settings and restricts the ability to generate mechanistic insights that could guide therapeutic innovation.

Mechanistic artificial intelligence offers a promising framework for addressing these limitations by integrating mechanistic models of biological processes with machine learning algorithms. Mechanistic models describe the causal relationships that govern immune responses, including cellular signaling pathways, cytokine networks, antigen presentation, immune cell migration, and tissue specific immune interactions. These models often rely on mathematical formulations such as differential equations, agent based simulations, or network models that represent the dynamics of

immune systems across molecular, cellular, and tissue scales. Machine learning methods complement these models by estimating unknown parameters, learning patterns from complex datasets, and refining predictions based on real world observations.

The integration of mechanistic modeling and artificial intelligence is particularly suitable for autoimmune diseases because immune systems operate through complex feedback loops and multiscale interactions. For example, autoreactive T cells may trigger cytokine cascades that recruit additional immune cells and amplify inflammation. Tissue damage releases additional autoantigens that further stimulate immune responses. Regulatory pathways attempt to suppress these responses but may fail due to genetic or environmental influences. Mechanistic models can represent these causal pathways explicitly, while machine learning algorithms analyze large biological datasets to identify patient specific variations in immune regulation.

Mechanistic AI can help explain why certain patients respond to targeted therapies while others do not, identify early biomarkers of disease onset, simulate immune responses under different therapeutic scenarios, and support development of precision medicine strategies. By linking mechanistic knowledge with data driven learning, this approach provides both predictive accuracy and

biological interpretability, which are essential for complex immunological disorders.

Foundations Of Mechanistic AI In Immune System Modeling

The immune system is composed of numerous interacting components including innate immune cells, adaptive immune cells, signaling molecules, regulatory pathways, and tissue specific microenvironments. Mechanistic modeling of immune processes has a long history in systems biology and immunology. Mathematical frameworks have been developed to represent antigen recognition, lymphocyte activation, cytokine signaling networks, immune cell proliferation, apoptosis, and migration between tissues. These models provide insights into how immune responses emerge from interactions between diverse biological components.

Mechanistic AI builds upon these frameworks by combining them with machine learning techniques that extract information from high dimensional biological datasets. Modern biomedical research generates massive amounts of data including genomic sequences, transcriptomic profiles, proteomic measurements, metabolomic signatures, and single cell sequencing results. In autoimmune diseases these datasets reveal complex patterns of immune dysregulation that vary among individuals. Machine learning algorithms analyze these datasets to identify relationships

that may not be evident through traditional statistical approaches.

In mechanistic AI systems, machine learning methods often serve several important roles. One role is parameter estimation. Mechanistic models frequently contain numerous parameters such as reaction rates, binding affinities, cellular activation thresholds, and migration speeds. Many of these parameters vary between individuals and are difficult to measure directly. Machine learning algorithms can infer these values from experimental and clinical data, allowing mechanistic models to represent patient specific immune dynamics.

Another role involves state estimation. Some biological variables such as concentrations of signaling molecules within tissues or activation states of immune cells cannot be directly observed in clinical settings. Machine learning models can infer these hidden states from observable data such as blood biomarkers or imaging findings. These estimates are then integrated into mechanistic models to produce more accurate simulations.

Machine learning can also improve mechanistic models by identifying missing interactions or nonlinear relationships within immune networks. For instance, if mechanistic equations fail to capture observed clinical patterns, machine learning can detect additional features that may represent previously unrecognized regulatory mechanisms.

These discoveries can guide refinement of biological hypotheses and experimental research.

Mechanistic AI models are often organized across multiple biological scales. At the molecular level they describe gene regulation and intracellular signaling pathways. At the cellular level they represent interactions between immune cells such as T lymphocytes, B cells, dendritic cells, and macrophages. At the tissue level they capture inflammation within organs such as joints, skin, intestines, or the central nervous system. At the systemic level they simulate immune cell circulation and interactions between organs. Integrating these scales allows mechanistic AI systems to capture the full complexity of autoimmune diseases.

Mechanistic AI In Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disease characterized by persistent inflammation of synovial joints, leading to cartilage destruction, bone erosion, pain, and functional disability. The disease involves complex interactions between immune cells, synovial fibroblasts, cytokines, and structural tissues within joints. Key mediators include tumor necrosis factor, interleukin six, interleukin one, and various chemokines that recruit inflammatory cells.

Mechanistic models of rheumatoid arthritis often focus on cytokine signaling networks and immune cell interactions within the synovial environment. Differential equation models represent how immune cells proliferate, secrete inflammatory mediators, and recruit additional cells to inflamed tissues. These models simulate feedback loops that sustain chronic inflammation.

Machine learning contributes by analyzing patient level data such as gene expression profiles, synovial biopsy results, imaging studies, and clinical outcomes. These analyses reveal molecular subtypes of rheumatoid arthritis that correspond to different immune pathways. Mechanistic AI combines these insights with mechanistic models to simulate disease progression for individual patients.

For example, machine learning may identify patients with high activity in the tumor necrosis factor signaling pathway. Mechanistic models can simulate how blocking this pathway with biologic drugs affects inflammatory dynamics and tissue damage. The integrated model can predict treatment response, optimal dosing schedules, and potential relapse risk.

Mechanistic AI also supports early diagnosis by identifying patterns that precede clinical disease onset. Autoantibodies and inflammatory biomarkers often appear years before symptoms develop. Mechanistic models simulate how immune tolerance breaks down over time, while machine learning detects early biomarker combinations as-

sociated with progression to clinical arthritis.

Mechanistic AI In Systemic Lupus Erythematosus

Systemic lupus erythematosus is a complex autoimmune disease characterized by production of autoantibodies against nuclear components, immune complex deposition, complement activation, and inflammation affecting multiple organs including kidneys, skin, joints, and the nervous system. The disease exhibits remarkable heterogeneity, with symptoms ranging from mild skin rashes to severe organ damage.

Mechanistic models of lupus often focus on B cell activation, autoantibody production, immune complex formation, and complement system dynamics. These models describe how self antigens stimulate B cells and T helper cells, leading to generation of autoantibodies that bind nuclear material released from dying cells. Immune complexes formed by these interactions trigger inflammatory cascades and tissue injury.

Machine learning analyzes large datasets including genomic risk variants, transcriptomic signatures, and proteomic profiles from patients with lupus. These analyses identify molecular signatures such as interferon pathway activation that play central roles in disease pathogenesis. Mechanistic AI integrates these molecular signatures into models that simulate immune responses in differ-

ent organs.

In lupus nephritis, mechanistic models describe immune complex deposition within kidney glomeruli and resulting inflammatory responses. Machine learning analyzes kidney biopsy images and laboratory data to estimate disease severity and predict progression. Combining these elements allows simulation of kidney inflammation under different therapeutic strategies.

Mechanistic AI may also help explain why certain therapies such as interferon inhibitors benefit only subsets of patients. By simulating immune network dynamics in individuals with different molecular profiles, these models can identify patient groups most likely to respond to specific interventions.

Mechanistic AI In Multiple Sclerosis

Multiple sclerosis is an autoimmune disease of the central nervous system characterized by immune mediated destruction of myelin sheaths surrounding nerve fibers. The disease leads to neurological symptoms including visual disturbances, motor weakness, sensory deficits, and cognitive impairment. Immune cells infiltrate the brain and spinal cord, causing inflammation, demyelination, and neurodegeneration.

Mechanistic models of multiple sclerosis describe interactions between T cells, B cells, microglia, and oligodendrocytes within the central nervous

system. These models simulate how autoreactive lymphocytes cross the blood brain barrier, trigger inflammatory responses, and damage myelin producing cells. They also represent processes of remyelination and neurodegeneration.

Machine learning contributes by analyzing brain imaging data such as magnetic resonance imaging, which reveals lesions associated with demyelination. Deep learning models detect subtle imaging patterns that indicate early disease activity. Mechanistic AI integrates these imaging features with immune system models to simulate disease progression.

These integrated models can predict relapse probability, progression to secondary progressive disease, and response to disease modifying therapies. Mechanistic simulations also help evaluate potential therapies aimed at promoting remyelination or reducing neuroinflammation.

Mechanistic AI In Inflammatory Bowel Disease

Inflammatory bowel disease includes Crohn disease and ulcerative colitis, which involve chronic inflammation of the gastrointestinal tract. These diseases arise from interactions between genetic susceptibility, immune dysregulation, gut microbiota composition, and environmental factors.

Mechanistic models of inflammatory bowel disease represent immune responses within intes-

tinal tissues, including interactions between epithelial cells, dendritic cells, macrophages, and T lymphocytes. These models also capture effects of microbial metabolites and microbial community structure on immune activation.

Machine learning analyzes microbiome sequencing data, dietary patterns, metabolomic profiles, and clinical outcomes. These analyses identify microbial signatures associated with disease activity. Mechanistic AI integrates microbial dynamics with immune response models to simulate intestinal inflammation.

This approach can predict disease flares, evaluate the effects of dietary interventions, and optimize treatment strategies including biologic therapies targeting tumor necrosis factor or integrin pathways.

Digital Twins And Personalized Immunology

One of the most promising applications of mechanistic AI in autoimmune diseases is the development of digital twins of the immune system. A digital twin is a computational representation of an individual patient that integrates clinical data, molecular profiles, and mechanistic models to simulate disease behavior over time.

In autoimmune diseases, a digital twin may include models of immune cell dynamics, cytokine signaling pathways, genetic risk factors, and tis-

sue specific inflammation. Machine learning continuously updates model parameters using new data such as laboratory tests, imaging studies, and wearable sensor data.

Clinicians can use digital twins to simulate treatment scenarios and predict outcomes before implementing therapies in real patients. For example, a digital twin could simulate how a patient with rheumatoid arthritis might respond to different biologic therapies or how changes in medication dosage could influence disease activity.

Digital twins could also assist in drug development by enabling virtual clinical trials. Researchers can simulate treatment responses in large populations of digital patients, reducing costs and accelerating development of new therapies.

Challenges And Future Directions

Despite its promise, mechanistic AI in autoimmune diseases faces several challenges. High quality longitudinal datasets are needed to accurately train and validate models. Integrating diverse data types such as genomics, imaging, and clinical records remains technically complex. Mechanistic models of immune systems are inherently complicated and require careful calibration to ensure biological realism.

Computational demands may also be substantial, particularly when modeling immune dynamics

across multiple organs and molecular pathways. Advances in computational methods and high performance computing will help address these challenges.

Ethical considerations include protecting patient privacy, ensuring transparency of algorithms, and avoiding biases that may arise from incomplete datasets.

Future research will likely focus on integrating single cell sequencing, spatial transcriptomics, microbiome data, and wearable health monitoring with mechanistic immune models. Such integration will enable deeper understanding of immune dysregulation and more accurate prediction of disease trajectories.

Mechanistic AI represents a powerful approach for studying autoimmune diseases because it bridges data driven analytics with biologically grounded modeling. By capturing causal mechanisms underlying immune dysfunction, this approach has the potential to transform diagnosis, treatment selection, and long term disease management, ultimately advancing the goal of precision immunology.

REFERENCES

1. Al-Maini M, Maindarkar M, Kitas GD, Khanna NN, Misra DP, Johri AM, et al. Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review. Rheumatol Int. 2023;43(11):1965-82.
2. Alshehri ZS. Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer's diseases. Neuroscience. 2025;586:44-57.
3. Baldi S, Sarikaya D, Lotti S, Cuffaro F, Fink D, Colombini B, et al. From traditional to artificial intelligence-driven approaches: Revolutionizing personalized and precision nutrition in inflammatory bowel disease. Clin Nutr ESPEN. 2025;68:106-17.
4. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703-15.
5. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov. 2021;11(4):900-15.
6. Bhuiyan MNI, Saha BK, Satter MA. Harnessing Artificial Intelligence and Precision Diets for Brain Health and Cognitive Resilience. J Nutr. 2025;155(10):3179-90.
7. Corti C, Cobanaj M, Dee EC, Criscitiello C, Tolaney SM, Celi LA, et al. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. Cancer Treat Rev. 2023;112:102498.
8. Darbandi MR, Darbandi M, Darbandi S, Bado I, Hadizadeh M, Khorram Khorshid HR. Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study. Eur J Cancer. 2024;209:114227.
9. Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020;18:2300-11.
10. Ferreira DD, Ferreira LG, Amorim KA, Delfino DCT, Ferreira A, Souza L. Assessing the Links Between Artificial Intelligence and Precision Nutrition. Curr Nutr Rep. 2025;14(1):47.
11. Hassan YM, Wanas A, Ali AA, El-Sayed WM. Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases. J Nanobiotechnology. 2025;23(1):668.
12. Hou GL, Dong BQ, Yu BX, Dai JY, Lin XX, Cheng ZZ. Artificial intelligence in acupuncture: bridging traditional knowledge and preci-

sion integrative medicine. Front Med (Lausanne). 2025;12:1633416.
13. Huss R, Raffler J, Märkl B. Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology. Cancer Rep (Hoboken). 2023;6(7):e1796.
14. Jiang B, Wu Y, Chen X, Jian C, Wang W. Artificial intelligence and multi-omics convergence in breast cancer: Revolutionizing diagnosis, prognostication, and precision oncology. Crit Rev Oncol Hematol. 2026;220:105160.
15. Karuppan Perumal MK, Rajan Renuka R, Kumar Subbiah S, Manickam Natarajan P. Artificial intelligence-driven clinical decision support systems for early detection and precision therapy in oral cancer: a mini review. Front Oral Health. 2025;6:1592428.
16. Khalighi S, Reddy K, Midya A, Pandav KB, Madabhushi A, Abedalthagafi M. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. NPJ Precis Oncol. 2024;8(1):80.
17. Kopylov U, Verstockt B, Marigorta UM, Noviello D, Bossuyt P, Mookhoek A, et al. Results of the Ninth Scientific Workshop of the European Crohn's and Colitis Organisation (ECCO): Artificial Intelligence in medical management and precision medicine. J Crohns Colitis. 2026;20(4).
18. Li T, Mohamedikbal S, Bestry M, Batley J, Edwards D. Pangenomics combined with artificial intelligence and precision breeding can accelerate crop improvement. Curr Opin Plant Biol. 2025;88:102825.
19. Liang G, Fan W, Luo H, Zhu X. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020;128:110255.
20. Mehta S, Huey SL, Fahim SM, Sinha S, Rajagopalan K, Ahmed T, et al. Advances in artificial intelligence and precision nutrition approaches to improve maternal and child health in low resource settings. Nat Commun. 2025;16(1):7673.
21. Pammi M, Aghaeepour N, Neu J. Multiomics, artificial intelligence, and precision medicine in perinatology. Pediatr Res. 2023;93(2):308-15.
22. Philip AK, Samuel BA, Bhatia S, Khalifa SAM, El-Seedi HR. Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors. Life (Basel). 2022;13(1).
23. Pinton P. Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion. Ann Med. 2023;55(2):2300670.
24. Saba L, Maindarkar M, Johri AM, Mantella L, Laird JR, Khanna NN, et al. UltraAIGenomics: Artificial Intelligence-Based Cardiovascular Disease Risk Assessment by Fusion of Ultrasound-Based Radiomics and Genomics Features for Preventive, Personalized and Precision Medicine: A Narrative

Review. Rev Cardiovasc Med. 2024;25(5):184.
25. Sahoo K, Lingasamy P, Khatun M, Sudhakaran SL, Salumets A, Sundararajan V, et al. Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine. Epigenetics Chromatin. 2025;18(1):35.
26. Selvaraj C, Cho WC, Langeswaran K, Alothaim AS, Vijayakumar R, Jayaprakashvel M, et al. Artificial intelligence in cancer care: revolutionizing diagnosis, treatment, and precision medicine amid emerging challenges and future opportunities. 3 Biotech. 2025;15(10):355.
27. Shao J, Feng J, Li J, Liang S, Li W, Wang C. Novel tools for early diagnosis and precision treatment based on artificial intelligence. Chin Med J Pulm Crit Care Med. 2023;1(3):148-60.
28. Shen JP. Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. Emerg Top Life Sci. 2021;5(6):747-56.
29. Shen Y, Zhang P, Luo J, Chen S, Gu S, Lin Z, et al. Artificial Intelligence Drives Advances in Multi-Omics Analysis and Precision Medicine for Sepsis. Biomedicines. 2026;14(2).
30. Shujaat S, Riaz M, Jacobs R. Synergy between artificial intelligence and precision medicine for computer-assisted oral and maxillofacial surgical planning. Clin Oral Investig. 2023;27(3):897-906.
31. Shyam M, Kaushal N, Yadav M, Srirangan P, Prince SE. Transforming Epilepsy Care: A Comprehensive Review of Technological Innovations, Artificial Intelligence Advancements, and Precision Tools for Enhanced Seizure Management and Patient Outcomes. Scientifica (Cairo). 2026;2026:5915062.
32. Sussman L, Garcia-Robledo JE, Ordóñez-Reyes C, Forero Y, Mosquera AF, Ruíz-Patiño A, et al. Integration of artificial intelligence and precision oncology in Latin America. Front Med Technol. 2022;4:1007822.
33. Theodros E, Nagaraju GP. Artificial Intelligence and Precision Medicine: Outcome of Immunotherapy in Hepatocellular Carcinoma. Crit Rev Immunol. 2022;42(6):1-8.
34. Wang MH. Integrating Artificial Intelligence and Precision Therapeutics for Advancing the Diagnosis and Treatment of Age-Related Macular Degeneration. Bioengineering (Basel). 2025;12(5).
35. Zeng S, Qing Q, Xu W, Yu S, Zheng M, Tan H, et al. Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors. Front Med (Lausanne). 2024;11:1365524.
36. Zhang P, Guo Z, Ullah S, Melagraki G, Afantitis A, Lynch I. Nanotechnology and artificial intelligence to enable sustainable and precision agriculture. Nat Plants. 2021;7(7):864-76.
37. Zhang W, Xie H, Ying S, Zeng X, Liao X, Hu S, et al. Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics. Front

Immunol. 2026;17:1774889.
38. Zhu H, He H, Yang M, Zhu H, Hagiwara A, Shu L, et al. Artificial intelligence empowers gut microbiota research in neurodegenerative diseases molecular mechanisms and precision therapy. iScience. 2025;28(12):114044.
39. Farrokhi M, Abbasmofrad H, Karami M, Hezarani HB, Alemohammad SS, Atighi J, et al. AI for Self-Diagnosis, Self-Monitoring, and Personalized Medicine. Kindle. 2026;6(1):1-226.
40. Tahavvori A, Chelan RJ, Aminoleslami S, Moghadam OF, Haghighi L, Abdian Y, et al. Large Language Models and ChatGPT in Medical Sciences: Foundations, Capabilities, and Challenges. Kindle. 2025;5(1):1-222.
41. Ramezanian M, Benis DS, Nikakhtar R, Gorjizadeh N, Asadi F, Bagherianlemraski M, et al. Artificial Intelligence in Genomic Medicine: Improving Diagnostic Accuracy and Treatment Outcomes. Kindle. 2025;5(1):1-215.
42. Rahmani E, Farrokhi M, Aghajan A, Gholampour G, Ghoodjani E, Shemshadigolafzani R, et al. AI-Driven Strategies for Improving Patient Quality of Life. Kindle. 2025;5(1):1-214.
43. Rahaeimehr R, Babakhani Z, Moghadam OF, Nasir SM, Safaei P, Abdollahi MAA, et al. Application of AI in Research and Data Science. Kindle. 2025;5(1):1-362.
44. Niakosari V, Mosaddeghi-Heris R, Hezarani HB, Farrokhi M, Safaei P, Nikseresht H, et al. AI in Medical Imaging and Early Disease Detection. Kindle. 2025;5(1):1-203.

45. Louia S, Mosaddeghi-Heris R, Kamvar R, Zahmatkesh N, Damiri M, Esfahani MA, et al. Artificial Intelligence in Cancer Genomics: Transforming Diagnosis, Treatment, and Precision Medicine. Kindle. 2025;5(1):1-234.
46. Louia S, Moghadam OF, Chelan RJ, Taheri N, Amini F, Ahmadi S, et al. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Diseases. Kindle. 2025;5(1):1-222.
47. Javadzadeh A, Shafiei D, Amlash RS, Mehrvar R, Sepehrian S, Shafiee A, et al. The Brain-Body Connection: Neuroscience's Role Across Medical Sciences Disciplines. Kindle. 2025;5(1):1-210.
48. Hedayati F, Chelan RJ, Alijaniha M, Koma KK, Irajian P, Rajabi N, et al. Explainable Artificial Intelligence for Reducing the Global Cancer Burden. Kindle. 2025;5(1):1-195.
49. Harati K, Tahernejad M, Saddam SMS, Farshi M, Saeedfar M, Gheibi M, et al. The Future of Prosthetics and Organ Transplantation: A Therapeutic Approach Across Various Medical Disciplines. Kindle. 2025;5(1):1-193.
50. Harati K, Mosaddeghi-Heris R, Kiani K, Saligheh Rad M, Morovatshoar R, Kamali M, et al. The AI Revolution: Predicting and Managing the Next Global Health Challenges and Emerging Disease Outbreaks. Kindle. 2025;5(1):1-326.
51. Harati K, Abbasmofrad H, Ebrahimi M, Hashemlu L, Chelan RJ, Hashemzadeh A, et al. Intelligent Patient Engagement: Education and

Follow-Up through AI and Telemedicine. Kindle. 2025;5(1):1-185.
52. Gheibi M, Rajabloo Y, Alipour-Khabir Y, Azami P, Louia S, Bojnordi TE, et al. Artificial Intelligence in Biomarker Discovery: Applications Across Medical Specialties. Kindle. 2025;5(1):1-209.
53. Farrokhi M, Taheri N, Moghadam OF, Armoon M, Samimi S, Torkashvand N, et al. Artificial Intelligence for Hard-to-Treat and Unknown-Origin Cancers. Kindle. 2025;5(1):1-296.
54. Farrokhi M, Mehrtabar S, Harati K, Pourlak T, Ghadirzadeh E, Abbasmofrad H, et al. Clinical Decision-Making Using Artificial Intelligence. Kindle. 2025;5(1):1-236.
55. Farrokhi M, Ghalamkarpour N, Nouri S, Babaei M, Rajabloo Y, Sattari M, et al. Innovative Vaccination: A New Era in Cancer Prevention. Kindle. 2025;5(1):1-194.
56. Babaheidarian P, Soltanattar A, Sajadi SK, Rostamian L, Foroutani L, Soleymanpourshamsi T, et al. Robotics in Healthcare. Kindle. 2025;5(1):1-178.
57. Zahmatkesh N, Babaei SS, Manesh SH, Abbaspour M, Ghadirzadeh E, Salimian N, et al. Artificial Intelligence for Prediction of Metastasis Risk and Survival. Kindle. 2024;4(1):1-205.
58. Sabzehie H, Farrokhi M, Nochian MA. Statistical analysis in CBCT-based third molar evaluation. Oral Maxillofac Surg. 2025;30(1):10.
59. Amiri S, Mirahmadi A, Parvandi A,

Moshfegh MZ, Hashemi Abatari SP, Farrokhi M, et al. Excellent accuracy of magnetic resonance imaging for diagnosis of discoid meniscus tears: A systematic review and meta-analysis. J Exp Orthop. 2024;11(3):e12051.
60. Farrokhi M. Statistical comments on "Does player time-in-game affect tackle technique in elite level rugby union?". J Sci Med Sport. 2018;21(9):872.
61. Farrokhi M. Assessment of bioelectrical activity of pelvic floor muscles. Eur J Phys Rehabil Med. 2018;54(4):645.
62. Farrokhi M, Ahadiat SA. Stability of distinct symptom experiences in patients with COPD. Respir Med. 2023;210:107166.
63. Farrokhi M, Amani-Beni A. Statistical Comments on "Assessment of Musculoskeletal Strength and Levels of Fatigue During Different Phases of Menstrual Cycle in Young Adults". J Clin Diagn Res. 2017;11(7):Cl01.
64. Farrokhi M, Arjaki D. Statistical Comments on "Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder". Neuroimmunomodulation. 2017;24(2):120.
65. Farrokhi M, Arjaki D, Peykanpour F. Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women. Osteoporos Int. 2020;31(10):2061.
66. Farrokhi M, Ebrahimi M, Peykanpour F. Effect of surgical intraocular pressure lowering on

retinal structures-nerve fibre layer, foveal avascular zone, peripapillary and macular vessel density: 1 year results. Eye (Lond). 2020;34(9):1710.
67. Farrokhi M, Fallahian AH, Rahmani E, Aghajan A, Alipour M, Jafari Khouzani P, et al. Current Applications, Challenges, and Future Directions of Artificial Intelligence in Emergency Medicine: A Narrative Review. Arch Acad Emerg Med. 2025;13(1):e45.
68. Farrokhi M, Harati K. Audio sensory methods in oral hygiene maintenance. Eur Arch Paediatr Dent. 2025;26(6):1077.
69. Farrokhi M, Khurshid M, Mohammadi S, Yarmohammadi B, Bahramvand Y, Nasrollahi E, et al. Comparison of ultrasound-accelerated versus conventional catheter-directed thrombolysis for deep vein thrombosis: A systematic review and meta-analysis. Vascular. 2022;30(2):365-74.
70. Farrokhi M, Khurshid M, Yarmohammadi B, Mangouri A, Alipour-Khabir Y, Alipour-Khabir S, et al. Comparison of outcomes and complications in conventional versus ultrasound-accelerated catheter directed thrombolysis for treatment of pulmonary embolism: A systematic review and meta-analysis. Perfusion. 2023;38(6):1123-32.
71. Farrokhi M, Manavi SP, Taheri F. Non-invasive monitoring of pH and oxygen using miniaturized electrochemical sensors. J Transl Med. 2021;19(1):252.
72. Farrokhi M, Nochian MA. Longitudinal Methods in Orthognathic Surgery Studies. Maxillofac Plast Reconstr Surg. 2025;47(1):44.
73. Farrokhi M, Nochian MA. The Impact of Leadership in Gender Diversity of Annual Meeting Speakers in the American Society for Surgery of the Hand. J Hand Surg Glob Online. 2025;7(6):100823.
74. Farrokhi M, Nourian NA. Intestinal transplantation and quality of life. Clin Nutr. 2021;40(2):658.
75. Farrokhi M, Nourian NA. Nonselective Laryngeal Reinnervation Versus Type 1 Thyroplasty in Patients With Unilateral Vocal Fold Paralysis. J Voice. 2022;36(6):874.
76. Farrokhi M, Nourian NA, Nourian SM. Letter to the editor regarding, "Potential significance of facet joint fusion or posteromedial fusion observed on CT imaging following attempted posterolateral or posterior interbody fusion" by Kim et al. Spine J. 2020;20(11):1889.
77. Farrokhi M, Peykanpour F. Vascular Endothelial Growth Factor-loaded Bioresorbable Delivery System for Pulp Regeneration. J Endod. 2017;43(9):1414.
78. Farrokhi M, Yarmohammadi B, Mangouri A, Hekmatnia Y, Bahramvand Y, Kiani M, et al. Screening performance characteristics of ultrasonography in confirmation of endotracheal intubation; a systematic review and meta-analysis. Archives of Academic Emergency Medicine. 2021;9(1):e68.
79. Goodarzy B, Rahmani E, Farrokhi M, Ta-

vakoli R, Moghadam Fard A, Ranjbaran Ghaleh M, et al. Diagnostic Value of Chest Computed Tomography Scan for Identification of Foreign Body Aspiration in Children: A Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2025;13(1):e3.
80. Hosseini Khameneh SM, Amani-Beni R, Ahadiat SA, Kahrizi MS, Jafari S, Seyedinnavade S, et al. Diagnostic Accuracy of Ultrasonography for Identification of Elbow Fractures in Children; a Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2023;11(1):e62.
81. Jafari Khouzani P, Rahmani E, Rezaei M, Pohrbagher Benam S, Moghadam Fard A, Amani-Beni R, et al. Optic Nerve Sheath Diameter in Predicting the Neurological Outcomes of Cardiac Arrest Survivors: A Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2025;13(1):e29.
82. Kazemi SM, Khorram R, Fayyazishishavan E, Amani-Beni R, Haririan Y, Hosseini Khameneh SM, et al. Diagnostic Accuracy of Ottawa Knee Rule for Diagnosis of Fracture in Patients with Knee Trauma; a Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2023;11(1):e30.
83. Kazemi SM, Mirahmadi A, Hosseini-Monfared P, Moghimi HR, Mahboubi A, Gandomkarzadeh M, et al. Impact of saline irrigation on the early mechanical characteristics and microstructure of bone cement. Sci Rep. 2024;14(1):31299.
84. Mirahmadi A, Hosseini-Monfared P, Amiri S, Taheri F, Farokhi M, Minaei Noshahr R, et

al. Cross-cultural adaptation and validation of the Persian version of the new Knee Society Knee Scoring System (KSS). J Orthop Surg Res. 2023;18(1):858.
85. Mirahmadi A, Hosseini-Monfared P, Farrokhi M, Minaie R, Bateni A, Kazemi SM. Extended oral antibiotics fail to reduce surgical site infection in orthopedic surgeries: A comparative study. PLoS One. 2025;20(9):e0330685.
86. Mirahmadi A, Kouhestani E, Farrokhi M, Kazemi SM, Noshahr RM. Hip and pelvic geometry as predictors of knee osteoarthritis severity. Medicine (Baltimore). 2024;103(28):e38888.
87. Moteshakereh SM, Zarei H, Nosratpour M, Zaker Moshfegh M, Shirvani P, Mirahmadi A, et al. Evaluating the Diagnostic Performance of MRI for Identification of Meniscal Ramp Lesions in ACL-Deficient Knees: A Systematic Review and Meta-Analysis. J Bone Joint Surg Am. 2024;106(12):1117-27.
88. Nosratpour M, Zarei H, Zaker Moshfegh M, Mahdavi M, Moteshakereh SM, Shirvani P, et al. Diagnostic accuracy of magnetic resonance imaging for detecting superior labrum anterior to posterior lesions: a systematic review and meta-analysis. JSES Int. 2025;9(6):1972-87.
89. Rahmani E, Farrokhi M, Farrokhi M, Nouri S, Moghadam Fard A, Hoorshad B, et al. Accuracy of Lung Ultrasonography for Diagnosis of Heart Failure; a Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2025;13(1):e33.

90. Rahmani E, Fayyazishishavan E, Afzalian A, Varshochi S, Amani-Beni R, Ahadiat SA, et al. Point-Of-Care Ultrasonography for Identification of Skin and Soft Tissue Abscess in Adult and Pediatric Patients; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2023;11(1):e49.
91. Taheri F, Farrokhi M. Re: Changes in Condylar Position Within 12 Months After Bilateral Sagittal Split Ramus Osteotomy. J Oral Maxillofac Surg. 2022;80(4):581.
92. Taheri F, Farrokhi M. Nutritional status, body composition, and blood biochemical parameters of patients following sleeve gastrectomy. Clin Nutr ESPEN. 2022;49:668.
93. Tahririan MA, Nodushan S, Farrokhi M. Chronic recurrent multifocal osteomyelitis in a 3.5-year-old boy. J Res Med Sci. 2021;26:32.
94. Talebi S, Rahmani E, Abdinejad M, Ahmadzade M, Hoorshad B, Fard AM, et al. Diagnostic performance of SPECT/CT for identification of aseptic loosening after total knee and hip arthroplasty: a systematic review and meta-analysis. Acta Orthop Belg. 2024;90(3):503-11.
95. Hassani M, Hassabi M, Khodabakhshian S, Javanbakht M, Aliabbar S, Movahedi A, et al. Exploring the relationship between ankle strength and endurance factors and the severity and level of ischemia in patients with peripheral arterial disease. Journal of Cardiothoracic Surgery. 2025;20(1):280.
96. Hassani M, Mohebbi M, Tavallaei M, Hosseini Nodoushan SMR, Mirzadeh M, Hashemi R. May position of hemodialysis catheter tip have a direct effect on its patency? Positive results of a preliminary study on its rotation. European Journal of Translational Myology. 2022;32(2):10537.
97. Hatami H, Mohebbi M, Tabatabaei Nodoushan MH. Validity index of ultrasonography findings, fine needle aspiration cytology, PSA and DRE in patients suspicious for prostate cancer. Researcher Bulletin of Medical Sciences. 2023;28(1).
98. Hedayat A, Esrafilian Soltani A, Hakiminezhad M, Zareian F, Saneian M, Moradmand M, et al. Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts. European Journal of Translational Myology. 2024;34(1):12029.
99. Abonamah AA, Tariq MU, Shilbayeh S. On the Commoditization of Artificial Intelligence. Front Psychol. 2021;12:696346.
100. Alsharqi M, Woodward WJ, Mumith JA, Markham DC, Upton R, Leeson P. Artificial intelligence and echocardiography. Echo Res Pract. 2018;5(4):R115-r25.
101. Amin M, Martínez-Heras E, Ontaneda D, Prados Carrasco F. Artificial Intelligence and Multiple Sclerosis. Curr Neurol Neurosci Rep. 2024;24(8):233-43.
102. Aminoshariae A, Nosrat A, Nagendrababu V, Dianat O, Mohammad-Rahimi H, O'Keefe AW, et al. Artificial Intelligence in Endodontic Education. J Endod. 2024;50(5):562-78.

103. Asaadi S, Martins KN, Lee MM, Pantoja JL. Artificial intelligence for the vascular surgeon. Semin Vasc Surg. 2023;36(3):394-400.
104. Attia ZI, Harmon DM, Behr ER, Friedman PA. Application of artificial intelligence to the electrocardiogram. Eur Heart J. 2021;42(46):4717-30.
105. Auffermann WF, Gozansky EK, Tridandapani S. Artificial Intelligence in Cardiothoracic Radiology. AJR Am J Roentgenol. 2019;212(5):997-1001.
106. Ayoub NF, Glicksman JT. Artificial Intelligence in Rhinology. Otolaryngol Clin North Am. 2024;57(5):831-42.
107. Azadi Moghadam P, Bashashati A, Goldenberg SL. Artificial Intelligence and Pathomics: Prostate Cancer. Urol Clin North Am. 2024;51(1):15-26.
108. Bai L, Su J. Artificial Intelligence Virtual Organoids (AIVOs). Bioact Mater. 2026;59:45-68.
109. Batra P, Tagra H, Katyal S. Artificial Intelligence in Teledentistry. Discoveries (Craiova). 2022;10(3):153.
110. Benzakour A, Altsitzioglou P, Lemée JM, Ahmad A, Mavrogenis AF, Benzakour T. Artificial intelligence in spine surgery. Int Orthop. 2023;47(2):457-65.
111. Bhalla S, Laganà A. Artificial Intelligence for Precision Oncology. Adv Exp Med Biol. 2022;1361:249-68.
112. Bhandari A. Revolutionizing Radiology With Artificial Intelligence. Cureus.

2024;16(10):e72646.
113. Bhardwaj A, Kishore S, Pandey DK. Artificial Intelligence in Biological Sciences. Life (Basel). 2022;12(9).
114. Bonderman D. Artificial intelligence in cardiology. Wien Klin Wochenschr. 2017;129(23-24):866-8.
115. Boyle AJ, Gaudet VC, Black SE, Vasdev N, Rosa-Neto P, Zukotynski KA. Artificial intelligence for molecular neuroimaging. Ann Transl Med. 2021;9(9):822.
116. Brower D, Sengupta S, Bhatt AN, Allen S, Bechara R, Islam S, et al. Artificial Intelligence in Interventional Pulmonology. Ther Adv Pulm Crit Care Med. 2025;20:29768675251353390.
117. Callegarin D, Maaziz N, Mosca AL, Marle N, Opale M, Nicolle C, et al. Artificial Intelligence and Chromothripsis. Methods Mol Biol. 2025;2968:281-9.
118. Cao CL, Li QL, Tong J, Shi LN, Li WX, Xu Y, et al. Artificial intelligence in thyroid ultrasound. Front Oncol. 2023;13:1060702.
119. Cao LL, Peng M, Xie X, Chen GQ, Huang SY, Wang JY, et al. Artificial intelligence in liver ultrasound. World J Gastroenterol. 2022;28(27):3398-409.
120. Caranfil E, Lami K, Uegami W, Fukuoka J. Artificial Intelligence and Lung Pathology. Adv Anat Pathol. 2024;31(5):344-51.
121. Chang TG, Park S, Schäffer AA, Jiang P, Ruppin E. Hallmarks of artificial intelligence

contributions to precision oncology. Nat Cancer. 2025;6(3):417-31.
122. Chassagnon G, Vakalopoulou M, Paragios N, Revel MP. Artificial intelligence applications for thoracic imaging. Eur J Radiol. 2020;123:108774.
123. Chen MK, Liu X, Sun Y, Tsai DP. Artificial Intelligence in Meta-optics. Chem Rev. 2022;122(19):15356-413.
124. Chen X, Owen CA, Huang EC, Maggard BD, Latif RK, Clifford SP, et al. Artificial Intelligence in Echocardiography for Anesthesiologists. J Cardiothorac Vasc Anesth. 2021;35(1):251-61.
125. Choe J, Lee SM, Hwang HJ, Lee SM, Yun J, Kim N, et al. Artificial Intelligence in Lung Imaging. Semin Respir Crit Care Med. 2022;43(6):946-60.
126. Chu KY, Nassau DE, Arora H, Lokeshwar SD, Madhusoodanan V, Ramasamy R. Artificial Intelligence in Reproductive Urology. Curr Urol Rep. 2019;20(9):52.
127. Chu YS, An HG, Oh BH, Yang S. Artificial Intelligence in Cutaneous Oncology. Front Med (Lausanne). 2020;7:318.
128. Clark Lambert W, Grzybowski A. Dermatology and artificial intelligence. Clin Dermatol. 2024;42(3):207-9.
129. Cui M, Zhang DY. Artificial intelligence and computational pathology. Lab Invest. 2021;101(4):412-22.
130. David L, Brata AM, Mogosan C, Pop C, Czako Z, Muresan L, et al. Artificial Intelligence and Antibiotic Discovery. Antibiotics (Basel). 2021;10(11).
131. Deshmukh R, Rathi P. Artificial Intelligence in Medicine. J Assoc Physicians India. 2022;70(3):11-2.
132. Dhopte A, Bagde H. Smart Smile: Revolutionizing Dentistry With Artificial Intelligence. Cureus. 2023;15(6):e41227.
133. Dias RD, Shah JA, Zenati MA. Artificial intelligence in cardiothoracic surgery. Minerva Cardioangiol. 2020;68(5):532-8.
134. Dicle O. Artificial intelligence in diagnostic ultrasonography. Diagn Interv Radiol. 2023;29(1):40-5.
135. Duong D, Solomon BD. Artificial intelligence in clinical genetics. Eur J Hum Genet. 2025;33(3):281-8.
136. El Sherbini A, Rosenson RS, Al Rifai M, Virk HUH, Wang Z, Virani S, et al. Artificial intelligence in preventive cardiology. Prog Cardiovasc Dis. 2024;84:76-89.
137. Elsabagh AA, Elhadary M, Elsayed B, Elshoeibi AM, Ferih K, Kaddoura R, et al. Artificial intelligence in sickle disease. Blood Rev. 2023;61:101102.
138. Farooq MA, Gao S, Hassan MA, Huang Z, Rasheed A, Hearne S, et al. Artificial intelligence in plant breeding. Trends Genet. 2024;40(10):891-908.
139. Farzan R. Artificial intelligence in Immuno-genetics. Bioinformation. 2024;20(1):29-35.

140. Fedewa R, Puri R, Fleischman E, Lee J, Prabhu D, Wilson DL, et al. Artificial Intelligence in Intracoronary Imaging. Curr Cardiol Rep. 2020;22(7):46.
141. Feuerecker B, Heimer MM, Geyer T, Fabritius MP, Gu S, Schachtner B, et al. Artificial Intelligence in Oncological Hybrid Imaging. Nuklearmedizin. 2023;62(5):296-305.
142. Feuerecker B, Heimer MM, Geyer T, Fabritius MP, Gu S, Schachtner B, et al. Artificial Intelligence in Oncological Hybrid Imaging. Rofo. 2023;195(2):105-14.
143. Fogel AL, Kvedar JC. Artificial intelligence powers digital medicine. NPJ Digit Med. 2018;1:5.
144. Försch S, Klauschen F, Hufnagl P, Roth W. Artificial Intelligence in Pathology. Dtsch Arztebl Int. 2021;118(12):194-204.
145. Ganesan V, Pearle MS. Artificial intelligence in stone disease. Curr Opin Urol. 2021;31(4):391-6.
146. García-Vázquez FA. Artificial intelligence and porcine breeding. Anim Reprod Sci. 2024;269:107538.
147. Garmany A, Terzic A. Artificial intelligence powers regenerative medicine into predictive realm. Regen Med. 2024;19(12):611-6.
148. Gensure RH, Chiang MF, Campbell JP. Artificial intelligence for retinopathy of prematurity. Curr Opin Ophthalmol. 2020;31(5):312-7.
149. Gomes B, Ashley EA. Artificial Intelligence in Molecular Medicine. N Engl J Med.

2023;388(26):2456-65.
150. Gulati S, Emmanuel A, Patel M, Williams S, Haji A, Hayee B, et al. Artificial intelligence in luminal endoscopy. Ther Adv Gastrointest Endosc. 2020;13:2631774520935220.
151. Gunning D, Stefik M, Choi J, Miller T, Stumpf S, Yang GZ. XAI-Explainable artificial intelligence. Sci Robot. 2019;4(37).
152. Gutman MJ, Schroeder GD, Murphy H, Flanders AE, Vaccaro AR. Artificial Intelligence in Spine Care. Clin Spine Surg. 2021;34(4):121-4.
153. Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69s:S36-s40.
154. Hann A, Meining A. Artificial Intelligence in Endoscopy. Visc Med. 2021;37(6):471-5.
155. Harris J, Matthews J. Artificial Intelligence: Predicting Perioperative Problems. Br J Hosp Med (Lond). 2024;85(8):1-4.
156. Hassabis D, Kumaran D, Summerfield C, Botvinick M. Neuroscience-Inspired Artificial Intelligence. Neuron. 2017;95(2):245-58.
157. Heinzinger M, Rost B. Artificial Intelligence Learns Protein Prediction. Cold Spring Harb Perspect Biol. 2024;16(9).
158. Herskovits EH. Artificial intelligence in molecular imaging. Ann Transl Med. 2021;9(9):824.
159. Ho D, Wang P, Kee T. Artificial intelligence in nanomedicine. Nanoscale Horiz. 2019;4(2):365-77.
160. Hoopes PC, Jr., Moin KA, Moshirfar M. Ar-

tificial intelligence in refractive surgery. Curr Opin Ophthalmol. 2025;36(4):271-5.
161. Hormel TT, Hwang TS, Bailey ST, Wilson DJ, Huang D, Jia Y. Artificial intelligence in OCT angiography. Prog Retin Eye Res. 2021;85:100965.
162. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500-10.
163. Hou H, Zhang R, Li J. Artificial intelligence in the clinical laboratory. Clin Chim Acta. 2024;559:119724.
164. Huang AE, Valdez TA. Artificial Intelligence and Pediatric Otolaryngology. Otolaryngol Clin North Am. 2024;57(5):853-62.
165. Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, et al. Artificial intelligence in pancreatic cancer. Theranostics. 2022;12(16):6931-54.
166. Iftikhar M, Saqib M, Zareen M, Mumtaz H. Artificial intelligence: revolutionizing robotic surgery: review. Ann Med Surg (Lond). 2024;86(9):5401-9.
167. Inglada Galiana L, Corral Gudino L, Miramontes González P. Ethics and artificial intelligence. Rev Clin Esp (Barc). 2024;224(3):178-86.
168. Ishiwata T, Yasufuku K. Artificial intelligence in interventional pulmonology. Curr Opin Pulm Med. 2024;30(1):92-8.
169. Itchhaporia D. Artificial intelligence in cardiology. Trends Cardiovasc Med. 2022;32(1):34-41.
170. Ivanov D, Chezhegov A, Kiselev M, Grunin

A, Larionov D. Neuromorphic artificial intelligence systems. Front Neurosci. 2022;16:959626.
171. Jartarkar SR. Artificial intelligence: Its role in dermatopathology. Indian J Dermatol Venereol Leprol. 2023;89(4):549-52.
172. Jartarkar SR, Cockerell CJ, Patil A, Kassir M, Babaei M, Weidenthaler-Barth B, et al. Artificial intelligence in Dermatopathology. J Cosmet Dermatol. 2023;22(4):1163-7.
173. Jeste DV, Graham SA, Nguyen TT, Depp CA, Lee EE, Kim HC. Beyond artificial intelligence: exploring artificial wisdom. Int Psychogeriatr. 2020;32(8):993-1001.
174. Jin X, Liu C, Xu T, Su L, Zhang X. Artificial intelligence biosensors: Challenges and prospects. Biosens Bioelectron. 2020;165:112412.
175. Johnson KW, Torres Soto J, Glicksberg BS, Shameer K, Miotto R, Ali M, et al. Artificial Intelligence in Cardiology. J Am Coll Cardiol. 2018;71(23):2668-79.
176. Johnson R, Li MM, Noori A, Queen O, Zitnik M. Graph Artificial Intelligence in Medicine. Annu Rev Biomed Data Sci. 2024;7(1):345-68.
177. Joseph J, LePage EM, Cheney CP, Pawa R. Artificial intelligence in colonoscopy. World J Gastroenterol. 2021;27(29):4802-17.
178. Kachman MM, Brennan I, Oskvarek JJ, Waseem T, Pines JM. How artificial intelligence could transform emergency care. Am J Emerg Med. 2024;81:40-6.
179. Kallini JR, Moriarty JM. Artificial Intelli-

gence in Interventional Radiology. Semin Intervent Radiol. 2022;39(3):341-7.
180. Kang L, Ballouz D, Woodward MA. Artificial intelligence and corneal diseases. Curr Opin Ophthalmol. 2022;33(5):407-17.
181. Kania B, Montecinos K, Goldberg DJ. Artificial intelligence in cosmetic dermatology. J Cosmet Dermatol. 2024;23(10):3305-11.
182. Kann BH, Hosny A, Aerts H. Artificial intelligence for clinical oncology. Cancer Cell. 2021;39(7):916-27.
183. Karthika M, Sreedharan JK, Shevade M, Mathew CS, Ray S. Artificial intelligence in respiratory care. Front Digit Health. 2024;6:1502434.
184. Kaur T, Diwakar A, Kirandeep, Mirpuri P, Tripathi M, Chandra PS, et al. Artificial Intelligence in Epilepsy. Neurol India. 2021;69(3):560-6.
185. Keskinbora K, Güven F. Artificial Intelligence and Ophthalmology. Turk J Ophthalmol. 2020;50(1):37-43.
186. Keskinbora KH. Medical ethics considerations on artificial intelligence. J Clin Neurosci. 2019;64:277-82.
187. Khossravi AS, Chen Q, Adelman RA. Artificial intelligence in ophthalmology. Curr Opin Ophthalmol. 2025;36(1):35-8.
188. Kolla L, Parikh RB. Uses and limitations of artificial intelligence for oncology. Cancer. 2024;130(12):2101-7.
189. Korteling JEH, van de Boer-Visschedijk GC, Blankendaal RAM, Boonekamp RC, Eikelboom AR.

Human- versus Artificial Intelligence. Front Artif Intell. 2021;4:622364.
190. Koseoglu ND, Corrêa ZM, Liu TYA. Artificial intelligence for ocular oncology. Curr Opin Ophthalmol. 2023;34(5):437-40.
191. Krittanawong C, Johnson KW, Choi E, Kaplin S, Venner E, Murugan M, et al. Artificial Intelligence and Cardiovascular Genetics. Life (Basel). 2022;12(2).
192. Labaki C, Uche-Anya EN, Berzin TM. Artificial Intelligence in Gastrointestinal Endoscopy. Gastroenterol Clin North Am. 2024;53(4):773-86.
193. Ledziński Ł, Grześk G. Artificial Intelligence Technologies in Cardiology. J Cardiovasc Dev Dis. 2023;10(5).
194. Lee I. Artificial Intelligence in Teledermatology. Dermatol Clin. 2025;43(4):553-61.
195. Leiderman YI, Gerber MJ, Hubschman JP, Yi D. Artificial intelligence applications in ophthalmic surgery. Curr Opin Ophthalmol. 2024;35(6):526-32.
196. Leite KRM, Melo PAS. Artificial Intelligence in Uropathology. Diagnostics (Basel). 2024;14(20).
197. Leong YY, Vasseneix C, Finkelstein MT, Milea D, Najjar RP. Artificial Intelligence Meets Neuro-Ophthalmology. Asia Pac J Ophthalmol (Phila). 2022;11(2):111-25.
198. Li G, Wu X, Ma X. Artificial intelligence in radiotherapy. Semin Cancer Biol. 2022;86(Pt 2):160-71.
199. Li W, Hu R, Zhang Q, Yu Z, Deng L, Zhu X,

et al. Artificial intelligence in prostate cancer. Chin Med J (Engl). 2025;138(15):1769-82.
200. Lim JI, Rachitskaya AV, Hallak JA, Gholami S, Alam MN. Artificial intelligence for retinal diseases. Asia Pac J Ophthalmol (Phila). 2024;13(4):100096.
201. Liu S, Russo C, Suero Molina E, Di Ieva A. Artificial Intelligence Methods. Adv Exp Med Biol. 2024;1462:21-38.
202. Liu W, Liu X, Peng M, Chen GQ, Liu PH, Cui XW, et al. Artificial intelligence for hepatitis evaluation. World J Gastroenterol. 2021;27(34):5715-26.
203. Longuet-Higgins C. Artificial intelligence. Br Med Bull. 1971;27(3):218-21.
204. López C. Artificial Intelligence and Advanced Materials. Adv Mater. 2023;35(23):e2208683.
205. Luo G, Jiang X, Hu C, Li L, Yan L, Xiao G, et al. Artificial intelligence-powered nanomedicine. Chem Soc Rev. 2026;55(4):2070-119.
206. Malycha J, Bacchi S, Redfern O. Artificial intelligence and clinical deterioration. Curr Opin Crit Care. 2022;28(3):315-21.
207. Mansour NM. Artificial Intelligence in Colonoscopy. Curr Gastroenterol Rep. 2023;25(6):122-9.
208. Marzi SJ, Schilder BM, Nott A, Frigerio CS, Willaime-Morawek S, Bucholc M, et al. Artificial intelligence for neurodegenerative experimental models. Alzheimers Dement.

2023;19(12):5970-87.
209. McGrow K. Artificial intelligence: Essentials for nursing. Nursing. 2019;49(9):46-9.
210. Mendizabal-Ruiz G, Paredes O, Álvarez Á, Acosta-Gómez F, Hernández-Morales E, González-Sandoval J, et al. Artificial Intelligence in Human Reproduction. Arch Med Res. 2024;55(8):103131.
211. Miller RJH. Artificial Intelligence in Nuclear Cardiology. Cardiol Clin. 2023;41(2):151-61.
212. Mintz Y, Brodie R. Introduction to artificial intelligence in medicine. Minim Invasive Ther Allied Technol. 2019;28(2):73-81.
213. Mishra K, Leng T. Artificial intelligence and ophthalmic surgery. Curr Opin Ophthalmol. 2021;32(5):425-30.
214. Mofatteh M. Neurosurgery and artificial intelligence. AIMS Neurosci. 2021;8(4):477-95.
215. Mouridsen K, Thurner P, Zaharchuk G. Artificial Intelligence Applications in Stroke. Stroke. 2020;51(8):2573-9.
216. Mukherjee J, Sharma R, Dutta P, Bhunia B. Artificial intelligence in healthcare: a mastery. Biotechnol Genet Eng Rev. 2024;40(3):1659-708.
217. Muthukrishnan N, Maleki F, Ovens K, Reinhold C, Forghani B, Forghani R. Brief History of Artificial Intelligence. Neuroimaging Clin N Am. 2020;30(4):393-9.
218. Naidoo J, Shelmerdine SC, Charcape CFU, Sodhi AS. Artificial Intelligence in Paediatric Tuberculosis. Pediatr Radiol. 2023;53(9):1733-45.
219. Nakhate V, Gonzalez Castro LN. Artificial

intelligence in neuro-oncology. Front Neurosci. 2023;17:1217629.
220. Nazha A, Elemento O, Ahuja S, Lam B, Miles M, Shouval R, et al. Artificial intelligence in hematology. Blood. 2025;146(19):2283-92.
221. Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine. J Nucl Med. 2019;60(Suppl 2):29s-37s.
222. Newby D, Orgeta V, Marshall CR, Lourida I, Albertyn CP, Tamburin S, et al. Artificial intelligence for dementia prevention. Alzheimers Dement. 2023;19(12):5952-69.
223. Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20(5):e253-e61.
224. Nordblom NF, Büttner M, Schwendicke F. Artificial Intelligence in Orthodontics: Critical Review. J Dent Res. 2024;103(6):577-84.
225. Obrezanova O. Artificial intelligence for compound pharmacokinetics prediction. Curr Opin Struct Biol. 2023;79:102546.
226. Okagawa Y, Abe S, Yamada M, Oda I, Saito Y. Artificial Intelligence in Endoscopy. Dig Dis Sci. 2022;67(5):1553-72.
227. Oshika T. Artificial Intelligence Applications in Ophthalmology. Jma j. 2025;8(1):66-75.
228. Pham KT, Nabizadeh A, Selek S. Artificial Intelligence and Chatbots in Psychiatry. Psychiatr Q. 2022;93(1):249-53.
229. Popescu Patoni SI, Muşat AAM, Patoni C, Popescu MN, Munteanu M, Costache IB, et al. Artificial intelligence in ophthalmology. Rom J Ophthalmol. 2023;67(3):207-13.
230. Pozzi E, Velasquez DA, Varnum AA, Kava BR, Ramasamy R. Artificial Intelligence Modeling and Priapism. Curr Urol Rep. 2024;25(10):261-5.
231. Prabhu VD, Saidath K, Suvarna N, Mohtesham I, Shenoy S, Prabhu RV. Artificial Intelligence and Dentistry: The Future. J Pharm Bioallied Sci. 2024;16(Suppl 5):S4257-s61.
232. Prasad P, Khair AMB, Saeed M, Shetty N. Artificial Intelligence in Histopathology. J Pharm Bioallied Sci. 2024;16(Suppl 5):S4226-s9.
233. Puticiu M, Pop F, Butoi MA, Banicioiu-Covei M, Rotaru LT, Blaga T, et al. Artificial Intelligence in Cardiopulmonary Resuscitation. Medicina (Kaunas). 2025;61(12).
234. Qiu Y, Chen X, Wu X, Li Y, Xu P, Jin K, et al. Embodied artificial intelligence in ophthalmology. NPJ Digit Med. 2025;8(1):351.
235. Rahman MA, Yilmaz I, Albadri ST, Salem FE, Dangott BJ, Taner CB, et al. Artificial Intelligence Advances in Transplant Pathology. Bioengineering (Basel). 2023;10(9).
236. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl. 2004;86(5):334-8.
237. Ranschaert E, Topff L, Pianykh O. Optimization of Radiology Workflow with Artificial Intelligence. Radiol Clin North Am. 2021;59(6):955-66.
238. Rapoport N, Pavelchek C, Michelson AP,

Shew MA. Artificial Intelligence in Otology and Neurotology. Otolaryngol Clin North Am. 2024;57(5):791-802.
239. Ray A, Bhardwaj A, Malik YK, Singh S, Gupta R. Artificial intelligence and Psychiatry: An overview. Asian J Psychiatr. 2022;70:103021.
240. Razavian N, Knoll F, Geras KJ. Artificial Intelligence Explained for Nonexperts. Semin Musculoskelet Radiol. 2020;24(1):3-11.
241. Reed C. How should we regulate artificial intelligence? Philos Trans A Math Phys Eng Sci. 2018;376(2128).
242. Reid JE, Eaton E. Artificial intelligence for pediatric ophthalmology. Curr Opin Ophthalmol. 2019;30(5):337-46.
243. Richardson A, Robbins CB, Wisely CE, Henao R, Grewal DS, Fekrat S. Artificial intelligence in dementia. Curr Opin Ophthalmol. 2022;33(5):425-31.
244. Robert C, Meyer P, Séroussi B, Leroy T, Bibault JE. Artificial intelligence and radiotherapy: Evolution or revolution? Cancer Radiother. 2024;28(6-7):503-9.
245. Robert N. How artificial intelligence is changing nursing. Nurs Manage. 2019;50(9):30-9.
246. Román-Belmonte JM, Corte-Rodríguez H, Rodríguez-Merchán EC. Artificial intelligence in musculoskeletal conditions. Front Biosci (Landmark Ed). 2021;26(11):1340-8.
247. Romm EL, Tsigelny IF. Artificial Intelligence in Drug Treatment. Annu Rev Pharmacol

Toxicol. 2020;60:353-69.
248. Saboury B, Morris M, Siegel E. Future Directions in Artificial Intelligence. Radiol Clin North Am. 2021;59(6):1085-95.
249. Safdar NM, Banja JD, Meltzer CC. Ethical considerations in artificial intelligence. Eur J Radiol. 2020;122:108768.
250. Salvagno M, Taccone FS, Gerli AG. Can artificial intelligence help for scientific writing? Crit Care. 2023;27(1):75.
251. Sana MK, Hussain ZM, Shah PA, Maqsood MH. Artificial intelligence in celiac disease. Comput Biol Med. 2020;125:103996.
252. Santhanam P, Nath T, Peng C, Bai H, Zhang H, Ahima RS, et al. Artificial intelligence and body composition. Diabetes Metab Syndr. 2023;17(3):102732.
253. Sarris J, Halman A, Urokohara A, Lehrner M, Perkins D. Artificial intelligence and psychedelic medicine. Ann N Y Acad Sci. 2024;1540(1):5-12.
254. Schattenberg JM, Chalasani N, Alkhouri N. Artificial Intelligence Applications in Hepatology. Clin Gastroenterol Hepatol. 2023;21(8):2015-25.
255. Scheer JK, Ames CP. Artificial Intelligence in Spine Surgery. Neurosurg Clin N Am. 2024;35(2):253-62.
256. Schena FP, Magistroni R, Narducci F, Abbrescia DI, Anelli VW, Di Noia T. Artificial intelligence in glomerular diseases. Pediatr Nephrol. 2022;37(11):2533-45.

257. Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunović H. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67:1-29.
258. Schwendicke F, Mohammad Rahimi H, Tichy A. Artificial Intelligence in Prosthodontics. Dent Clin North Am. 2025;69(2):315-26.
259. Scott Wang HH, Vasdev R, Nelson CP. Artificial Intelligence in Pediatric Urology. Urol Clin North Am. 2024;51(1):91-103.
260. Sehrawat O, Kashou AH, Noseworthy PA. Artificial intelligence and atrial fibrillation. J Cardiovasc Electrophysiol. 2022;33(8):1932-43.
261. Seyahi N, Ozcan SG. Artificial intelligence and kidney transplantation. World J Transplant. 2021;11(7):277-89.
262. Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagn Pathol. 2023;18(1):109.
263. Shan T, Tay FR, Gu L. Application of Artificial Intelligence in Dentistry. J Dent Res. 2021;100(3):232-44.
264. Shen YT, Chen L, Yue WW, Xu HX. Artificial intelligence in ultrasound. Eur J Radiol. 2021;139:109717.
265. Shimizu H, Nakayama KI. Artificial intelligence in oncology. Cancer Sci. 2020;111(5):1452-60.
266. Siebelmann S, Hayashi T, Matthaei M, Bachmann BO, Stammen J, Cursiefen C. Artificial Intelligence for Lamellar Keratoplasty. Klin Monbl Augenheilkd. 2024;241(6):722-6.

267. Sinz FH, Pitkow X, Reimer J, Bethge M, Tolias AS. Engineering a Less Artificial Intelligence. Neuron. 2019;103(6):967-79.
268. Soliman A, Li Z, Parwani AV. Artificial intelligence's impact on breast cancer pathology: a literature review. Diagn Pathol. 2024;19(1):38.
269. Stubberud A, Langseth H, Nachev P, Matharu MS, Tronvik E. Artificial intelligence and headache. Cephalalgia. 2024;44(8):3331024241268290.
270. Su J, Zhang Y, Ke QQ, Su JK, Yang QH. Mobilizing artificial intelligence to cardiac telerehabilitation. Rev Cardiovasc Med. 2022;23(2):45.
271. Suero Molina E, Azemi G, Russo C, Liu S, Di Ieva A. Artificial Intelligence in Brain Tumors. Adv Exp Med Biol. 2024;1462:201-20.
272. Tamam MO, Tamam MC. Artificial intelligence technologies in nuclear medicine. World J Radiol. 2022;14(6):151-4.
273. Tano ZE, Cumpanas AD, Gorgen ARH, Rojhani A, Altamirano-Villarroel J, Landman J. Surgical Artificial Intelligence: Endourology. Urol Clin North Am. 2024;51(1):77-89.
274. TerKonda SP, TerKonda AA, Sacks JM, Kinney BM, Gurtner GC, Nachbar JM, et al. Artificial Intelligence: Singularity Approaches. Plast Reconstr Surg. 2024;153(1):204e-17e.
275. Tontini GE, Neumann H. Artificial intelligence: Thinking outside the box. Best Pract Res Clin Gastroenterol. 2021;52-53:101720.
276. Tsai AY, Carter SR, Greene AC. Artificial

intelligence in pediatric surgery. Semin Pediatr Surg. 2024;33(1):151390.
277. van Assen M, Muscogiuri G, Caruso D, Lee SJ, Laghi A, De Cecco CN. Artificial intelligence in cardiac radiology. Radiol Med. 2020;125(11):1186-99.
278. Vandevenne MM, Favuzza E, Veta M, Lucenteforte E, Berendschot TT, Mencucci R, et al. Artificial intelligence for detecting keratoconus. Cochrane Database Syst Rev. 2023;11(11):Cd014911.
279. Varghese C, Harrison EM, O'Grady G, Topol EJ. Artificial intelligence in surgery. Nat Med. 2024;30(5):1257-68.
280. Vemulapalli K, Gandhewar R, Safitri A, Ng SM, Michelessi M, Azuara-Blanco A, et al. Artificial intelligence for glaucoma. Cochrane Database Syst Rev. 2025;6(6):Cd016114.
281. Vilhekar RS, Rawekar A. Artificial Intelligence in Genetics. Cureus. 2024;16(1):e52035.
282. Villa-Camacho JC, Baikpour M, Chou SS. Artificial Intelligence for Breast US. J Breast Imaging. 2023;5(1):11-20.
283. Waisberg E, Ong J, Kamran SA, Masalkhi M, Paladugu P, Zaman N, et al. Generative artificial intelligence in ophthalmology. Surv Ophthalmol. 2025;70(1):1-11.
284. Wang R, Pan W, Jin L, Li Y, Geng Y, Gao C, et al. Artificial intelligence in reproductive medicine. Reproduction. 2019;158(4):R139-r54.
285. Wang Y, Shi X, Efferth T, Shang D. Artificial

intelligence-directed acupuncture: a review. Chin Med. 2022;17(1):80.
286. Wei ML, Tada M, So A, Torres R. Artificial intelligence and skin cancer. Front Med (Lausanne). 2024;11:1331895.
287. Wu GG, Zhou LQ, Xu JW, Wang JY, Wei Q, Deng YB, et al. Artificial intelligence in breast ultrasound. World J Radiol. 2019;11(2):19-26.
288. Yoon YE, Kim S, Chang HJ. Artificial Intelligence and Echocardiography. J Cardiovasc Imaging. 2021;29(3):193-204.
289. Young AT, Xiong M, Pfau J, Keiser MJ, Wei ML. Artificial Intelligence in Dermatology: A Primer. J Invest Dermatol. 2020;140(8):1504-12.
290. Yousif M, van Diest PJ, Laurinavicius A, Rimm D, van der Laak J, Madabhushi A, et al. Artificial intelligence applied to breast pathology. Virchows Arch. 2022;480(1):191-209.
291. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719-31.
292. Zeng J, Lin Z, Zhang X, Zheng T, Xu H, Liu T. Leveraging Artificial Intelligence for Neoantigen Prediction. Cancer Res. 2025;85(13):2376-87.
293. Zhang J, Chen D, Xia Y, Huang YP, Lin X, Han X, et al. Artificial Intelligence Enhanced Molecular Simulations. J Chem Theory Comput. 2023;19(14):4338-50.
294. Zhang K, Chen K. Artificial intelligence: opportunities in lung cancer. Curr Opin Oncol. 2022;34(1):44-53.

295. Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nat Med. 2025;31(1):45-59.
296. Zhang Y, Hu Y, Jiang N, Yetisen AK. Wearable artificial intelligence biosensor networks. Biosens Bioelectron. 2023;219:114825.
297. Zheng C, Johnson TV, Garg A, Boland MV. Artificial intelligence in glaucoma. Curr Opin Ophthalmol. 2019;30(2):97-103.
298. Zhong F, Xing J, Li X, Liu X, Fu Z, Xiong Z, et al. Artificial intelligence in drug design. Sci China Life Sci. 2018;61(10):1191-204.

Proof